<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Philip Morris International Inc.</td><td># í•„ë¦½ëª¨ë¦¬ìŠ¤ ì¸í„°ë‚´ì…”ë„ Inc.</td></tr>
<tr><td>(PM) Q4 2025 Earnings Call February 6, 2026 9:00 AM EST<br><br>Company Participants<br><br>James Bushnell - Vice President of Investor Relations & Financial Communications<br>Jacek Olczak - Group CEO & Director<br>Emmanuel Babeau - Group Chief Financial Officer<br><br>Conference Call Participants<br><br>Matthew Smith - Stifel, Nicolaus & Company, Incorporated, Research Division<br>Eric Serotta - Morgan Stanley, Research Division<br>Bonnie Herzog - Goldman Sachs Group, Inc., Research Division<br>Mirza Faham Baig - UBS Investment Bank, Research Division<br>Gerald Pascarelli - Needham & Company, LLC, Research Division<br>Damian McNeela - Deutsche Bank AG, Research Division<br><br>Presentation<br><br>Operator<br><br>Good day, and thank you for standing by.</td><td># (PM) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2026ë…„ 2ì›” 6ì¼ ì˜¤ì „ 9ì‹œ (ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>## íšŒì‚¬ ì°¸ì„ì<br><br>ì œì„ìŠ¤ ë¶€ì‹œë„¬ - íˆ¬ìì ê´€ê³„ ë° ì¬ë¬´ ì»¤ë®¤ë‹ˆì¼€ì´ì…˜ ë¶€ì‚¬ì¥<br>ì•¼ì²µ ì˜¬ì°¨í¬ - ê·¸ë£¹ CEO ê²¸ ì´ì‚¬<br>ì— ë§ˆë‰´ì—˜ ë°”ë³´ - ê·¸ë£¹ ìµœê³ ì¬ë¬´ì±…ì„ì<br><br>## ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>ë§¤íŠœ ìŠ¤ë¯¸ìŠ¤ - ìŠ¤í‹°í  ë‹ˆì½œë¼ìš°ìŠ¤, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì—ë¦­ ì„¸ë¡œíƒ€ - ëª¨ê±´ìŠ¤íƒ ë¦¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë³´ë‹ˆ í—¤ë¥´ì¡°ê·¸ - ê³¨ë“œë§Œì‚­ìŠ¤ ê·¸ë£¹, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë¯¸ë¥´ì íŒŒí•¨ ë°”ì´ê·¸ - UBS ì¸ë² ìŠ¤íŠ¸ë¨¼íŠ¸ ë±…í¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì œëŸ´ë“œ íŒŒìŠ¤ì¹´ë ë¦¬ - ë‹ˆë¤ ì•¤ ì»´í¼ë‹ˆ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë°ë¯¸ì•ˆ ë§¥ë‹ë¼ - ë„ì´ì²´ë°©í¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>## ë°œí‘œ<br><br>### ìš´ì˜ì<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Welcome to the Philip Morris International Inc. 2025 Fourth Quarter Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, James Bushnell, VP of Investor Relations and Financial Communications. Please go ahead. James Bushnell<br>Vice President of Investor Relations & Financial Communications<br><br>Welcome. Thank you for joining us. Earlier today, we issued a press release containing detailed information on our 2025 fourth quarter and full year results. The press release is available on our website at pmi.com.</td><td>í•„ë¦½ëª¨ë¦¬ìŠ¤ ì¸í„°ë‚´ì…”ë„ 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. [ìš´ì˜ì ì•ˆë‚´ì‚¬í•­] ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ëŠ” ë…¹ìŒë˜ê³  ìˆìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤. ì´ì œ ì˜¤ëŠ˜ ë°œí‘œìì´ì‹  ì œì„ìŠ¤ ë¶€ì‰¬ë„¬ íˆ¬ìì ê´€ê³„ ë° ì¬ë¬´ ì»¤ë®¤ë‹ˆì¼€ì´ì…˜ ë¶€ì‚¬ì¥ë‹˜ê»˜ ì§„í–‰ì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ë§ì”€í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>ì œì„ìŠ¤ ë¶€ì‰¬ë„¬<br>íˆ¬ìì ê´€ê³„ ë° ì¬ë¬´ ì»¤ë®¤ë‹ˆì¼€ì´ì…˜ ë¶€ì‚¬ì¥<br><br>í™˜ì˜í•©ë‹ˆë‹¤. ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì˜¤ì „ ë‹¹ì‚¬ëŠ” 2025ë…„ 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì ì— ëŒ€í•œ ìƒì„¸ ì •ë³´ê°€ ë‹´ê¸´ ë³´ë„ìë£Œë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ë³´ë„ìë£ŒëŠ” ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ pmi.comì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>A glossary of terms, including the definition for smoke-free products as well as adjustments, other calculations and reconciliations to the most directly comparable U.S. GAAP measures for non-GAAP financial measures cited in this presentation are available in the company's Form 8-K dated today's date and on our IR website. Today's remarks contain forward-looking statements and projections of future results. I direct your attention to the forward-looking and cautionary statements disclosure in today's presentation and press release for a review of the various factors that could cause actual results to differ materially from projections or forward-looking statements.</td><td>ìš©ì–´ì§‘ì—ëŠ” ë¬´ì—° ì œí’ˆì˜ ì •ì˜ì™€ ì¡°ì •ì‚¬í•­, ê¸°íƒ€ ê³„ì‚° ë° ë¹„GAAP ì¬ë¬´ì§€í‘œì™€ ê°€ì¥ ì§ì ‘ì ìœ¼ë¡œ ë¹„êµ ê°€ëŠ¥í•œ ë¯¸êµ­ GAAP ê¸°ì¤€ê³¼ì˜ ì¡°ì •ë‚´ì—­ì´ í¬í•¨ë˜ì–´ ìˆìœ¼ë©°, ì´ëŠ” ì˜¤ëŠ˜ ë‚ ì§œë¡œ ì œì¶œëœ íšŒì‚¬ì˜ Form 8-K ë° ë‹¹ì‚¬ IR ì›¹ì‚¬ì´íŠ¸ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ë°œí‘œ ë‚´ìš©ì—ëŠ” ë¯¸ë˜ ì‹¤ì ì— ëŒ€í•œ ì „ë§ ì§„ìˆ  ë° ì˜ˆì¸¡ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì‹¤ì œ ê²°ê³¼ê°€ ì˜ˆì¸¡ì´ë‚˜ ì „ë§ ì§„ìˆ ê³¼ ì¤‘ëŒ€í•˜ê²Œ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆëŠ” ë‹¤ì–‘í•œ ìš”ì¸ë“¤ì— ëŒ€í•œ ê²€í† ë¥¼ ìœ„í•´ ì˜¤ëŠ˜ ë°œí‘œìë£Œ ë° ë³´ë„ìë£Œì˜ ì „ë§ ì§„ìˆ  ë° ì£¼ì˜ì‚¬í•­ ê³µì‹œ ë¶€ë¶„ì„ ì°¸ê³ í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>I'm joined today by Jacek Olczak, Group CEO of PMI; and Emmanuel Babeau, Chief Financial Officer. Over to you, Jacek. Jacek Olczak<br>Group CEO & Director<br><br>Thank you, James, and welcome, everyone. 2025 was another outstanding year for PMI. The shift of adult smokers to better alternatives is the lasting structural movement, one that we continue to lead and from which we are generating strong sustained growth. Our leading global position in smoke-free products enables us to deliver a fifth consecutive year of positive volumes with a rapid topline progress and significant margin expansion.</td><td>ì˜¤ëŠ˜ ì €ì™€ í•¨ê»˜ PMIì˜ ê·¸ë£¹ CEOì¸ ì•¼ì²µ ì˜¬ì°¨í¬(Jacek Olczak)ì™€ ìµœê³ ì¬ë¬´ì±…ì„ì(CFO) ì— ë§ˆëˆ„ì—˜ ë°”ë³´(Emmanuel Babeau)ê°€ í•¨ê»˜ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•¼ì²µ, ì‹œì‘í•˜ì‹œì£ .<br><br>ì•¼ì²µ ì˜¬ì°¨í¬<br>ê·¸ë£¹ CEO ê²¸ ì´ì‚¬<br><br>ì œì„ìŠ¤, ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ëª¨ë‘ í™˜ì˜í•©ë‹ˆë‹¤. 2025ë…„ì€ PMIì—ê²Œ ë˜ ë‹¤ë¥¸ íƒì›”í•œ í•œ í•´ì˜€ìŠµë‹ˆë‹¤. ì„±ì¸ í¡ì—°ìë“¤ì˜ ë” ë‚˜ì€ ëŒ€ì•ˆìœ¼ë¡œì˜ ì „í™˜ì€ ì§€ì†ì ì¸ êµ¬ì¡°ì  ë³€í™”ì´ë©°, ìš°ë¦¬ëŠ” ì´ë¥¼ ê³„ì†í•´ì„œ ì„ ë„í•˜ê³  ìˆê³  ì´ë¡œë¶€í„° ê°•ë ¥í•˜ê³  ì§€ì†ì ì¸ ì„±ì¥ì„ ì°½ì¶œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬´ì—°(smoke-free) ì œí’ˆì—ì„œì˜ ìš°ë¦¬ì˜ ì„ ë„ì ì¸ ê¸€ë¡œë²Œ ì…ì§€ëŠ” 5ë…„ ì—°ì† ê¸ì •ì ì¸ íŒë§¤ëŸ‰ ì¦ê°€ì™€ í•¨ê»˜ ë¹ ë¥¸ ë§¤ì¶œ ì„±ì¥ ë° ìƒë‹¹í•œ ë§ˆì§„ í™•ëŒ€ë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆê²Œ í•´ì£¼ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We grew our smoke-free products volumes by an excellent 12.8% with the increasing profitability of the portfolio reflected in organic smoke-free gross profit growth of 18.7%. IQOS remains the core driver, with both shipments and adjusted IMS growing around 11%. This includes an impressive acceleration in the fourth quarter with a return to strong double-digit growth in Italy and a very promising start in Taiwan, just two examples of the broad growth across geographies. This performance also reflects the success of our multi-category strategy with both ZYN ex-Nordics and VEEV more than doubling shipment volumes in international markets.</td><td>ìš°ë¦¬ëŠ” ë¬´ì—° ì œí’ˆ íŒë§¤ëŸ‰ì„ 12.8%ë¼ëŠ” ë›°ì–´ë‚œ ì„±ì¥ë¥ ë¡œ í™•ëŒ€í–ˆìœ¼ë©°, í¬íŠ¸í´ë¦¬ì˜¤ì˜ ìˆ˜ìµì„± ì¦ê°€ëŠ” ë¬´ì—° ì œí’ˆ ìœ ê¸°ì  ë§¤ì¶œì´ì´ìµ 18.7% ì„±ì¥ì— ë°˜ì˜ë˜ì—ˆìŠµë‹ˆë‹¤. IQOSëŠ” ì—¬ì „íˆ í•µì‹¬ ì„±ì¥ ë™ë ¥ìœ¼ë¡œ, ì¶œí•˜ëŸ‰ê³¼ ì¡°ì • IMS ëª¨ë‘ ì•½ 11% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” 4ë¶„ê¸°ì˜ ì¸ìƒì ì¸ ê°€ì†í™”ê°€ í¬í•¨ë˜ì–´ ìˆëŠ”ë°, ì´íƒˆë¦¬ì•„ì—ì„œ ë‘ ìë¦¿ìˆ˜ ê°•ë ¥í•œ ì„±ì¥ì„¸ë¡œ ë³µê·€í–ˆê³  ëŒ€ë§Œì—ì„œ ë§¤ìš° ìœ ë§í•œ ì¶œë°œì„ ë³´ì˜€ìœ¼ë©°, ì´ëŠ” ì§€ì—­ ì „ë°˜ì— ê±¸ì¹œ ê´‘ë²”ìœ„í•œ ì„±ì¥ì˜ ë‘ ê°€ì§€ ì‚¬ë¡€ì— ë¶ˆê³¼í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì‹¤ì ì€ ë˜í•œ ìš°ë¦¬ì˜ ë‹¤ì¤‘ ì¹´í…Œê³ ë¦¬ ì „ëµì˜ ì„±ê³µì„ ë°˜ì˜í•˜ëŠ” ê²ƒìœ¼ë¡œ, ë¶ìœ ëŸ½ ì§€ì—­ ì™¸ ZYNê³¼ VEEV ëª¨ë‘ êµ­ì œ ì‹œì¥ì—ì„œ ì¶œí•˜ëŸ‰ì´ ë‘ ë°° ì´ìƒ ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our strong brand offering, which includes high-quality science-backed products in all 3 smoke-free products categories, allows us to better serve consumers and enhance our financial performance. While the nicotine pouch category remains nascent in most geographies, ZYN gained significant international share as we expanded the product portfolio and market reach. The more established e-vapor category, VEEV is the fastest-growing brand of any major player in international closed pods and holds the #1 position in 8 markets with a substantial increase in gross profit.</td><td>ìš°ë¦¬ì˜ ê°•ë ¥í•œ ë¸Œëœë“œ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” 3ê°€ì§€ ë¬´ì—° ì œí’ˆ ì¹´í…Œê³ ë¦¬ ëª¨ë‘ì—ì„œ ê³¼í•™ì ìœ¼ë¡œ ê²€ì¦ëœ ê³ í’ˆì§ˆ ì œí’ˆì„ í¬í•¨í•˜ê³  ìˆì–´, ì†Œë¹„ìë“¤ì—ê²Œ ë” ë‚˜ì€ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ê³  ì¬ë¬´ ì„±ê³¼ë¥¼ í–¥ìƒì‹œí‚¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë‹ˆì½”í‹´ íŒŒìš°ì¹˜ ì¹´í…Œê³ ë¦¬ëŠ” ëŒ€ë¶€ë¶„ì˜ ì§€ì—­ì—ì„œ ì—¬ì „íˆ ì´ˆê¸° ë‹¨ê³„ì— ìˆì§€ë§Œ, ZYNì€ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ì™€ ì‹œì¥ ë²”ìœ„ë¥¼ í™•ëŒ€í•˜ë©´ì„œ ìƒë‹¹í•œ êµ­ì œ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ë³´í–ˆìŠµë‹ˆë‹¤. ë³´ë‹¤ ì„±ìˆ™í•œ ì „ìë‹´ë°° ì¹´í…Œê³ ë¦¬ì—ì„œ VEEVëŠ” êµ­ì œ íì‡„í˜• í¬ë“œ ì‹œì¥ì˜ ì£¼ìš” ì—…ì²´ë“¤ ì¤‘ ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ë¸Œëœë“œì´ë©°, 8ê°œ ì‹œì¥ì—ì„œ 1ìœ„ë¥¼ ì°¨ì§€í•˜ê³  ìˆìœ¼ë©° ë§¤ì¶œì´ì´ìµì´ í¬ê²Œ ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Although our performance continues to be fueled by the international business, we generated the vast majority of total PMI organic net revenue growth led by SFPs. We have a substantial opportunity in the U.S., where ZYN grew shipments by 37% despite supply constraints in the first half, a significant price premium and the competitive portfolio gaps. Our Aspeya wellness business also grew organic net revenue strongly. Combustibles delivered robust top and bottom line performance, notwithstanding a more normalized industry volume decline and supply chain issues in Turkey.</td><td>ìš°ë¦¬ì˜ ì‹¤ì ì´ ê³„ì†í•´ì„œ êµ­ì œ ì‚¬ì—…ì— ì˜í•´ ê²¬ì¸ë˜ê³  ìˆì§€ë§Œ, ìš°ë¦¬ëŠ” SFP(ì—°ê¸° ì—†ëŠ” ì œí’ˆ)ê°€ ì£¼ë„í•˜ëŠ” ì „ì²´ PMI ìœ ê¸°ì  ìˆœë§¤ì¶œ ì„±ì¥ì˜ ëŒ€ë¶€ë¶„ì„ ì°½ì¶œí–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ì„œ ìƒë‹¹í•œ ê¸°íšŒê°€ ìˆìœ¼ë©°, ZYNì€ ìƒë°˜ê¸° ê³µê¸‰ ì œì•½, ìƒë‹¹í•œ ê°€ê²© í”„ë¦¬ë¯¸ì—„, ê·¸ë¦¬ê³  ê²½ìŸ í¬íŠ¸í´ë¦¬ì˜¤ ê³µë°±ì—ë„ ë¶ˆêµ¬í•˜ê³  ì¶œí•˜ëŸ‰ì´ 37% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ Aspeya ì›°ë‹ˆìŠ¤ ì‚¬ì—… ë˜í•œ ìœ ê¸°ì  ìˆœë§¤ì¶œì´ ê°•ë ¥í•˜ê²Œ ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ê°€ì—°ì„± ì œí’ˆì€ ë³´ë‹¤ ì •ìƒí™”ëœ ì—…ê³„ ë¬¼ëŸ‰ ê°ì†Œì™€ í„°í‚¤ì˜ ê³µê¸‰ë§ ë¬¸ì œì—ë„ ë¶ˆêµ¬í•˜ê³  ê²¬ê³ í•œ ë§¤ì¶œ ë° ìˆ˜ìµ ì‹¤ì ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We accomplished this with strong pricing, portfolio resilience and disciplined execution, with Marlboro reaching a historic high share. Managing this business responsibly enables us to invest boldly in better alternatives and sustain our smoke-free momentum. Together, these factors enabled us to deliver 15% adjusted diluted EPS growth in dollar terms, the strongest growth since 2011, excluding the pandemic recovery year of 2021. This reflects currency-neutral growth of 14%, well above our expectations at the start of the year and the second year of mid-teens progress. Indeed, we have successfully achieved our 3-year CAGR targets for organic OI and currency-neutral EPS in 2 years.</td><td>ìš°ë¦¬ëŠ” ê°•ë ¥í•œ ê°€ê²© ì •ì±…, í¬íŠ¸í´ë¦¬ì˜¤ íšŒë³µë ¥, ê·¸ë¦¬ê³  ê·œìœ¨ ìˆëŠ” ì‹¤í–‰ì„ í†µí•´ ì´ë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, ë§ë³´ë¡œëŠ” ì—­ì‚¬ì  ìµœê³  ì ìœ ìœ¨ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ ì‚¬ì—…ì„ ì±…ì„ê° ìˆê²Œ ê´€ë¦¬í•¨ìœ¼ë¡œì¨ ìš°ë¦¬ëŠ” ë” ë‚˜ì€ ëŒ€ì•ˆì— ê³¼ê°í•˜ê²Œ íˆ¬ìí•˜ê³  ë¬´ì—°(smoke-free) ëª¨ë©˜í…€ì„ ì§€ì†í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìš”ì¸ë“¤ì´ ê²°í•©ë˜ì–´ ìš°ë¦¬ëŠ” ë‹¬ëŸ¬ ê¸°ì¤€ìœ¼ë¡œ 15%ì˜ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ(adjusted diluted EPS) ì„±ì¥ì„ ë‹¬ì„±í•  ìˆ˜ ìˆì—ˆìœ¼ë©°, ì´ëŠ” íŒ¬ë°ë¯¹ íšŒë³µì˜ í•´ì¸ 2021ë…„ì„ ì œì™¸í•˜ë©´ 2011ë…„ ì´í›„ ê°€ì¥ ê°•ë ¥í•œ ì„±ì¥ì…ë‹ˆë‹¤. ì´ëŠ” í™˜ìœ¨ì¤‘ë¦½ ê¸°ì¤€ìœ¼ë¡œ 14%ì˜ ì„±ì¥ì„ ë°˜ì˜í•˜ëŠ” ê²ƒìœ¼ë¡œ, ì—°ì´ˆ ìš°ë¦¬ì˜ ì˜ˆìƒì„ í›¨ì”¬ ìƒíšŒí•˜ë©° 2ë…„ ì—°ì† 10%ëŒ€ ì¤‘ë°˜ì˜ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ìš°ë¦¬ëŠ” ìœ ê¸°ì  ì˜ì—…ì´ìµ(organic OI)ê³¼ í™˜ìœ¨ì¤‘ë¦½ EPSì— ëŒ€í•œ 3ê°œë…„ ì—°í‰ê· ì„±ì¥ë¥ (CAGR) ëª©í‘œë¥¼ 2ë…„ ë§Œì— ì„±ê³µì ìœ¼ë¡œ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With another strong performance expected in 2026, despite some transitory headwinds, we are today renewing these growth targets for the next 3 years, further validating our best-in-class growth profile within the consumer packaged goods. Importantly, this is accompanied by strong and increasing cash generation, and we target a leverage ratio of close to 2x by the end of 2026 at prevailing exchange rates. With our dividend payout now close to our objective of around 75% of adjusted diluted EPS, this provides capacity for strong returns to shareholders.</td><td>2026ë…„ì—ë„ ì¼ë¶€ ì¼ì‹œì ì¸ ì—­í’ì—ë„ ë¶ˆêµ¬í•˜ê³  ë˜ ë‹¤ë¥¸ ê°•ë ¥í•œ ì‹¤ì ì´ ì˜ˆìƒë¨ì— ë”°ë¼, ì˜¤ëŠ˜ ìš°ë¦¬ëŠ” í–¥í›„ 3ë…„ê°„ì˜ ì´ëŸ¬í•œ ì„±ì¥ ëª©í‘œë¥¼ ì¬í™•ì¸í•˜ë©°, ì†Œë¹„ì¬ ì‚°ì—… ë‚´ì—ì„œ ìš°ë¦¬ì˜ ë™ì¢… ìµœê³  ìˆ˜ì¤€ì˜ ì„±ì¥ í”„ë¡œí•„ì„ ë”ìš± ì…ì¦í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¤‘ìš”í•œ ì ì€, ì´ê²ƒì´ ê°•ë ¥í•˜ê³  ì¦ê°€í•˜ëŠ” í˜„ê¸ˆ ì°½ì¶œì„ ë™ë°˜í•œë‹¤ëŠ” ê²ƒì´ë©°, ìš°ë¦¬ëŠ” í˜„í–‰ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ 2026ë…„ ë§ê¹Œì§€ ë ˆë²„ë¦¬ì§€ ë¹„ìœ¨ì„ 2ë°° ìˆ˜ì¤€ì— ê·¼ì ‘í•˜ë„ë¡ ëª©í‘œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë°°ë‹¹ì„±í–¥ì´ ì´ì œ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµì˜ ì•½ 75%ë¼ëŠ” ìš°ë¦¬ì˜ ëª©í‘œì— ê·¼ì ‘í•¨ì— ë”°ë¼, ì´ëŠ” ì£¼ì£¼ë“¤ì—ê²Œ ê°•ë ¥í•œ ìˆ˜ìµì„ í™˜ì›í•  ìˆ˜ ìˆëŠ” ì—¬ë ¥ì„ ì œê³µí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Before I turn it over to Emmanuel, I would like to highlight the achievement of several important milestones as we entered the second decade of our smoke-free journey. Our total net revenues reached over $40 billion in 2025 with 41.5% or close to $17 billion generated by our smoke-free business. Even more impressive is the smoke-free gross profit contribution, which has essentially doubled in 5 years to 43% of total PMI. Our adjusted operating margin also returned to above 40% this year as our transformation expands profitably.</td><td>ì— ë§ˆë‰´ì—˜ì—ê²Œ ë„˜ê¸°ê¸° ì „ì—, ìš°ë¦¬ê°€ ë¹„ì—°ì†Œ ì‚¬ì—… ì—¬ì •ì˜ ë‘ ë²ˆì§¸ 10ë…„ì— ì§„ì…í•˜ë©´ì„œ ë‹¬ì„±í•œ ëª‡ ê°€ì§€ ì¤‘ìš”í•œ ì´ì •í‘œë¥¼ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. 2025ë…„ ìš°ë¦¬ì˜ ì´ ìˆœë§¤ì¶œì€ 400ì–µ ë‹¬ëŸ¬ë¥¼ ë„˜ì–´ì„°ìœ¼ë©°, ì´ ì¤‘ 41.5% ì¦‰ ì•½ 170ì–µ ë‹¬ëŸ¬ê°€ ë¹„ì—°ì†Œ ì‚¬ì—…ì—ì„œ ì°½ì¶œë˜ì—ˆìŠµë‹ˆë‹¤. ë”ìš± ì¸ìƒì ì¸ ê²ƒì€ ë¹„ì—°ì†Œ ì‚¬ì—…ì˜ ë§¤ì¶œì´ì´ìµ ê¸°ì—¬ë„ì¸ë°, ì´ëŠ” 5ë…„ ë§Œì— ì‚¬ì‹¤ìƒ ë‘ ë°° ì¦ê°€í•˜ì—¬ ì „ì²´ PMIì˜ 43%ë¥¼ ì°¨ì§€í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ë˜í•œ ìš°ë¦¬ì˜ ì¡°ì • ì˜ì—…ì´ìµë¥ ë„ ì˜¬í•´ 40% ì´ìƒìœ¼ë¡œ íšŒë³µë˜ì—ˆëŠ”ë°, ì´ëŠ” ìš°ë¦¬ì˜ ì‚¬ì—… ì „í™˜ì´ ìˆ˜ìµì„± ìˆê²Œ í™•ëŒ€ë˜ê³  ìˆìŒì„ ë³´ì—¬ì¤ë‹ˆë‹¤.</td></tr>
<tr><td>Our business is increasingly smoke-free, with 27 markets exceeding the 50% net revenue milestone, including South Korea, Poland, Italy, Romania and of course, the U.S., which is also 1 of 8 markets exceeding 75%. In last quarter of 2025, the Europe region also surpassed 50%, making 3 out of 4 regional segments majority smoke-free. We continued to scale our global smoke-free presence, reaching 106 markets, 52 of which have already deployed a multi-category strategy, which is a critical accelerator of consumer adoption and long-term growth. As adult nicotine consumers search for better alternatives to smoking, we continue to lead the broader industry transformation.</td><td>ìš°ë¦¬ ì‚¬ì—…ì€ ì ì  ë” ë¹„ì—°ì†Œ ì œí’ˆ ì¤‘ì‹¬ìœ¼ë¡œ ì „í™˜ë˜ê³  ìˆìœ¼ë©°, 27ê°œ ì‹œì¥ì—ì„œ ìˆœë§¤ì¶œì˜ 50% ì´ì •í‘œë¥¼ ì´ˆê³¼í–ˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” í•œêµ­, í´ë€ë“œ, ì´íƒˆë¦¬ì•„, ë£¨ë§ˆë‹ˆì•„, ê·¸ë¦¬ê³  ë¬¼ë¡  ë¯¸êµ­ì´ í¬í•¨ë˜ëŠ”ë°, ë¯¸êµ­ì€ 75%ë¥¼ ì´ˆê³¼í•œ 8ê°œ ì‹œì¥ ì¤‘ í•˜ë‚˜ì´ê¸°ë„ í•©ë‹ˆë‹¤. 2025ë…„ ë§ˆì§€ë§‰ ë¶„ê¸°ì—ëŠ” ìœ ëŸ½ ì§€ì—­ë„ 50%ë¥¼ ë„˜ì–´ì„œë©´ì„œ 4ê°œ ì§€ì—­ ë¶€ë¬¸ ì¤‘ 3ê°œê°€ ë¹„ì—°ì†Œ ì œí’ˆì´ ê³¼ë°˜ì„ ì°¨ì§€í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê¸€ë¡œë²Œ ë¹„ì—°ì†Œ ì œí’ˆ ì‚¬ì—…ì„ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•˜ì—¬ 106ê°œ ì‹œì¥ì— ì§„ì¶œí–ˆìœ¼ë©°, ì´ ì¤‘ 52ê°œ ì‹œì¥ì—ì„œëŠ” ì´ë¯¸ ë‹¤ì¤‘ ì¹´í…Œê³ ë¦¬ ì „ëµì„ êµ¬ì¶•í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì†Œë¹„ì ì±„íƒê³¼ ì¥ê¸° ì„±ì¥ì˜ í•µì‹¬ ê°€ì† ìš”ì¸ì…ë‹ˆë‹¤. ì„±ì¸ ë‹ˆì½”í‹´ ì†Œë¹„ìë“¤ì´ í¡ì—°ì— ëŒ€í•œ ë” ë‚˜ì€ ëŒ€ì•ˆì„ ì°¾ìœ¼ë©´ì„œ, ìš°ë¦¬ëŠ” ê´‘ë²”ìœ„í•œ ì—…ê³„ ì „í™˜ì„ ê³„ì† ì„ ë„í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>A prime example is Japan, where the heat-not-burn category crossed the 50% total industry threshold in December, driven by the undiminished strength of IQOS. Across our 106 smoke-free markets, our double-digit adjusted IMS volume growth continues to outpace the industry, demonstrating the collective strength of our leading brands. While we are proud of what we have accomplished so far, our focus remains sharply on the future, with an exciting pipeline of initiatives and innovations over the next 3 years. This is supported by increasing digitalization and our new organizational model.</td><td>ëŒ€í‘œì ì¸ ì˜ˆê°€ ì¼ë³¸ì…ë‹ˆë‹¤. ì¼ë³¸ì—ì„œëŠ” IQOSì˜ ë³€í•¨ì—†ëŠ” ê°•ì„¸ì— í˜ì…ì–´ 12ì›”ì— ê¶ë ¨í˜• ì „ìë‹´ë°° ì¹´í…Œê³ ë¦¬ê°€ ì „ì²´ ì—…ê³„ì˜ 50% ê¸°ì¤€ì ì„ ë„˜ì–´ì„°ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ì˜ 106ê°œ ë¬´ì—° ì‹œì¥ ì „ë°˜ì— ê±¸ì³, ë‘ ìë¦¿ìˆ˜ ì¡°ì • IMS íŒë§¤ëŸ‰ ì¦ê°€ì„¸ê°€ ì—…ê³„ë¥¼ ì§€ì†ì ìœ¼ë¡œ ì•ì§€ë¥´ê³  ìˆìœ¼ë©°, ì´ëŠ” ë‹¹ì‚¬ ì„ ë„ ë¸Œëœë“œë“¤ì˜ ì¢…í•©ì ì¸ ê°•ì ì„ ì…ì¦í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ ì´ë£¬ ì„±ê³¼ì— ìë¶€ì‹¬ì„ ëŠë¼ì§€ë§Œ, í–¥í›„ 3ë…„ê°„ í¥ë¯¸ë¡œìš´ ì´ë‹ˆì…”í‹°ë¸Œì™€ í˜ì‹  íŒŒì´í”„ë¼ì¸ì„ í†µí•´ ë¯¸ë˜ì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì¦ê°€í•˜ëŠ” ë””ì§€í„¸í™”ì™€ ìƒˆë¡œìš´ ì¡°ì§ ëª¨ë¸ì˜ ì§€ì›ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With that, I will hand over to Emmanuel to discuss our results and outlook in more detail, and I will come back at the end of this presentation. Emmanuel Babeau<br>Group Chief Financial Officer<br><br>Thank you, Jacek. I will begin with the headline financials for the year, which were indeed impressive. Organic top line and operating income growth were in line with our forecast ranges set at the start of 2025, and currency-neutral adjusted diluted EPS growth exceeded with expectation by 1.7 points.</td><td>ì´ì œ Emmanuelì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê²¨ ì‹¤ì ê³¼ ì „ë§ì— ëŒ€í•´ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ë„ë¡ í•˜ê² ìœ¼ë©°, í”„ë ˆì  í…Œì´ì…˜ ë§ˆì§€ë§‰ì— ë‹¤ì‹œ ëŒì•„ì˜¤ê² ìŠµë‹ˆë‹¤.<br><br>Emmanuel Babeau<br>ê·¸ë£¹ ìµœê³ ì¬ë¬´ì±…ì„ì(CFO)<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Jacek. ì˜¬í•´ì˜ ì£¼ìš” ì¬ë¬´ ì‹¤ì ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì •ë§ ì¸ìƒì ì¸ ê²°ê³¼ì˜€ìŠµë‹ˆë‹¤. ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥ ê³¼ ì˜ì—…ì´ìµ ì„±ì¥ë¥ ì€ 2025ë…„ ì´ˆ ì„¤ì •í•œ ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì— ë¶€í•©í–ˆìœ¼ë©°, í™˜ìœ¨ì¤‘ë¦½ ê¸°ì¤€ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ(EPS) ì„±ì¥ë¥ ì€ ì˜ˆìƒì¹˜ë¥¼ 1.7%p ìƒíšŒí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Positive shipment volumes, strong smoke-free category mix and pricing drove organic top line growth of plus 6.5% or plus 7.9% excluding the technical Indonesia impact, positioning us at the high end of our plus 6% to plus 8% midterm CAGR target. We delivered another year of double-digit organic operating income growth at plus 10.6%, above our midterm target range and reflecting plus 140 basis points of organic margin expansion. In dollar terms, adjusted operating income grew by plus 11.8% to $16.4 billion. Excellent currency-neutral adjusted diluted EPS growth of plus 14.2% was ahead of our expectation.</td><td>ê¸ì •ì ì¸ ì¶œí•˜ëŸ‰, ê°•ë ¥í•œ ë¬´ì—° ì œí’ˆ ì¹´í…Œê³ ë¦¬ ë¯¹ìŠ¤, ê·¸ë¦¬ê³  ê°€ê²© ì¸ìƒì— í˜ì…ì–´ ìœ ê¸°ì  ë§¤ì¶œì€ 6.5% ì¦ê°€í–ˆìœ¼ë©°, ì¸ë„ë„¤ì‹œì•„ ê¸°ìˆ ì  ìš”ì¸ì„ ì œì™¸í•˜ë©´ 7.9% ì„±ì¥í•˜ì—¬ ì¤‘ê¸° ì—°í‰ê· ì„±ì¥ë¥ (CAGR) ëª©í‘œì¹˜ì¸ 6%~8% ë²”ìœ„ì˜ ìƒë‹¨ì— ìœ„ì¹˜í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìœ ê¸°ì  ì˜ì—…ì´ìµì—ì„œ 10.6%ì˜ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë˜ë‹¤ì‹œ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ëŠ” ì¤‘ê¸° ëª©í‘œ ë²”ìœ„ë¥¼ ìƒíšŒí•˜ëŠ” ê²ƒìœ¼ë¡œ ìœ ê¸°ì  ë§ˆì§„ì´ 140bp í™•ëŒ€ëœ ê²ƒì„ ë°˜ì˜í•©ë‹ˆë‹¤. ë‹¬ëŸ¬ ê¸°ì¤€ìœ¼ë¡œ ì¡°ì • ì˜ì—…ì´ìµì€ 11.8% ì¦ê°€í•˜ì—¬ 164ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. í™˜ìœ¨ ì¤‘ë¦½ ê¸°ì¤€ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ(EPS)ì€ 14.2%ì˜ ìš°ìˆ˜í•œ ì„±ì¥ë¥ ì„ ë³´ì´ë©° ìš°ë¦¬ì˜ ì˜ˆìƒì„ ìƒíšŒí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This was driven by strong underlying business performance, notably in international multi-category and incombustible, coupled with a more favorable effective tax rate and lower net financing costs. In dollar terms, adjusted diluted EPS of $7.54 was at the high end of our last guidance range despite a lower-than-expected currency tailwind of $0.04 due to nonrecurring transactional losses in Q4 largely related to the Russian ruble and the Swiss franc. Robust cash generation enabled us to deliver operating cash flow of $12.2 billion, matching the record delivery of 2024.</td><td>ì´ëŠ” êµ­ì œ ë©€í‹°ì¹´í…Œê³ ë¦¬ì™€ ë¹„ì—°ì†Œ ì œí’ˆ ë¶€ë¬¸ì˜ ê°•ë ¥í•œ ê¸°ë³¸ ì‚¬ì—… ì„±ê³¼ì™€ ë”ë¶ˆì–´ ë³´ë‹¤ ìœ ë¦¬í•œ ì‹¤íš¨ì„¸ìœ¨ ë° ìˆœê¸ˆìœµë¹„ìš© ê°ì†Œì— ê¸°ì¸í•œ ê²ƒì…ë‹ˆë‹¤. ë‹¬ëŸ¬ ê¸°ì¤€ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµì€ 7.54ë‹¬ëŸ¬ë¡œ ìµœê·¼ ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì˜ ìƒë‹¨ì— ìœ„ì¹˜í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” 4ë¶„ê¸°ì— ëŸ¬ì‹œì•„ ë£¨ë¸”í™”ì™€ ìŠ¤ìœ„ìŠ¤ í”„ë‘ ê´€ë ¨ ë¹„ê²½ìƒì  ê±°ë˜ ì†ì‹¤ë¡œ ì¸í•´ ì˜ˆìƒë³´ë‹¤ ë‚®ì€ 0.04ë‹¬ëŸ¬ì˜ í™˜ìœ¨ ìˆœí’íš¨ê³¼ì—ë„ ë¶ˆêµ¬í•˜ê³  ë‹¬ì„±í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ê²¬ê³ í•œ í˜„ê¸ˆì°½ì¶œë ¥ ë•ë¶„ì— 122ì–µ ë‹¬ëŸ¬ì˜ ì˜ì—…í˜„ê¸ˆíë¦„ì„ ë‹¬ì„±í•˜ì—¬ 2024ë…„ì˜ ê¸°ë¡ì ì¸ ì‹¤ì ê³¼ ë™ë“±í•œ ìˆ˜ì¤€ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Now looking at Q4 specifically, while growth rates were below the overall year, partly due to the shipment and phasing factors outlined last quarter, underlying performance was ahead of our expectations. This enabled us to deliver almost plus 10% in adjusted diluted earnings per share growth to $1.70 or plus 9%, excluding a $0.01 currency tailwind. I will now cover our 2025 performance in more detail, starting with volumes. As Jacek mentioned, we delivered our fifth consecutive year of positive volumes with total shipment growth of plus 1.4%.</td><td>ì´ì œ 4ë¶„ê¸°ë¥¼ êµ¬ì²´ì ìœ¼ë¡œ ì‚´í´ë³´ë©´, ì„±ì¥ë¥ ì´ ì—°ê°„ ì „ì²´ ì‹¤ì ë³´ë‹¤ ë‚®ì•˜ëŠ”ë°, ì´ëŠ” ë¶€ë¶„ì ìœ¼ë¡œ ì§€ë‚œ ë¶„ê¸°ì— ì„¤ëª…ë“œë¦° ì¶œí•˜ ë° ì‹œê¸°ì  ìš”ì¸ ë•Œë¬¸ì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ê¸°ì € ì‹¤ì ì€ ìš°ë¦¬ì˜ ì˜ˆìƒì„ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµì´ ê±°ì˜ 10% ì¦ê°€í•œ 1.70ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, 0.01ë‹¬ëŸ¬ì˜ í™˜ìœ¨ í˜¸ì¬ë¥¼ ì œì™¸í•˜ë©´ 9% ì„±ì¥ì…ë‹ˆë‹¤. ì´ì œ ë¬¼ëŸ‰ë¶€í„° ì‹œì‘í•˜ì—¬ 2025ë…„ ì‹¤ì ì„ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Jacekì´ ì–¸ê¸‰í–ˆë“¯ì´, ìš°ë¦¬ëŠ” 5ë…„ ì—°ì† í”ŒëŸ¬ìŠ¤ ë¬¼ëŸ‰ ì„±ì¥ì„ ë‹¬ì„±í–ˆìœ¼ë©° ì´ ì¶œí•˜ëŸ‰ì€ 1.4% ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This was driven by the continued dynamism of our smoke-free business, which generated more than 100 billion incremental units over the past 5 years, combined with a very resilient cigarette performance. In 2025, smoke-free shipments grew plus 12.8% or plus 20 billion units to 179 billion, more than offsetting the 1.5% decline in cigarette shipments. All smoke-free categories grew strongly, with IQOS HTU shipment growth of plus 11% to 155 billion units. VEEV, plus 102% to 3.3 billion equivalent units and oral smoke-free product, plus 18.5% to 20.7 billion units. Notably, this includes plus 37% growth from U.S.</td><td>ì´ëŠ” ì§€ë‚œ 5ë…„ê°„ 1,000ì–µ ê°œë¹„ ì´ìƒì˜ ì¦ë¶„ ë¬¼ëŸ‰ì„ ì°½ì¶œí•œ ë¬´ì—° ì‚¬ì—…ì˜ ì§€ì†ì ì¸ ì—­ë™ì„±ê³¼ ë§¤ìš° íšŒë³µë ¥ ìˆëŠ” ê¶ë ¨ ì‹¤ì ì´ ê²°í•©ëœ ê²°ê³¼ì…ë‹ˆë‹¤. 2025ë…„ ë¬´ì—° ì œí’ˆ ì¶œí•˜ëŸ‰ì€ ì „ë…„ ëŒ€ë¹„ 12.8% ë˜ëŠ” 200ì–µ ê°œë¹„ ì¦ê°€í•œ 1,790ì–µ ê°œë¹„ë¥¼ ê¸°ë¡í•˜ì—¬ ê¶ë ¨ ì¶œí•˜ëŸ‰ 1.5% ê°ì†Œë¶„ì„ ì¶©ë¶„íˆ ìƒì‡„í–ˆìŠµë‹ˆë‹¤. ëª¨ë“  ë¬´ì—° ì¹´í…Œê³ ë¦¬ê°€ ê°•ë ¥í•˜ê²Œ ì„±ì¥í–ˆìœ¼ë©°, IQOS ê°€ì—´ë‹´ë°° ì¶œí•˜ëŸ‰ì€ 11% ì¦ê°€í•œ 1,550ì–µ ê°œë¹„ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. VEEVëŠ” 102% ì¦ê°€í•œ 33ì–µ ë“±ê°€ ê°œë¹„, êµ¬ê°•ìš© ë¬´ì—° ì œí’ˆì€ 18.5% ì¦ê°€í•œ 207ì–µ ê°œë¹„ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. íŠ¹íˆ ì—¬ê¸°ì—ëŠ” ë¯¸êµ­ì—ì„œì˜ 37% ì„±ì¥ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>ZYN to 11.9 billion pouches, making up close to 7% of total smoke-free product volumes. As expected, adjusted IMS growth for IQOS HTU accelerated in Q4 to plus 12%, while shipment volumes were impacted by the dynamic flagged last quarter and grew by plus 7.5%. Notwithstanding this impact, total Q4 smoke-free product volume increased by a healthy plus 8.5%. The full year cigarette volume decline of 1.5% was slightly better than our expectation of around 2%, with our category share performance in the second half proving resilient in several markets, including Egypt and India.</td><td>ZYNì€ 119ì–µ ê°œì˜ íŒŒìš°ì¹˜ë¥¼ ê¸°ë¡í•˜ë©° ì „ì²´ ë¬´ì—° ì œí’ˆ ë¬¼ëŸ‰ì˜ ì•½ 7%ë¥¼ ì°¨ì§€í–ˆìŠµë‹ˆë‹¤. ì˜ˆìƒëŒ€ë¡œ IQOS HTUì˜ ì¡°ì • IMS ì„±ì¥ë¥ ì€ 4ë¶„ê¸°ì— í”ŒëŸ¬ìŠ¤ 12%ë¡œ ê°€ì†í™”ë˜ì—ˆìœ¼ë©°, ì¶œí•˜ ë¬¼ëŸ‰ì€ ì§€ë‚œ ë¶„ê¸°ì— ì–¸ê¸‰ëœ ì—­í•™ì  ìš”ì¸ì˜ ì˜í–¥ì„ ë°›ì•„ í”ŒëŸ¬ìŠ¤ 7.5% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì˜í–¥ì—ë„ ë¶ˆêµ¬í•˜ê³  4ë¶„ê¸° ì „ì²´ ë¬´ì—° ì œí’ˆ ë¬¼ëŸ‰ì€ í”ŒëŸ¬ìŠ¤ 8.5%ì˜ ê²¬ì¡°í•œ ì¦ê°€ì„¸ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ì—°ê°„ ë‹´ë°° ë¬¼ëŸ‰ ê°ì†Œìœ¨ì€ 1.5%ë¡œ ë‹¹ì‚¬ì˜ ì˜ˆìƒì¹˜ì¸ ì•½ 2%ë³´ë‹¤ ì†Œí­ ì–‘í˜¸í–ˆìœ¼ë©°, í•˜ë°˜ê¸° ì¹´í…Œê³ ë¦¬ ì ìœ ìœ¨ ì‹¤ì ì€ ì´ì§‘íŠ¸ì™€ ì¸ë„ë¥¼ í¬í•¨í•œ ì—¬ëŸ¬ ì‹œì¥ì—ì„œ íšŒë³µë ¥ì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The total international cigarette industry, excluding China, declined by an estimated 1.1% with continued divergence between markets where smoke-free products are available, which declined by around 3%, and markets where smoke-free products are not permitted or still at low level of penetration, which were broadly flat. The composition of our 2025 top line performance was extremely consistent with the 5-year average of each key component, demonstrating the sustainability of these dynamic drivers. Continued volume growth is the first pillar of our growth model. The second is pricing, which contributed plus 4.1 points.</td><td>ì¤‘êµ­ì„ ì œì™¸í•œ ì „ì²´ êµ­ì œ ë‹´ë°° ì‚°ì—…ì€ ì•½ 1.1% ê°ì†Œí•œ ê²ƒìœ¼ë¡œ ì¶”ì •ë˜ë©°, ë¬´ì—° ì œí’ˆì´ íŒë§¤ë˜ëŠ” ì‹œì¥(ì•½ 3% ê°ì†Œ)ê³¼ ë¬´ì—° ì œí’ˆì´ í—ˆìš©ë˜ì§€ ì•Šê±°ë‚˜ ì¹¨íˆ¬ìœ¨ì´ ì—¬ì „íˆ ë‚®ì€ ì‹œì¥(ëŒ€ì²´ë¡œ ë³´í•©ì„¸) ê°„ì˜ ê²©ì°¨ê°€ ì§€ì†ë˜ì—ˆìŠµë‹ˆë‹¤. 2025ë…„ ë‹¹ì‚¬ ë§¤ì¶œ ì„±ê³¼ì˜ êµ¬ì„±ì€ ê° í•µì‹¬ ìš”ì†Œì˜ 5ê°œë…„ í‰ê· ê³¼ ë§¤ìš° ì¼ê´€ë˜ì–´, ì´ëŸ¬í•œ ì—­ë™ì  ì„±ì¥ ë™ë ¥ì˜ ì§€ì†ê°€ëŠ¥ì„±ì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤. ì§€ì†ì ì¸ íŒë§¤ëŸ‰ ì„±ì¥ì€ ë‹¹ì‚¬ ì„±ì¥ ëª¨ë¸ì˜ ì²« ë²ˆì§¸ ì¶•ì…ë‹ˆë‹¤. ë‘ ë²ˆì§¸ëŠ” ê°€ê²© ì¸ìƒìœ¼ë¡œ, 4.1%í¬ì¸íŠ¸ë¥¼ ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The 2025 impact reflect plus 7.6% pricing from combustible and low single-digit pricing on IQOS, partly offset by the H2 normalization of U.S. ZYN promotional activities. The third pillar of growth is smoke-free mix, which contributed plus 3.5 points in 2025. Combustible geographic mix and other factors had an unfavorable impact of 1.1 points, whereas currency and scope effect added plus 0.8 points. Breaking down our full year performance by category. Both smoke-free and combustible contributed to our strong net revenue and gross profit delivery, with gross margin expanding organically by plus 220 basis points to over 67%.</td><td>2025ë…„ ì˜í–¥ì€ ê°€ì—°ì„± ì œí’ˆì˜ +7.6% ê°€ê²© ì¸ìƒê³¼ IQOSì˜ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ê°€ê²© ì¸ìƒì„ ë°˜ì˜í•˜ë©°, ì´ëŠ” ë¯¸êµ­ ZYNì˜ í•˜ë°˜ê¸° í”„ë¡œëª¨ì…˜ í™œë™ ì •ìƒí™”ë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. ì„¸ ë²ˆì§¸ ì„±ì¥ ë™ë ¥ì€ ë¬´ì—° ì œí’ˆ ë¯¹ìŠ¤ë¡œ, 2025ë…„ì— +3.5%p ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. ê°€ì—°ì„± ì œí’ˆì˜ ì§€ì—­ë³„ ë¯¹ìŠ¤ ë° ê¸°íƒ€ ìš”ì¸ë“¤ì€ 1.1%pì˜ ë¶€ì •ì  ì˜í–¥ì„ ë¯¸ì³¤ìœ¼ë©°, í™˜ìœ¨ ë° ë²”ìœ„ íš¨ê³¼ëŠ” +0.8%pë¥¼ ì¶”ê°€í–ˆìŠµë‹ˆë‹¤. <br><br>ì¹´í…Œê³ ë¦¬ë³„ ì—°ê°„ ì‹¤ì ì„ ë¶„ì„í•˜ë©´, ë¬´ì—° ì œí’ˆê³¼ ê°€ì—°ì„± ì œí’ˆ ëª¨ë‘ ê°•ë ¥í•œ ìˆœë§¤ì¶œê³¼ ë§¤ì¶œì´ì´ìµ ë‹¬ì„±ì— ê¸°ì—¬í–ˆìœ¼ë©°, ë§¤ì¶œì´ì´ìµë¥ ì€ ìœ ê¸°ì ìœ¼ë¡œ +220bp í™•ëŒ€ë˜ì–´ 67%ë¥¼ ë„˜ì–´ì„°ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Smoke-free net revenue grew organically by plus 14.1%, while gross profit advanced by plus 18.7%. As a result, adjusted gross margin increased by 270 basis points to reach 69.5%, further widening the gap to combustible to 4 points for the year. IQOS was again the primary driver of this performance, combining global top line momentum with increasing scale and cost efficiencies. VEEV's improving profitability also contributed positively. And while the normalization of U.S. ZYN commercial activity in H2 had a dilutive year-over-year impact, its gross margins remain best-in-class, above the average of our IQOS business, including in Q4.</td><td>ë¬´ì—° ì œí’ˆ ìˆœë§¤ì¶œì€ ìœ ê¸°ì ìœ¼ë¡œ 14.1% ì„±ì¥í–ˆìœ¼ë©°, ë§¤ì¶œì´ì´ìµì€ 18.7% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ê·¸ ê²°ê³¼, ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ ì€ 270bp ìƒìŠ¹í•˜ì—¬ 69.5%ë¥¼ ê¸°ë¡í–ˆê³ , ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ê°€ì—°ì„± ì œí’ˆê³¼ì˜ ê²©ì°¨ë¥¼ 4%pê¹Œì§€ í™•ëŒ€í–ˆìŠµë‹ˆë‹¤. IQOSê°€ ë‹¤ì‹œ í•œë²ˆ ì´ëŸ¬í•œ ì‹¤ì ì˜ ì£¼ìš” ë™ë ¥ì´ ë˜ì—ˆìœ¼ë©°, ê¸€ë¡œë²Œ ë§¤ì¶œ ì„±ì¥ ëª¨ë©˜í…€ê³¼ ê·œëª¨ì˜ ê²½ì œ ë° ë¹„ìš© íš¨ìœ¨ì„± ì¦ëŒ€ë¥¼ ê²°í•©í–ˆìŠµë‹ˆë‹¤. VEEVì˜ ìˆ˜ìµì„± ê°œì„ ë„ ê¸ì •ì ìœ¼ë¡œ ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í•˜ë°˜ê¸° ë¯¸êµ­ ZYNì˜ ìƒì—… í™œë™ ì •ìƒí™”ê°€ ì „ë…„ ëŒ€ë¹„ í¬ì„ íš¨ê³¼ë¥¼ ê°€ì ¸ì™”ì§€ë§Œ, 4ë¶„ê¸°ë¥¼ í¬í•¨í•˜ì—¬ ZYNì˜ ë§¤ì¶œì´ì´ìµë¥ ì€ ì—¬ì „íˆ ì—…ê³„ ìµœê³  ìˆ˜ì¤€ì„ ìœ ì§€í•˜ë©° IQOS ì‚¬ì—… í‰ê· ì„ ìƒíšŒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As mentioned last quarter, we expect this to be an enduring positive mix driver. Combustible performed well in 2025 with low single-digit top line growth and low to mid-single-digit gross profit growth, a proxy of what we expect this business to deliver over time. Strong pricing more than offset volume declines and unfavorable mix, with disciplined cost management supporting gross margin expansion of plus 160 basis points to reach 65.5%. Moving to operating margins. We delivered full year organic expansion of plus 140 basis points and plus 160 basis points in dollar terms to reach an adjusted operating income margin of 40.4%.</td><td>ì§€ë‚œ ë¶„ê¸°ì— ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì´ëŠ” ì§€ì†ì ì¸ ê¸ì •ì  ë¯¹ìŠ¤ íš¨ê³¼ ìš”ì¸ì´ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ê°€ì—°ì„± ì œí’ˆ ë¶€ë¬¸ì€ 2025ë…„ì— í•œ ìë¦¿ìˆ˜ ì´ˆë°˜ì˜ ë§¤ì¶œ ì„±ì¥ê³¼ í•œ ìë¦¿ìˆ˜ ì´ˆë°˜ì—ì„œ ì¤‘ë°˜ì˜ ë§¤ì¶œì´ì´ìµ ì„±ì¥ì„ ê¸°ë¡í•˜ë©° ì–‘í˜¸í•œ ì‹¤ì ì„ ë³´ì˜€ëŠ”ë°, ì´ëŠ” í–¥í›„ ì´ ì‚¬ì—…ë¶€ê°€ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ëŠ” ìˆ˜ì¤€ì„ ë³´ì—¬ì£¼ëŠ” ì§€í‘œì…ë‹ˆë‹¤. ê°•ë ¥í•œ ê°€ê²© ì •ì±…ì´ íŒë§¤ëŸ‰ ê°ì†Œì™€ ë¶ˆë¦¬í•œ ì œí’ˆ ë¯¹ìŠ¤ë¥¼ ìƒì‡„í•˜ê³ ë„ ë‚¨ì•˜ìœ¼ë©°, ê·œìœ¨ ìˆëŠ” ë¹„ìš© ê´€ë¦¬ë¥¼ í†µí•´ ë§¤ì¶œì´ì´ìµë¥ ì´ 160bp í™•ëŒ€ë˜ì–´ 65.5%ì— ë„ë‹¬í–ˆìŠµë‹ˆë‹¤. ì˜ì—…ì´ìµë¥ ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ìœ ê¸°ì  ì˜ì—…ì´ìµë¥ ì„ 140bp, ë‹¬ëŸ¬ ê¸°ì¤€ìœ¼ë¡œëŠ” 160bp í™•ëŒ€í•˜ì—¬ ì¡°ì • ì˜ì—…ì´ìµë¥  40.4%ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We achieved this in a year of strong investment in commercial, marketing and brand building behind our smoke-free portfolio, including international multi-category deployments and U.S. ZYN. We also continue to invest in expanding our U.S. capabilities to capture the substantial growth opportunities ahead. This performance was supported by a relentless focus on both cost of goods sold and back-office efficiency, enabling meaningful margin expansion even as we continue to invest for growth. We have delivered around $1.5 billion in gross cost savings since 2024, placing us firmly on track to achieve our $2 billion objective for the '24-'26 period.</td><td>ìš°ë¦¬ëŠ” êµ­ì œ ë©€í‹° ì¹´í…Œê³ ë¦¬ ì „ê°œì™€ ë¯¸êµ­ ZYNì„ í¬í•¨í•œ ë¬´ì—° í¬íŠ¸í´ë¦¬ì˜¤ì— ëŒ€í•œ ìƒì—…, ë§ˆì¼€íŒ… ë° ë¸Œëœë“œ êµ¬ì¶•ì— ëŒ€í•œ ê°•ë ¥í•œ íˆ¬ìê°€ ì´ë£¨ì–´ì§„ í•œ í•´ì— ì´ëŸ¬í•œ ì„±ê³¼ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë˜í•œ ìš°ë¦¬ëŠ” ì•ìœ¼ë¡œì˜ ìƒë‹¹í•œ ì„±ì¥ ê¸°íšŒë¥¼ í¬ì°©í•˜ê¸° ìœ„í•´ ë¯¸êµ­ ì—­ëŸ‰ í™•ì¥ì— ëŒ€í•œ íˆ¬ìë¥¼ ì§€ì†í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì‹¤ì ì€ ë§¤ì¶œì›ê°€ì™€ ë°±ì˜¤í”¼ìŠ¤ íš¨ìœ¨ì„± ëª¨ë‘ì— ëŒ€í•œ ëŠì„ì—†ëŠ” ì§‘ì¤‘ìœ¼ë¡œ ë’·ë°›ì¹¨ë˜ì—ˆìœ¼ë©°, ì´ë¥¼ í†µí•´ ì„±ì¥ì„ ìœ„í•œ íˆ¬ìë¥¼ ì§€ì†í•˜ë©´ì„œë„ ì˜ë¯¸ ìˆëŠ” ë§ˆì§„ í™•ëŒ€ë¥¼ ì‹¤í˜„í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” 2024ë…„ ì´í›„ ì•½ 15ì–µ ë‹¬ëŸ¬ì˜ ì´ ë¹„ìš© ì ˆê°ì„ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ëŠ” '24-'26ë…„ ê¸°ê°„ ë™ì•ˆ 20ì–µ ë‹¬ëŸ¬ ëª©í‘œë¥¼ ë‹¬ì„±í•˜ê¸° ìœ„í•œ í™•ê³ í•œ ê¶¤ë„ì— ì˜¬ë¼ ìˆìŒì„ ì˜ë¯¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Focusing now on our smoke-free business, where all categories have an important role to play. Our global presence continues to grow, with PMI smoke-free products now available in 106 markets. This includes the recent launch of ZYN in Argentina and IQOS in Taiwan. We increased the number of markets with all 3 categories to 26 compared with 9 markets 2 years ago. We continue to outpace the smoke-free market. Measured in the categories where we are present across these 106 markets, we delivered over plus 12% estimated in-market sales volume growth for the year compared to over 9% for the industry.</td><td>ì´ì œ ë¬´ì—° ì‚¬ì—…ì— ì§‘ì¤‘í•´ë³´ê² ìŠµë‹ˆë‹¤. ëª¨ë“  ì¹´í…Œê³ ë¦¬ê°€ ì¤‘ìš”í•œ ì—­í• ì„ ë‹´ë‹¹í•˜ê³  ìˆìŠµë‹ˆë‹¤. PMIì˜ ë¬´ì—° ì œí’ˆì€ í˜„ì¬ 106ê°œ ì‹œì¥ì—ì„œ íŒë§¤ë˜ê³  ìˆì–´ ê¸€ë¡œë²Œ ì…ì§€ê°€ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ìµœê·¼ ì•„ë¥´í—¨í‹°ë‚˜ì—ì„œì˜ ZYN ì¶œì‹œì™€ ëŒ€ë§Œì—ì„œì˜ IQOS ì¶œì‹œê°€ í¬í•¨ë©ë‹ˆë‹¤. 3ê°œ ì¹´í…Œê³ ë¦¬ ëª¨ë‘ë¥¼ ë³´ìœ í•œ ì‹œì¥ ìˆ˜ëŠ” 2ë…„ ì „ 9ê°œ ì‹œì¥ì—ì„œ 26ê°œ ì‹œì¥ìœ¼ë¡œ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¬´ì—° ì‹œì¥ì„ ê³„ì†í•´ì„œ ì•ì„œê°€ê³  ìˆìŠµë‹ˆë‹¤. ì´ë“¤ 106ê°œ ì‹œì¥ì—ì„œ ìš°ë¦¬ê°€ ì§„ì¶œí•œ ì¹´í…Œê³ ë¦¬ë¥¼ ê¸°ì¤€ìœ¼ë¡œ ì¸¡ì •í–ˆì„ ë•Œ, ì—…ê³„ ì „ì²´ì˜ 9% ì´ìƒ ì„±ì¥ì— ë¹„í•´ ìš°ë¦¬ëŠ” ì—°ê°„ 12% ì´ìƒì˜ ì‹œì¥ ë‚´ íŒë§¤ëŸ‰ ì„±ì¥ë¥ ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We estimate our volume share of smoke-free products on this basis is around 60%, and our 2025 share of category growth is over 70%. With our portfolio of leading premium brands, our share of smoke-free in value term is notably higher than 60%. As we expanded our portfolio and geographic reach, the number of legal age consumers of our smoke-free product, which an estimated 43.5 million as of December 31, an increase of around 10 million users in 2 years with broad-based growth across categories. IQOS adjusted IMS growth accelerated to an outstanding plus 12% in the fourth quarter, reflecting strong momentum across the globe and a presence now in 79 markets.</td><td>ì´ëŸ¬í•œ ê¸°ì¤€ìœ¼ë¡œ ì¶”ì •í•  ë•Œ, ë¹„ì—°ì†Œ ì œí’ˆì—ì„œ ë‹¹ì‚¬ì˜ ë¬¼ëŸ‰ ì ìœ ìœ¨ì€ ì•½ 60% ìˆ˜ì¤€ì´ë©°, 2025ë…„ ì¹´í…Œê³ ë¦¬ ì„±ì¥ì—ì„œ ë‹¹ì‚¬ê°€ ì°¨ì§€í•˜ëŠ” ë¹„ì¤‘ì€ 70%ë¥¼ ë„˜ì–´ì„­ë‹ˆë‹¤. ì„ ë„ì ì¸ í”„ë¦¬ë¯¸ì—„ ë¸Œëœë“œ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë³´ìœ í•œ ë•ë¶„ì—, ê°€ì¹˜ ê¸°ì¤€ ë¹„ì—°ì†Œ ì œí’ˆ ì ìœ ìœ¨ì€ 60%ë¥¼ í¬ê²Œ ìƒíšŒí•˜ê³  ìˆìŠµë‹ˆë‹¤. í¬íŠ¸í´ë¦¬ì˜¤ì™€ ì§€ë¦¬ì  ë²”ìœ„ë¥¼ í™•ëŒ€í•˜ë©´ì„œ, ë‹¹ì‚¬ ë¹„ì—°ì†Œ ì œí’ˆì˜ ì„±ì¸ ì†Œë¹„ì ìˆ˜ëŠ” 12ì›” 31ì¼ ê¸°ì¤€ ì•½ 4,350ë§Œ ëª…ìœ¼ë¡œ ì¶”ì •ë˜ë©°, ì´ëŠ” 2ë…„ ë§Œì— ì•½ 1,000ë§Œ ëª…ì´ ì¦ê°€í•œ ìˆ˜ì¹˜ë¡œ ì „ ì¹´í…Œê³ ë¦¬ì— ê±¸ì³ ê´‘ë²”ìœ„í•œ ì„±ì¥ì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. IQOS ì¡°ì • IMS ì„±ì¥ë¥ ì€ 4ë¶„ê¸°ì— ë†€ë¼ìš´ +12%ë¡œ ê°€ì†í™”ë˜ì—ˆìœ¼ë©°, ì´ëŠ” ì „ ì„¸ê³„ì ìœ¼ë¡œ ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ë°˜ì˜í•˜ëŠ” ê²ƒìœ¼ë¡œ í˜„ì¬ 79ê°œ ì‹œì¥ì— ì§„ì¶œí•´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>All regions contributed, as illustrated by exceptional performance in key cities such as Mexico City, Manila, Riyadh, Rome, London, Madrid and Munich. You can find further key city and European shared data in the appendix to these slides. This enabled us to achieve full year growth of plus 10.5%, within our target range. Annual adjusted IMS again increased by around 15 billion units despite the continued headwind of the EU characterizing flavor ban and a step-up in competitive intensity. Our global share of the heat-not-burn category remains impressively resilient at approximately 76%.</td><td>ëª¨ë“  ì§€ì—­ì´ ê¸°ì—¬í–ˆìœ¼ë©°, ë©•ì‹œì½”ì‹œí‹°, ë§ˆë‹ë¼, ë¦¬ì•¼ë“œ, ë¡œë§ˆ, ëŸ°ë˜, ë§ˆë“œë¦¬ë“œ, ë®Œí—¨ ë“± ì£¼ìš” ë„ì‹œì—ì„œì˜ íƒì›”í•œ ì‹¤ì ì´ ì´ë¥¼ ë³´ì—¬ì¤ë‹ˆë‹¤. ì£¼ìš” ë„ì‹œ ë° ìœ ëŸ½ ì ìœ ìœ¨ ë°ì´í„°ëŠ” ë³¸ ìŠ¬ë¼ì´ë“œì˜ ë¶€ë¡ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ëª©í‘œ ë²”ìœ„ ë‚´ì—ì„œ ì—°ê°„ 10.5% ì„±ì¥ì„ ë‹¬ì„±í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì—°ê°„ ì¡°ì • IMSëŠ” EUì˜ í–¥ë¯¸ íŠ¹ì„±í™” ê¸ˆì§€ë¼ëŠ” ì§€ì†ì ì¸ ì—­í’ê³¼ ê²½ìŸ ì‹¬í™”ì—ë„ ë¶ˆêµ¬í•˜ê³  ì•½ 150ì–µ ê°œë¹„ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ê¶ë ¨í˜• ì „ìë‹´ë°° ì¹´í…Œê³ ë¦¬ì—ì„œ ë‹¹ì‚¬ì˜ ê¸€ë¡œë²Œ ì ìœ ìœ¨ì€ ì•½ 76%ë¡œ ì¸ìƒì ì¸ íšŒë³µë ¥ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This is supported by brand engagement initiatives and continuous innovation across devices and consumables, including the continued introduction of ILUMA i to reach a total of 55 markets. Importantly, IQOS profitability continued to increase significantly, driven by pricing, scale and productivity improvements on consumable and device costs. This is illustrated by a substantial increase in product contribution over time. Turning to nicotine pouches. ZYN is the global #1 brand with a 2025 PMI category share of around 40% in pouch terms. The U.S. represent approximately 2/3 of the category today, while international market, though still relatively small, are growing rapidly.</td><td>ì´ëŠ” ë¸Œëœë“œ ì°¸ì—¬ ì´ë‹ˆì…”í‹°ë¸Œì™€ ê¸°ê¸° ë° ì†Œëª¨í’ˆ ì „ë°˜ì— ê±¸ì¹œ ì§€ì†ì ì¸ í˜ì‹ ìœ¼ë¡œ ë’·ë°›ì¹¨ë˜ë©°, ì—¬ê¸°ì—ëŠ” ì´ 55ê°œ ì‹œì¥ì— ë„ë‹¬í•˜ê¸° ìœ„í•œ ILUMA iì˜ ì§€ì†ì ì¸ ì¶œì‹œê°€ í¬í•¨ë©ë‹ˆë‹¤. ì¤‘ìš”í•œ ì ì€ IQOSì˜ ìˆ˜ìµì„±ì´ ê°€ê²© ì±…ì •, ê·œëª¨ì˜ ê²½ì œ, ê·¸ë¦¬ê³  ì†Œëª¨í’ˆ ë° ê¸°ê¸° ë¹„ìš©ì˜ ìƒì‚°ì„± ê°œì„ ì— í˜ì…ì–´ í¬ê²Œ ì¦ê°€í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ì œí’ˆ ê¸°ì—¬ë„ê°€ ìƒë‹¹íˆ ì¦ê°€í•œ ê²ƒìœ¼ë¡œ í™•ì¸ë©ë‹ˆë‹¤. ë‹ˆì½”í‹´ íŒŒìš°ì¹˜ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ZYNì€ íŒŒìš°ì¹˜ ê¸°ì¤€ìœ¼ë¡œ ì•½ 40%ì˜ 2025ë…„ PMI ì¹´í…Œê³ ë¦¬ ì ìœ ìœ¨ì„ ë³´ìœ í•œ ê¸€ë¡œë²Œ 1ìœ„ ë¸Œëœë“œì…ë‹ˆë‹¤. ë¯¸êµ­ì€ í˜„ì¬ ì´ ì¹´í…Œê³ ë¦¬ì˜ ì•½ 2/3ë¥¼ ì°¨ì§€í•˜ê³  ìˆìœ¼ë©°, êµ­ì œ ì‹œì¥ì€ ì•„ì§ ìƒëŒ€ì ìœ¼ë¡œ ì‘ì§€ë§Œ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We made excellent progress this year expanding ZYN's presence by plus 19 markets to 56 and delivering plus 36% shipment growth to 13.6 billion pouches or 880 million cans, achieving our 2026 target 1 year early. U.S. shipments grew plus 37%, while international volume grew plus 31% or plus 112% excluding the more mature Nordics market, where Q4 performance was impacted by a demanding shipment comparison. We are focused on the future growth of the category, broadening our portfolio to address the need of legal age smoker looking to switch.</td><td>ì˜¬í•´ ìš°ë¦¬ëŠ” ZYNì˜ ì‹œì¥ ì§„ì¶œì„ 19ê°œ ì‹œì¥ í™•ëŒ€í•˜ì—¬ ì´ 56ê°œ ì‹œì¥ìœ¼ë¡œ ëŠ˜ë¦¬ê³ , ì¶œí•˜ëŸ‰ì„ 36% ì¦ê°€ì‹œì¼œ 136ì–µ ê°œ íŒŒìš°ì¹˜(8ì–µ 8ì²œë§Œ ìº”)ë¥¼ ë‹¬ì„±í•˜ëŠ” ë“± íƒì›”í•œ ì„±ê³¼ë¥¼ ê±°ë‘ì—ˆìœ¼ë©°, 2026ë…„ ëª©í‘œë¥¼ 1ë…„ ì•ë‹¹ê²¨ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ì¶œí•˜ëŸ‰ì€ 37% ì¦ê°€í–ˆê³ , í•´ì™¸ ë¬¼ëŸ‰ì€ 31% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ë³´ë‹¤ ì„±ìˆ™í•œ ë¶ìœ ëŸ½ ì‹œì¥ì„ ì œì™¸í•˜ë©´ 112% ì¦ê°€í–ˆëŠ”ë°, ë¶ìœ ëŸ½ì˜ 4ë¶„ê¸° ì‹¤ì ì€ ê¹Œë‹¤ë¡œìš´ ì¶œí•˜ëŸ‰ ë¹„êµ ê¸°ì¤€ì˜ ì˜í–¥ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì¹´í…Œê³ ë¦¬ì˜ ë¯¸ë˜ ì„±ì¥ì— ì§‘ì¤‘í•˜ê³  ìˆìœ¼ë©°, ì „í™˜ì„ ì›í•˜ëŠ” ë²•ì  í¡ì—° ì—°ë ¹ ì„±ì¸ í¡ì—°ìë“¤ì˜ ë‹ˆì¦ˆë¥¼ ì¶©ì¡±ì‹œí‚¤ê¸° ìœ„í•´ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This includes new strengths and flavor variance, including ZYN X-Low, 1.5 milligram, which was successfully rolled out to around of 2/3 of ZYN market, driving a significant improvement in first experience acceptance among adult nicotine consumers. While we are in the early stage of developing the category, which makes up only a low single-digit share of total nicotine in most markets, it's very encouraging to see ZYN's share of international pouches, excluding the Nordics, rise by around plus 60% in 2025 to reach 16% following the launches and relaunches of the past 1 to 2 years. In e-vapor, VEEV is the fastest-growing international vape brand of any major player within closed pods.</td><td>ì´ëŠ” ZYN X-Low, 1.5ë°€ë¦¬ê·¸ë¨ì„ í¬í•¨í•œ ìƒˆë¡œìš´ ê°•ë„ì™€ í–¥ ë³€í˜•ì„ í¬í•¨í•˜ë©°, ì´ëŠ” ZYN ì‹œì¥ì˜ ì•½ 2/3ì— ì„±ê³µì ìœ¼ë¡œ ì¶œì‹œë˜ì–´ ì„±ì¸ ë‹ˆì½”í‹´ ì†Œë¹„ìë“¤ì˜ ì²« ê²½í—˜ ìˆ˜ìš©ë„ë¥¼ í¬ê²Œ ê°œì„ ì‹œì¼°ìŠµë‹ˆë‹¤. ëŒ€ë¶€ë¶„ì˜ ì‹œì¥ì—ì„œ ì „ì²´ ë‹ˆì½”í‹´ì˜ í•œ ìë¦¿ìˆ˜ ì´ˆë°˜ ì ìœ ìœ¨ì— ë¶ˆê³¼í•œ ì´ˆê¸° ë‹¨ê³„ì˜ ì¹´í…Œê³ ë¦¬ë¥¼ ê°œë°œí•˜ê³  ìˆì§€ë§Œ, ë¶ìœ ëŸ½ì„ ì œì™¸í•œ êµ­ì œ íŒŒìš°ì¹˜ ì‹œì¥ì—ì„œ ZYNì˜ ì ìœ ìœ¨ì´ ì§€ë‚œ 1~2ë…„ê°„ì˜ ì¶œì‹œ ë° ì¬ì¶œì‹œì— í˜ì…ì–´ 2025ë…„ì— ì•½ 60% ì¦ê°€í•˜ì—¬ 16%ì— ë„ë‹¬í•œ ê²ƒì€ ë§¤ìš° ê³ ë¬´ì ì…ë‹ˆë‹¤. ì „ì ë² ì´í¼ ë¶€ë¬¸ì—ì„œ VEEVëŠ” íì‡„í˜• í¬ë“œ ë‚´ ì£¼ìš” ì—…ì²´ë“¤ ì¤‘ ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” êµ­ì œ ë² ì´í”„ ë¸Œëœë“œì…ë‹ˆë‹¤.</td></tr>
<tr><td>The pod segment is growing rapidly as disposable decline, and VEEV is gaining significant volume share in the fragmented landscape, sourcing primarily from legal age consumers of other vaping products and adult smoker. As covered earlier, shipments doubled for the year with a meaningful improvement in profitability. VEEV is now present in 47 markets and grew notably well in Italy, Romania, Greece, the U.K., Germany and Indonesia. Reviewing the smoke-free portfolio now by geography, starting with Europe, where as Jacek mentioned, smoke-free products now represent more than 50% of regional net revenue.</td><td>íŒŸ ì„¸ê·¸ë¨¼íŠ¸ëŠ” ì¼íšŒìš© ì œí’ˆì´ ê°ì†Œí•˜ë©´ì„œ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ê³  ìˆìœ¼ë©°, VEEVëŠ” ë¶„ì‚°ëœ ì‹œì¥ í™˜ê²½ì—ì„œ ìƒë‹¹í•œ ë¬¼ëŸ‰ ì ìœ ìœ¨ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì£¼ìš” ì†Œë¹„ìì¸µì€ ë‹¤ë¥¸ ë² ì´í•‘ ì œí’ˆì˜ ë²•ì  ì—°ë ¹ ì†Œë¹„ìì™€ ì„±ì¸ í¡ì—°ìë“¤ì…ë‹ˆë‹¤. ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´, ì—°ê°„ ì¶œí•˜ëŸ‰ì´ ë‘ ë°°ë¡œ ì¦ê°€í–ˆìœ¼ë©° ìˆ˜ìµì„±ë„ ì˜ë¯¸ ìˆê²Œ ê°œì„ ë˜ì—ˆìŠµë‹ˆë‹¤. VEEVëŠ” í˜„ì¬ 47ê°œ ì‹œì¥ì— ì§„ì¶œí•´ ìˆìœ¼ë©°, íŠ¹íˆ ì´íƒˆë¦¬ì•„, ë£¨ë§ˆë‹ˆì•„, ê·¸ë¦¬ìŠ¤, ì˜êµ­, ë…ì¼, ì¸ë„ë„¤ì‹œì•„ì—ì„œ ëˆˆì— ë„ê²Œ ì„±ì¥í–ˆìŠµë‹ˆë‹¤.<br><br>ì´ì œ ì§€ì—­ë³„ë¡œ ë¹„ì—°ì†Œ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê²€í† í•˜ê² ìŠµë‹ˆë‹¤. ë¨¼ì € ìœ ëŸ½ë¶€í„° ì‹œì‘í•˜ê² ëŠ”ë°, Jacekì´ ì–¸ê¸‰í•œ ë°”ì™€ ê°™ì´ ë¹„ì—°ì†Œ ì œí’ˆì´ ì´ì œ ì§€ì—­ ìˆœë§¤ì¶œì˜ 50% ì´ìƒì„ ì°¨ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Total IQOS, ZYN and VEEV volume grew by an impressive plus 13% for the year, with significant further growth potential given the overall penetration of SFP remains low compared to Japan or the U.S. IQOS delivered another strong quarter with an acceleration in adjusted IMS growth to plus 10.3%. This was led by an exceptional performance in Italy, where we successfully navigated the impact of the flavor ban, supported by recent innovation with an acceleration through the quarter of 2025 to deliver double-digit in-market sales growth for the year, quarterly market share passed 20% for the first time.</td><td>ì „ì²´ IQOS, ZYN ë° VEEV íŒë§¤ëŸ‰ì€ ì—°ê°„ 13% ì¦ê°€í•˜ëŠ” ì¸ìƒì ì¸ ì„±ì¥ì„ ê¸°ë¡í–ˆìœ¼ë©°, ì¼ë³¸ì´ë‚˜ ë¯¸êµ­ê³¼ ë¹„êµí•  ë•Œ ì „ì²´ SFP(smoke-free products, ë¬´ì—°ì œí’ˆ) ì¹¨íˆ¬ìœ¨ì´ ì—¬ì „íˆ ë‚®ë‹¤ëŠ” ì ì„ ê³ ë ¤í•˜ë©´ ìƒë‹¹í•œ ì¶”ê°€ ì„±ì¥ ì ì¬ë ¥ì´ ìˆìŠµë‹ˆë‹¤. IQOSëŠ” ì¡°ì • IMS(in-market sales, ì‹œì¥ë‚´ íŒë§¤) ì„±ì¥ë¥ ì´ 10.3% ì¦ê°€ë¡œ ê°€ì†í™”ë˜ë©° ë˜ ë‹¤ë¥¸ ê°•ë ¥í•œ ë¶„ê¸° ì‹¤ì ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì´íƒˆë¦¬ì•„ì—ì„œì˜ íƒì›”í•œ ì„±ê³¼ê°€ ì£¼ë„í–ˆëŠ”ë°, ìš°ë¦¬ëŠ” ìµœê·¼ í˜ì‹ ì˜ ì§€ì›ì„ ë°›ì•„ í–¥ë£Œ ê¸ˆì§€ ì¡°ì¹˜ì˜ ì˜í–¥ì„ ì„±ê³µì ìœ¼ë¡œ ê·¹ë³µí–ˆìœ¼ë©°, 2025ë…„ ë¶„ê¸° ë‚´ë‚´ ê°€ì†í™”ë¥¼ í†µí•´ ì—°ê°„ ë‘ ìë¦¿ìˆ˜ ì‹œì¥ë‚´ íŒë§¤ ì„±ì¥ì„ ë‹¬ì„±í–ˆê³ , ë¶„ê¸° ì‹œì¥ì ìœ ìœ¨ì´ ì²˜ìŒìœ¼ë¡œ 20%ë¥¼ ëŒíŒŒí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Other notable call outs with strong double-digit growth include Bulgaria, Germany, Greece, Spain and Romania. ZYN pouch shipment volumes grew plus 9% for the year. And while the Nordics make up close to 60% of regional volume, shipments more than doubled elsewhere with good progress in the U.K., Poland, Italy and Austria. As noted earlier, excellent VEEV momentum continued with shipment growth of plus 110%. In Japan, we reached an impressive milestone in December as the heat-not-burn category surpassed 50% of total industry offtake volumes, driven by the continued strength of IQOS.</td><td>ì£¼ëª©í•  ë§Œí•œ ë‹¤ë¥¸ êµ­ê°€ë“¤ë¡œëŠ” ë¶ˆê°€ë¦¬ì•„, ë…ì¼, ê·¸ë¦¬ìŠ¤, ìŠ¤í˜ì¸, ë£¨ë§ˆë‹ˆì•„ê°€ ë‘ ìë¦¿ìˆ˜ ê°•ë ¥í•œ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ZYN íŒŒìš°ì¹˜ ì¶œí•˜ëŸ‰ì€ ì—°ê°„ 9% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ë¶ìœ ëŸ½ ì§€ì—­ì´ ì§€ì—­ ë¬¼ëŸ‰ì˜ ì•½ 60%ë¥¼ ì°¨ì§€í•˜ê³  ìˆì§€ë§Œ, ê·¸ ì™¸ ì§€ì—­ì—ì„œëŠ” ì¶œí•˜ëŸ‰ì´ ë‘ ë°° ì´ìƒ ì¦ê°€í–ˆìœ¼ë©° ì˜êµ­, í´ë€ë“œ, ì´íƒˆë¦¬ì•„, ì˜¤ìŠ¤íŠ¸ë¦¬ì•„ì—ì„œ ì¢‹ì€ ì§„ì „ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ì•ì„œ ì–¸ê¸‰í•œ ë°”ì™€ ê°™ì´, VEEVì˜ íƒì›”í•œ ëª¨ë©˜í…€ì€ 110% ì¶œí•˜ëŸ‰ ì¦ê°€ì™€ í•¨ê»˜ ì§€ì†ë˜ì—ˆìŠµë‹ˆë‹¤. ì¼ë³¸ì—ì„œëŠ” 12ì›”ì— ì¸ìƒì ì¸ ì´ì •í‘œë¥¼ ë‹¬ì„±í–ˆëŠ”ë°, IQOSì˜ ì§€ì†ì ì¸ ê°•ì„¸ì— í˜ì…ì–´ ê°€ì—´ì‹ ë‹´ë°° ì¹´í…Œê³ ë¦¬ê°€ ì „ì²´ ì‚°ì—… íŒë§¤ëŸ‰ì˜ 50%ë¥¼ ë„˜ì–´ì„°ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The path to 50% has not been linear and following 2 years of very strong expansion in '23 and '24, category growth moderated in 2025. The adjusted in-market sales growth of IQOS HTUs has reflected this trend with a healthy plus 7% in 2025, representing very robust absolute growth. In Q4, the Japanese nicotine industry and the heat-not-burn category grew slightly below the full year trend with some impact from inflationary pressures on consumer purchasing power. Nonetheless, IQOS HTU adjusted IMS grew plus 5.8%, while Q4 adjusted share grew plus 2 points year-on-year to 32.6%.</td><td>IQOSì˜ ì‹œì¥ì ìœ ìœ¨ 50% ë‹¬ì„± ê²½ë¡œëŠ” ì§ì„ ì ì´ì§€ ì•Šì•˜ìœ¼ë©°, 2023ë…„ê³¼ 2024ë…„ 2ë…„ê°„ì˜ ë§¤ìš° ê°•ë ¥í•œ í™•ì¥ ì´í›„ 2025ë…„ì—ëŠ” ì¹´í…Œê³ ë¦¬ ì„±ì¥ì„¸ê°€ ë‘”í™”ë˜ì—ˆìŠµë‹ˆë‹¤. IQOS HTUì˜ ì¡°ì • ì‹œì¥ë‚´ ë§¤ì¶œ ì„±ì¥ë¥ ì€ ì´ëŸ¬í•œ ì¶”ì„¸ë¥¼ ë°˜ì˜í•˜ì—¬ 2025ë…„ì— ê²¬ì¡°í•œ +7%ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ì ˆëŒ€ì ìœ¼ë¡œ ë§¤ìš° ê°•ë ¥í•œ ì„±ì¥ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. 4ë¶„ê¸°ì—ëŠ” ì¼ë³¸ ë‹ˆì½”í‹´ ì‚°ì—…ê³¼ ê¶ë ¨í˜• ì „ìë‹´ë°° ì¹´í…Œê³ ë¦¬ê°€ ì¸í”Œë ˆì´ì…˜ ì••ë ¥ì´ ì†Œë¹„ì êµ¬ë§¤ë ¥ì— ì¼ë¶€ ì˜í–¥ì„ ë¯¸ì¹˜ë©´ì„œ ì—°ê°„ ì¶”ì„¸ë¥¼ ì†Œí­ í•˜íšŒí•˜ëŠ” ì„±ì¥ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³  IQOS HTU ì¡°ì • ì‹œì¥ë‚´ ë§¤ì¶œì€ +5.8% ì„±ì¥í–ˆìœ¼ë©°, 4ë¶„ê¸° ì¡°ì • ì‹œì¥ì ìœ ìœ¨ì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ +2%í¬ì¸íŠ¸ ì¦ê°€í•œ 32.6%ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>While competitive intensity increased markedly this year, IQOS category share was broadly stable, with most movements occurring among other players. We are encouraged by early signs that the increase in category activity is generating higher interest among more traditional adult smoker, a positive indicator for category growth. Looking forward, the upcoming excise tax increases on heat-not-burn in April and October make 2026 an atypical year.</td><td>ê²½ìŸ ê°•ë„ê°€ ì˜¬í•´ í˜„ì €íˆ ì¦ê°€í–ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³ , IQOSì˜ ì¹´í…Œê³ ë¦¬ ì ìœ ìœ¨ì€ ëŒ€ì²´ë¡œ ì•ˆì •ì ì´ì—ˆìœ¼ë©°, ëŒ€ë¶€ë¶„ì˜ ë³€ë™ì€ ë‹¤ë¥¸ ê²½ìŸì‚¬ë“¤ ì‚¬ì´ì—ì„œ ë°œìƒí–ˆìŠµë‹ˆë‹¤. ì¹´í…Œê³ ë¦¬ í™œë™ ì¦ê°€ê°€ ë³´ë‹¤ ì „í†µì ì¸ ì„±ì¸ í¡ì—°ìë“¤ ì‚¬ì´ì—ì„œ ë” ë†’ì€ ê´€ì‹¬ì„ ë¶ˆëŸ¬ì¼ìœ¼í‚¤ê³  ìˆë‹¤ëŠ” ì´ˆê¸° ì‹ í˜¸ì— ê³ ë¬´ë˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì¹´í…Œê³ ë¦¬ ì„±ì¥ì— ê¸ì •ì ì¸ ì§€í‘œì…ë‹ˆë‹¤. í–¥í›„ ì „ë§ì„ ë³´ë©´, 4ì›”ê³¼ 10ì›”ì— ì˜ˆì •ëœ ê¶ë ¨í˜• ì „ìë‹´ë°°ì— ëŒ€í•œ ì†Œë¹„ì„¸ ì¸ìƒìœ¼ë¡œ ì¸í•´ 2026ë…„ì€ ë¹„ì •í˜•ì ì¸ í•´ê°€ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>As discussed at the Morgan Stanley conference in December, the level of pass-on makes this a headwind for the category, representing about JPY 50 to JPY 100 per pack, which translates to 20% of current retail prices, with the greatest impact for product at lower price points. As announced recently, we have submitted an application to increase our prices in April. We anticipate these price increases will impact category growth and volume for 2026 despite the fact that heat-not-burn consumers have demonstrated higher price resilience than cigarette smokers in the past. Shipment volatility in 2026 is also possible, driven by in-market sales trends around April and October excise increases.</td><td>ì§€ë‚œ 12ì›” ëª¨ê±´ìŠ¤íƒ ë¦¬ ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ë…¼ì˜í•œ ë°”ì™€ ê°™ì´, ì´ëŸ¬í•œ ê°€ê²© ì „ê°€ ìˆ˜ì¤€ì€ ì¹´í…Œê³ ë¦¬ì— ì—­í’ìœ¼ë¡œ ì‘ìš©í•˜ë©°, íŒ©ë‹¹ ì•½ 50ì—”ì—ì„œ 100ì—”ì„ ë‚˜íƒ€ë‚´ëŠ”ë°, ì´ëŠ” í˜„ì¬ ì†Œë§¤ê°€ê²©ì˜ 20%ì— í•´ë‹¹í•˜ë©°, ë‚®ì€ ê°€ê²©ëŒ€ì˜ ì œí’ˆì— ê°€ì¥ í° ì˜í–¥ì„ ë¯¸ì¹©ë‹ˆë‹¤. ìµœê·¼ ë°œí‘œí•œ ë°”ì™€ ê°™ì´, ë‹¹ì‚¬ëŠ” 4ì›” ê°€ê²© ì¸ìƒì„ ìœ„í•œ ì‹ ì²­ì„œë¥¼ ì œì¶œí–ˆìŠµë‹ˆë‹¤. ê³¼ê±° ê¶ë ¨ í¡ì—°ìë“¤ì— ë¹„í•´ ê°€ì—´ì‹ ë‹´ë°° ì†Œë¹„ìë“¤ì´ ë” ë†’ì€ ê°€ê²© íƒ„ë ¥ì„±ì„ ë³´ì—¬ì£¼ì—ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³ , ì´ëŸ¬í•œ ê°€ê²© ì¸ìƒì´ 2026ë…„ ì¹´í…Œê³ ë¦¬ ì„±ì¥ê³¼ íŒë§¤ëŸ‰ì— ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë˜í•œ 4ì›”ê³¼ 10ì›” ì†Œë¹„ì„¸ ì¸ìƒ ì‹œì ì˜ ì‹œì¥ ë‚´ íŒë§¤ ì¶”ì„¸ë¡œ ì¸í•´ 2026ë…„ ì¶œí•˜ëŸ‰ ë³€ë™ì„±ë„ ë°œìƒí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Importantly, we do not expect the underlying category growth trend to change, and we target substantial further growth from IQOS in Japan in the years to come. We are also pleased to report ZYN's successful pilot launch in Tokyo. Outside of the U.S., Japan and Europe, all 3 of our smoke-free categories are delivering strong broad-based growth, with full year shipment up plus 17%. This includes IQOS strong start in Taiwan during Q4, where we exited the year with around 4% of offtake share and rapid progress in markets such as South Korea, Malaysia and the Philippines. This momentum was notably strong in Pakistan and Mexico. In e-vapor, we've achieved excellent results, particularly in Asia.</td><td>ì¤‘ìš”í•œ ì ì€, ìš°ë¦¬ëŠ” ê¸°ì € ì¹´í…Œê³ ë¦¬ ì„±ì¥ ì¶”ì„¸ê°€ ë³€í™”í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì§€ ì•Šìœ¼ë©°, í–¥í›„ ëª‡ ë…„ê°„ ì¼ë³¸ì—ì„œ IQOSì˜ ìƒë‹¹í•œ ì¶”ê°€ ì„±ì¥ì„ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ë„ì¿„ì—ì„œ ZYNì˜ ì„±ê³µì ì¸ íŒŒì¼ëŸ¿ ì¶œì‹œë¥¼ ë³´ê³ í•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. ë¯¸êµ­, ì¼ë³¸, ìœ ëŸ½ì„ ì œì™¸í•œ ì§€ì—­ì—ì„œëŠ” 3ê°œ ë¬´ì—° ì¹´í…Œê³ ë¦¬ ëª¨ë‘ ê°•ë ¥í•˜ê³  ê´‘ë²”ìœ„í•œ ì„±ì¥ì„ ë³´ì´ê³  ìˆìœ¼ë©°, ì—°ê°„ ì¶œí•˜ëŸ‰ì´ 17% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” 4ë¶„ê¸° ë™ì•ˆ ëŒ€ë§Œì—ì„œ IQOSì˜ ê°•ë ¥í•œ ì¶œë°œì´ í¬í•¨ë˜ëŠ”ë°, ì—°ë§ ê¸°ì¤€ ì•½ 4%ì˜ íŒë§¤ ì ìœ ìœ¨ì„ ê¸°ë¡í–ˆìœ¼ë©°, í•œêµ­, ë§ë ˆì´ì‹œì•„, í•„ë¦¬í•€ê³¼ ê°™ì€ ì‹œì¥ì—ì„œë„ ë¹ ë¥¸ ì§„ì „ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ëª¨ë©˜í…€ì€ íŠ¹íˆ íŒŒí‚¤ìŠ¤íƒ„ê³¼ ë©•ì‹œì½”ì—ì„œ ë‘ë“œëŸ¬ì§€ê²Œ ê°•í–ˆìŠµë‹ˆë‹¤. ì „ìë‹´ë°° ë¶€ë¬¸ì—ì„œëŠ” íŠ¹íˆ ì•„ì‹œì•„ ì§€ì—­ì—ì„œ íƒì›”í•œ ì„±ê³¼ë¥¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our Global Travel Retail business further support all 3 brands and continue to deliver impressive multi-category performance, serving as a powerful platform to showcase our portfolio. Turning now to the U.S., which made up around 7% of our global net revenues and around 8% of our adjusted operating income in 2025. Nicotine pouches remain the fastest-growing U.S. segment, representing a high single-digit percentage of total nicotine industry volume. Despite supply constraints, commercial normalization and portfolio gap, ZYN continued to lead the category in 2025, with its premium offer capturing around 50% of category growth, 61.5% can volume share and a value share of over 67%.</td><td>ê¸€ë¡œë²Œ ì—¬í–‰ ë¦¬í…Œì¼ ì‚¬ì—…ì€ 3ê°œ ë¸Œëœë“œ ëª¨ë‘ë¥¼ ì§€ì›í•˜ë©° ê³„ì†í•´ì„œ ì¸ìƒì ì¸ ë©€í‹° ì¹´í…Œê³ ë¦¬ ì‹¤ì ì„ ë‹¬ì„±í•˜ê³  ìˆìœ¼ë©°, ë‹¹ì‚¬ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì„ ë³´ì´ëŠ” ê°•ë ¥í•œ í”Œë«í¼ ì—­í• ì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ë¯¸êµ­ ì‹œì¥ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ë¯¸êµ­ì€ 2025ë…„ ê¸€ë¡œë²Œ ìˆœë§¤ì¶œì˜ ì•½ 7%, ì¡°ì • ì˜ì—…ì´ìµì˜ ì•½ 8%ë¥¼ ì°¨ì§€í–ˆìŠµë‹ˆë‹¤. ë‹ˆì½”í‹´ íŒŒìš°ì¹˜ëŠ” ë¯¸êµ­ì—ì„œ ê°€ì¥ ë¹ ë¥´ê²Œ ì„±ì¥í•˜ëŠ” ì„¸ê·¸ë¨¼íŠ¸ë¡œ, ì „ì²´ ë‹ˆì½”í‹´ ì‚°ì—… ë¬¼ëŸ‰ì˜ í•œ ìë¦¿ìˆ˜ í›„ë°˜ ë¹„ì¤‘ì„ ì°¨ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê³µê¸‰ ì œì•½, ìƒì—…ì  ì •ìƒí™”, í¬íŠ¸í´ë¦¬ì˜¤ ê³µë°±ì—ë„ ë¶ˆêµ¬í•˜ê³ , ZYNì€ 2025ë…„ì—ë„ í”„ë¦¬ë¯¸ì—„ ì œí’ˆìœ¼ë¡œ ì¹´í…Œê³ ë¦¬ ì„±ì¥ì˜ ì•½ 50%, ìº” ë¬¼ëŸ‰ ì ìœ ìœ¨ 61.5%, ê°€ì¹˜ ì ìœ ìœ¨ 67% ì´ìƒì„ ì°¨ì§€í•˜ë©° ì¹´í…Œê³ ë¦¬ë¥¼ ê³„ì† ì„ ë„í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>ZYN offtake volume also grew strongly by plus 25% for the year, as estimated by Nielsen. Shipment grew by plus 37% or 213 million cans to 794 million. The gap between shipment and offtake reflect a net channel inventory rebuild, and we estimate the underlying 2025 shipment base corresponding to consumer offtake was around 740 million to 750 million cans. This was notably concentrated in the first quarter of 2025, and we estimate the underlying shipment base by quarter for 2025 was around 160 million cans in Q1, 180 million cans in Q2, 205 million in Q3 and 200 million in Q4.</td><td>ZYNì˜ íŒë§¤ëŸ‰(offtake volume)ë„ Nielsen ì¶”ì •ì¹˜ ê¸°ì¤€ìœ¼ë¡œ ì—°ê°„ 25% ì¦ê°€í•˜ë©° ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ì¶œí•˜ëŸ‰(shipment)ì€ 37% ë˜ëŠ” 2ì–µ 1,300ë§Œ ìº” ì¦ê°€í•˜ì—¬ 7ì–µ 9,400ë§Œ ìº”ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì¶œí•˜ëŸ‰ê³¼ íŒë§¤ëŸ‰ ê°„ì˜ ê²©ì°¨ëŠ” ìœ í†µì±„ë„ ì¬ê³ ì˜ ìˆœì¦ê°€ë¥¼ ë°˜ì˜í•œ ê²ƒì´ë©°, ì†Œë¹„ì íŒë§¤ëŸ‰ì— ìƒì‘í•˜ëŠ” 2025ë…„ ê¸°ì € ì¶œí•˜ëŸ‰(underlying shipment base)ì€ ì•½ 7ì–µ 4,000ë§Œ~7ì–µ 5,000ë§Œ ìº”ìœ¼ë¡œ ì¶”ì •ë©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì¬ê³  ì¦ê°€ëŠ” íŠ¹íˆ 2025ë…„ 1ë¶„ê¸°ì— ì§‘ì¤‘ë˜ì—ˆìœ¼ë©°, 2025ë…„ ë¶„ê¸°ë³„ ê¸°ì € ì¶œí•˜ëŸ‰ì€ 1ë¶„ê¸° ì•½ 1ì–µ 6,000ë§Œ ìº”, 2ë¶„ê¸° 1ì–µ 8,000ë§Œ ìº”, 3ë¶„ê¸° 2ì–µ 500ë§Œ ìº”, 4ë¶„ê¸° 2ì–µ ìº”ìœ¼ë¡œ ì¶”ì •ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Indeed, Q4 saw a lower-than-expected destocking of about 5 million cans as we deploy promotion, limited time offers and announced a January list price increase of $0.10 per can in December. Looking ahead to 2026, we expect ZYN shipment volume to broadly reflect off the growth from this underlying base before any further channel inventory movement. We estimate the remainder around 25 million cans of surplus inventory in the downstream supply chain, which we assume will normalize in due course, most likely in the first quarter. The level of offtake growth for ZYN in 2026 will be influenced by 3 key factors in which we are investing.</td><td>ì‹¤ì œë¡œ 4ë¶„ê¸°ì—ëŠ” 12ì›”ì— ìº”ë‹¹ 0.10ë‹¬ëŸ¬ì˜ 1ì›” ì •ê°€ ì¸ìƒì„ ë°œí‘œí•˜ê³  í”„ë¡œëª¨ì…˜ê³¼ ê¸°ê°„ í•œì • ì˜¤í¼ë¥¼ ì‹œí–‰í•˜ë©´ì„œ ì•½ 500ë§Œ ìº”ì˜ ì˜ˆìƒë³´ë‹¤ ë‚®ì€ ì¬ê³  ê°ì¶•ì´ ìˆì—ˆìŠµë‹ˆë‹¤. 2026ë…„ì„ ì „ë§í•˜ë©´, ì¶”ê°€ì ì¸ ìœ í†µ ì¬ê³  ë³€ë™ì´ ì—†ë‹¤ëŠ” ê°€ì • í•˜ì— ZYN ì¶œí•˜ ë¬¼ëŸ‰ì€ ì´ëŸ¬í•œ ê¸°ì € ìˆ˜ì¤€ì—ì„œì˜ ì„±ì¥ì„ ëŒ€ì²´ë¡œ ë°˜ì˜í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” í•˜ë¥˜ ê³µê¸‰ë§ì— ì•½ 2,500ë§Œ ìº”ì˜ ì‰ì—¬ ì¬ê³ ê°€ ë‚¨ì•„ìˆëŠ” ê²ƒìœ¼ë¡œ ì¶”ì •í•˜ë©°, ì´ëŠ” ì ì ˆí•œ ì‹œê¸°ì—, ê°€ì¥ ê°€ëŠ¥ì„± ë†’ê²ŒëŠ” 1ë¶„ê¸°ì— ì •ìƒí™”ë  ê²ƒìœ¼ë¡œ ê°€ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ ZYNì˜ ì˜¤í”„í…Œì´í¬ ì„±ì¥ ìˆ˜ì¤€ì€ ìš°ë¦¬ê°€ íˆ¬ìí•˜ê³  ìˆëŠ” 3ê°€ì§€ í•µì‹¬ ìš”ì¸ì— ì˜í•´ ì˜í–¥ì„ ë°›ì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>The most critical over the mid- to long term is ZYN's brand equity as we strengthen marketing in a responsible manner, enhance point-of-sale visibility and deepen the connection with our legal age consumers. Accessing all segments of the U.S. nicotine pouch category will require us to navigate a dynamic and uncertain regulatory environment. We have developed and are preparing to launch innovation to address a broad spectrum of consumer preferences. We have a number of pending ZYN submission before the FDA, including ZYN Ultra, which is included in FDA's pilot program. ZYN Ultra offers higher strength and an expected range of adult-oriented flavors.</td><td>ì¤‘ì¥ê¸°ì ìœ¼ë¡œ ê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€ ZYNì˜ ë¸Œëœë“œ ìì‚°ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì±…ì„ê° ìˆëŠ” ë°©ì‹ìœ¼ë¡œ ë§ˆì¼€íŒ…ì„ ê°•í™”í•˜ê³ , íŒë§¤ ì‹œì  ê°€ì‹œì„±ì„ ë†’ì´ë©°, ë²•ì  ì„±ì¸ ì†Œë¹„ìë“¤ê³¼ì˜ ì—°ê²°ì„ ì‹¬í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ë‹ˆì½”í‹´ íŒŒìš°ì¹˜ ì¹´í…Œê³ ë¦¬ì˜ ëª¨ë“  ì„¸ê·¸ë¨¼íŠ¸ì— ì ‘ê·¼í•˜ê¸° ìœ„í•´ì„œëŠ” ì—­ë™ì ì´ê³  ë¶ˆí™•ì‹¤í•œ ê·œì œ í™˜ê²½ì„ í—¤ì³ ë‚˜ê°€ì•¼ í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê´‘ë²”ìœ„í•œ ì†Œë¹„ì ì„ í˜¸ë„ë¥¼ ì¶©ì¡±ì‹œí‚¤ê¸° ìœ„í•œ í˜ì‹  ì œí’ˆì„ ê°œë°œí–ˆìœ¼ë©° ì¶œì‹œë¥¼ ì¤€ë¹„í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ FDAì— ì—¬ëŸ¬ ê±´ì˜ ZYN ì œí’ˆ ìŠ¹ì¸ ì‹ ì²­ì´ ê³„ë¥˜ ì¤‘ì´ë©°, ì—¬ê¸°ì—ëŠ” FDAì˜ íŒŒì¼ëŸ¿ í”„ë¡œê·¸ë¨ì— í¬í•¨ëœ ZYN Ultraë„ ìˆìŠµë‹ˆë‹¤. ZYN UltraëŠ” ë” ë†’ì€ ê°•ë„ì™€ ì„±ì¸ ì§€í–¥ì  í–¥ë¯¸ì˜ ì˜ˆìƒ ë¼ì¸ì—…ì„ ì œê³µí•©ë‹ˆë‹¤.</td></tr>
<tr><td>We are taking steps to prepare for the launch of ZYN Ultra as soon as possible, pending FDA action. We also believe IQOS ILUMA strong application and demonstrated track record converting smokers to better alternatives warrants expeditious FDA action. We also continue to optimize ZYN's premium price position. Despite elevated promotional intensity across the category, ZYN remain the leading premium brand by a clear margin, fully aligned with our strategy for sustainable long-term growth. We have a comprehensive commercial program plan for 2026. And as a reminder, commercial activities, including promotions, were unusually low in the first half of 2025.</td><td>ì €í¬ëŠ” FDA ìŠ¹ì¸ì´ ë‚˜ëŠ” ëŒ€ë¡œ ê°€ëŠ¥í•œ í•œ ë¹¨ë¦¬ ZYN Ultra ì¶œì‹œë¥¼ ì¤€ë¹„í•˜ê¸° ìœ„í•œ ì¡°ì¹˜ë¥¼ ì·¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ IQOS ILUMAì˜ ê°•ë ¥í•œ ì‹ ì²­ì„œì™€ í¡ì—°ìë“¤ì„ ë” ë‚˜ì€ ëŒ€ì•ˆìœ¼ë¡œ ì „í™˜ì‹œí‚¨ ì…ì¦ëœ ì‹¤ì ì€ FDAì˜ ì‹ ì†í•œ ì¡°ì¹˜ë¥¼ ë°›ì„ ë§Œí•˜ë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ë˜í•œ ZYNì˜ í”„ë¦¬ë¯¸ì—„ ê°€ê²© í¬ì§€ì…”ë‹ì„ ì§€ì†ì ìœ¼ë¡œ ìµœì í™”í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¹´í…Œê³ ë¦¬ ì „ë°˜ì— ê±¸ì³ í”„ë¡œëª¨ì…˜ ê°•ë„ê°€ ë†’ì•„ì¡ŒìŒì—ë„ ë¶ˆêµ¬í•˜ê³ , ZYNì€ ëª…í™•í•œ ê²©ì°¨ë¡œ ì„ ë„ì ì¸ í”„ë¦¬ë¯¸ì—„ ë¸Œëœë“œë¡œ ë‚¨ì•„ ìˆìœ¼ë©°, ì´ëŠ” ì§€ì† ê°€ëŠ¥í•œ ì¥ê¸° ì„±ì¥ì„ ìœ„í•œ ì €í¬ ì „ëµê³¼ ì™„ì „íˆ ì¼ì¹˜í•©ë‹ˆë‹¤. ì €í¬ëŠ” 2026ë…„ì„ ìœ„í•œ í¬ê´„ì ì¸ ìƒì—… í”„ë¡œê·¸ë¨ ê³„íšì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì°¸ê³ ë¡œ, í”„ë¡œëª¨ì…˜ì„ í¬í•¨í•œ ìƒì—… í™œë™ì€ 2025ë…„ ìƒë°˜ê¸°ì— ë¹„ì •ìƒì ìœ¼ë¡œ ë‚®ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>As I mentioned before, we continue to expect ZYN to deliver best-in-class gross margin within PMI above the average of IQOS. We are very excited about the significant growth potential of the brand over the coming years, which fully justifies the above-mentioned investment. One example of our enhanced brand building effort is the recently announced global partnership between ZYN and Ferrari, which recognized our long-standing heritage in Formula 1, with smoke-free product now at the forefront. Formula 1's overwhelmingly adult audience provides a highly impact platform to engage consumer responsibly and reinforce ZYN's premium equity.</td><td>ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ì €í¬ëŠ” ZYNì´ PMI ë‚´ì—ì„œ IQOS í‰ê· ì„ ìƒíšŒí•˜ëŠ” ìµœê³  ìˆ˜ì¤€ì˜ ë§¤ì¶œì´ì´ìµë¥ ì„ ì§€ì†ì ìœ¼ë¡œ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ ìˆ˜ë…„ê°„ ì´ ë¸Œëœë“œì˜ ìƒë‹¹í•œ ì„±ì¥ ì ì¬ë ¥ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì•ì„œ ì–¸ê¸‰í•œ íˆ¬ìë¥¼ ì¶©ë¶„íˆ ì •ë‹¹í™”í•©ë‹ˆë‹¤. ì €í¬ì˜ ê°•í™”ëœ ë¸Œëœë“œ êµ¬ì¶• ë…¸ë ¥ì˜ í•œ ì˜ˆë¡œ, ìµœê·¼ ë°œí‘œëœ ZYNê³¼ í˜ë¼ë¦¬ ê°„ì˜ ê¸€ë¡œë²Œ íŒŒíŠ¸ë„ˆì‹­ì„ ë“¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” í¬ë®¬ëŸ¬ 1ì—ì„œì˜ ì €í¬ì˜ ì˜¤ëœ ì „í†µì„ ì¸ì •ë°›ì€ ê²ƒì´ë©°, ì´ì œ ë¬´ì—° ì œí’ˆì´ ìµœì „ì„ ì— ì„œê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. í¬ë®¬ëŸ¬ 1ì˜ ì••ë„ì ì¸ ì„±ì¸ ê´€ì¤‘ì¸µì€ ì†Œë¹„ìë“¤ê³¼ ì±…ì„ê° ìˆê²Œ ì†Œí†µí•˜ê³  ZYNì˜ í”„ë¦¬ë¯¸ì—„ ë¸Œëœë“œ ê°€ì¹˜ë¥¼ ê°•í™”í•  ìˆ˜ ìˆëŠ” ë§¤ìš° ì˜í–¥ë ¥ ìˆëŠ” í”Œë«í¼ì„ ì œê³µí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Finally, moving to combustible, which delivered another robust year of pricing of plus 7.6%, including plus 6.8% in Q4 and very good gross profit growth. Our full year cigarette share declined by 0.2 points to 25.3%, mainly due to Turkey, and was otherwise stable, including record high for Marlboro both for the full year and in Q4, where its share reached 11% of the international category, excluding China. For 2026, we forecast a comfortable pricing variance of around plus 6%, reflecting continued dynamic performance. With that, I will now hand it back to Jacek. Jacek Olczak<br>Group CEO & Director<br><br>Thank you, Emmanuel.</td><td>ë§ˆì§€ë§‰ìœ¼ë¡œ ì—°ì´ˆ ë¶€ë¬¸ì€ ë˜ í•œ í•´ ê²¬ì¡°í•œ ê°€ê²© ì¸ìƒì„ ë‹¬ì„±í–ˆìœ¼ë©°, 4ë¶„ê¸° +6.8%ë¥¼ í¬í•¨í•˜ì—¬ ì—°ê°„ +7.6%ë¥¼ ê¸°ë¡í–ˆê³ , ë§¤ìš° ì–‘í˜¸í•œ ì´ì´ìµ ì„±ì¥ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ì—°ê°„ ê¶ë ¨ ì‹œì¥ì ìœ ìœ¨ì€ ì£¼ë¡œ í„°í‚¤ì˜ ì˜í–¥ìœ¼ë¡œ 0.2%í¬ì¸íŠ¸ ê°ì†Œí•œ 25.3%ë¥¼ ê¸°ë¡í–ˆìœ¼ë‚˜, ê·¸ ì™¸ ì§€ì—­ì—ì„œëŠ” ì•ˆì •ì ì´ì—ˆìŠµë‹ˆë‹¤. ë§ë³´ë¡œëŠ” ì—°ê°„ ë° 4ë¶„ê¸° ëª¨ë‘ ì‚¬ìƒ ìµœê³ ì¹˜ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, 4ë¶„ê¸° ì ìœ ìœ¨ì€ ì¤‘êµ­ì„ ì œì™¸í•œ êµ­ì œ ì¹´í…Œê³ ë¦¬ì—ì„œ 11%ì— ë„ë‹¬í–ˆìŠµë‹ˆë‹¤. 2026ë…„ì—ëŠ” ì§€ì†ì ì¸ ì—­ë™ì  ì„±ê³¼ë¥¼ ë°˜ì˜í•˜ì—¬ ì•½ +6%ì˜ ì•ˆì •ì ì¸ ê°€ê²© ì°¨ì´ë¥¼ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ ì•¼ì²µì—ê²Œ ë‹¤ì‹œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ì•¼ì²µ ì˜¬ì°¨í¬<br>ê·¸ë£¹ CEO ê²¸ ì´ì‚¬<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ì— ë§ˆë‰´ì—˜.</td></tr>
<tr><td>This brings me to our outlook for 2026, where we expect another year of a strong and profitable growth despite several transitory headwinds. Starting with volumes. We expect continued strong underlying momentum in our smoke-free business for all 3 categories. Both shipments and adjusted IMS volumes are projected to grow in high single digits after factoring in the headwinds from Japan excise taxes and U.S. ZYN inventory comparisons described earlier. For combustibles, we forecast a cigarette decline of around 3%, with weaker industry volumes in India and Mexico following the recent excise tax increases and our ongoing recovery in Turkey likely to impact comparisons in the first half.</td><td>ì´ì œ 2026ë…„ ì „ë§ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì¼ë¶€ ì¼ì‹œì ì¸ ì—­í’ì—ë„ ë¶ˆêµ¬í•˜ê³  ì˜¬í•´ë„ ê°•ë ¥í•˜ê³  ìˆ˜ìµì„± ìˆëŠ” ì„±ì¥ì„ ì´ë£° ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë¨¼ì € ë¬¼ëŸ‰ë¶€í„° ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. 3ê°œ ì¹´í…Œê³ ë¦¬ ëª¨ë‘ì—ì„œ ë¹„ì—°ì†Œ ì œí’ˆ ì‚¬ì—…ì˜ ê°•ë ¥í•œ ê¸°ì € ëª¨ë©˜í…€ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì•ì„œ ì„¤ëª…ë“œë¦° ì¼ë³¸ì˜ ì†Œë¹„ì„¸ ì¸ìƒê³¼ ë¯¸êµ­ ZYN ì¬ê³  ë¹„êµ ê¸°ì € íš¨ê³¼ë¼ëŠ” ì—­í’ì„ ê°ì•ˆí•œ í›„ì—ë„, ì¶œí•˜ëŸ‰ê³¼ ì¡°ì • IMS ë¬¼ëŸ‰ ëª¨ë‘ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„ ê¸°ë¡í•  ê²ƒìœ¼ë¡œ ì „ë§ë©ë‹ˆë‹¤. ì—°ì†Œí˜• ì œí’ˆì˜ ê²½ìš°, ìµœê·¼ ì†Œë¹„ì„¸ ì¸ìƒ ì´í›„ ì¸ë„ì™€ ë©•ì‹œì½”ì˜ ì—…ê³„ ë¬¼ëŸ‰ ì•½ì„¸, ê·¸ë¦¬ê³  í„°í‚¤ì—ì„œì˜ ì§€ì†ì ì¸ íšŒë³µì„¸ê°€ ìƒë°˜ê¸° ë¹„êµ ê¸°ì €ì— ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ë³´ì—¬ ë‹´ë°° íŒë§¤ëŸ‰ì´ ì•½ 3% ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Altogether, these results in a broadly stable outlook for total shipment growth, subject to the usual variability in shipment timing and trade inventory movement as compared to a forecast total industry decline of around 2% for cigarettes and HTUs. We expect another strong year overall for pricing led by combustibles, notwithstanding the impact of a U.S. first half comparison and for continued positive smoke-free mix. Taking all these elements into account, we forecast 2026 organic net revenue growth of 5% to 7%.</td><td>ì „ì²´ì ìœ¼ë¡œ ì´ëŸ¬í•œ ê²°ê³¼ë“¤ì€ ì¶œí•˜ ì‹œê¸°ì˜ ì¼ë°˜ì ì¸ ë³€ë™ì„±ê³¼ ìœ í†µì¬ê³  ì´ë™ì„ ê³ ë ¤í•  ë•Œ ì „ì²´ ì¶œí•˜ëŸ‰ ì„±ì¥ì´ ëŒ€ì²´ë¡œ ì•ˆì •ì ì¸ ì „ë§ì„ ë³´ì—¬ì£¼ë©°, ì´ëŠ” ë‹´ë°°ì™€ HTUì˜ ì „ì²´ ì‚°ì—… ì „ë§ì¹˜ì¸ ì•½ 2% ê°ì†Œì™€ ë¹„êµë©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¯¸êµ­ ìƒë°˜ê¸° ë¹„êµì˜ ì˜í–¥ì—ë„ ë¶ˆêµ¬í•˜ê³  ì—°ì†Œí˜• ì œí’ˆì´ ì£¼ë„í•˜ëŠ” ê°€ê²© ì¸¡ë©´ì—ì„œ ë˜ ë‹¤ë¥¸ ê°•ë ¥í•œ í•œ í•´ë¥¼ ì˜ˆìƒí•˜ë©°, ë¬´ì—° ì œí’ˆ ë¯¹ìŠ¤ì˜ ì§€ì†ì ì¸ ê¸ì •ì  íš¨ê³¼ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ëª¨ë“  ìš”ì†Œë“¤ì„ ì¢…í•©ì ìœ¼ë¡œ ê³ ë ¤í•  ë•Œ, ìš°ë¦¬ëŠ” 2026ë…„ ìœ ê¸°ì  ìˆœë§¤ì¶œ ì„±ì¥ë¥ ì„ 5%ì—ì„œ 7%ë¡œ ì „ë§í•©ë‹ˆë‹¤.</td></tr>
<tr><td>We expect the same factors in addition to operating leverage and ongoing cost efficiencies to drive further robust margin expansion with projected organic operating income growth of 7% to 9%. This includes continued strong investment behind our smoke-free portfolio. We are forecasting currency-neutral adjusted diluted EPS growth of 7.5% to 9.5%, factoring in broadly stable net finance cost and an effective corporate tax rate approximately in line with 2025 at around 21.5%. Including an estimated $0.28 currency benefit at prevailing exchange rates, this translates to 11.3% to 13.3% growth to a range of $8.39 to $8.54, which would mark another year of double-digit EPS growth in dollar terms.</td><td>ì €í¬ëŠ” ë™ì¼í•œ ìš”ì¸ë“¤ì— ë”í•´ ì˜ì—… ë ˆë²„ë¦¬ì§€ì™€ ì§€ì†ì ì¸ ë¹„ìš© íš¨ìœ¨ì„±ì´ ì¶”ê°€ì ì¸ ê²¬ê³ í•œ ë§ˆì§„ í™•ëŒ€ë¥¼ ê²¬ì¸í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ìœ ê¸°ì  ì˜ì—…ì´ìµì€ 7%ì—ì„œ 9% ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ë¬´ì—° ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ì— ëŒ€í•œ ì§€ì†ì ì´ê³  ê°•ë ¥í•œ íˆ¬ìê°€ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” í™˜ìœ¨ì¤‘ë¦½ ê¸°ì¤€ ì¡°ì • í¬ì„ì£¼ë‹¹ìˆœì´ìµì´ 7.5%ì—ì„œ 9.5% ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ëŒ€ì²´ë¡œ ì•ˆì •ì ì¸ ìˆœê¸ˆìœµë¹„ìš©ê³¼ 2025ë…„ê³¼ ëŒ€ì²´ë¡œ ë¹„ìŠ·í•œ ìˆ˜ì¤€ì¸ ì•½ 21.5%ì˜ ì‹¤íš¨ë²•ì¸ì„¸ìœ¨ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. í˜„í–‰ í™˜ìœ¨ ê¸°ì¤€ ì•½ 0.28ë‹¬ëŸ¬ì˜ í™˜ìœ¨ ì´ìµì„ í¬í•¨í•˜ë©´, ì´ëŠ” ë‹¬ëŸ¬ ê¸°ì¤€ìœ¼ë¡œ 11.3%ì—ì„œ 13.3% ì„±ì¥í•œ 8.39ë‹¬ëŸ¬ì—ì„œ 8.54ë‹¬ëŸ¬ ë²”ìœ„ë¡œ í™˜ì‚°ë˜ë©°, ì´ëŠ” ë‹¬ëŸ¬ ê¸°ì¤€ìœ¼ë¡œ ë˜ í•œ í•´ì˜ ë‘ ìë¦¿ìˆ˜ ì£¼ë‹¹ìˆœì´ìµ ì„±ì¥ì„ ê¸°ë¡í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>We expect a significant acceleration in operating cash flow growth at around $13.5 billion at prevailing exchange rates and subject to year-end working capital requirements. The strong cash generation is expected to support further meaningful deleveraging in 2026, which I will come back to shortly. On a quarterly basis, we expect the first quarter to be the softest quarter of the year, reflecting demanding year-on-year comparisons and investment phasing. We expect first quarter combustible volumes to decline by up to 5% as we lap a prior year quarter of volume growth, whilst having the highest expected impact of the dynamics in Turkey, India and Mexico, which I mentioned for the full year.</td><td>ì €í¬ëŠ” í˜„ì¬ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ ì•½ 135ì–µ ë‹¬ëŸ¬ ìˆ˜ì¤€ì˜ ì˜ì—…í˜„ê¸ˆíë¦„ ì„±ì¥ì´ í¬ê²Œ ê°€ì†í™”ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” ì—°ë§ ìš´ì „ìë³¸ ìš”êµ¬ì‚¬í•­ì— ë”°ë¼ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê°•ë ¥í•œ í˜„ê¸ˆ ì°½ì¶œì€ 2026ë…„ì— ì¶”ê°€ì ì¸ ì˜ë¯¸ ìˆëŠ” ì°¨ì…ê¸ˆ ê°ì¶•ì„ ë’·ë°›ì¹¨í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ì´ì— ëŒ€í•´ì„œëŠ” ê³§ ë‹¤ì‹œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¶„ê¸°ë³„ë¡œ ë³´ë©´, 1ë¶„ê¸°ê°€ ì—°ì¤‘ ê°€ì¥ ë¶€ì§„í•œ ë¶„ê¸°ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ”ë°, ì´ëŠ” ì „ë…„ ë™ê¸° ëŒ€ë¹„ ê¹Œë‹¤ë¡œìš´ ë¹„êµ ê¸°ì¤€ê³¼ íˆ¬ì ì‹œê¸° ë°°ë¶„ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. 1ë¶„ê¸° ê°€ì—°ì„± ì œí’ˆ íŒë§¤ëŸ‰ì€ ìµœëŒ€ 5% ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ”ë°, ì´ëŠ” ì „ë…„ ë™ê¸°ì˜ íŒë§¤ëŸ‰ ì¦ê°€ì„¸ì™€ ë¹„êµë˜ëŠ” ê²ƒì´ë©°, ì œê°€ ì—°ê°„ ì „ë§ì—ì„œ ì–¸ê¸‰í–ˆë˜ í„°í‚¤, ì¸ë„, ë©•ì‹œì½”ì˜ ì‹œì¥ ì—­í•™ ì˜í–¥ì´ ê°€ì¥ í¬ê²Œ ë‚˜íƒ€ë‚  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Smoke-free product shipments will also be impacted by the U.S. ZYN shipment dynamics explained by Emmanuel and the strong HTU comparator. With low levels of commercial activity on ZYN in prior year, impacting the net revenue per can comparison and a higher quarter of investment globally behind our smoke-free due to phasing, we anticipate broadly flat year-on-year first quarter organic net revenue and operating income. We forecast high single-digit adjusted diluted EPS growth of $1.80 to $1.85, including a $0.14 tailwind at prevailing rates, supported by a favorable comparison to transactional currency impacts in the prior year.</td><td>ë¬´ì—° ì œí’ˆ ì¶œí•˜ëŸ‰ë„ Emmanuelì´ ì„¤ëª…í•œ ë¯¸êµ­ ZYN ì¶œí•˜ ì—­í•™ê³¼ ê°•ë ¥í•œ HTU ë¹„êµ ê¸°ì €ì˜ ì˜í–¥ì„ ë°›ì„ ê²ƒì…ë‹ˆë‹¤. ì „ë…„ë„ ZYNì— ëŒ€í•œ ë‚®ì€ ìˆ˜ì¤€ì˜ ìƒì—… í™œë™ì´ ìº”ë‹¹ ìˆœìˆ˜ìµ ë¹„êµì— ì˜í–¥ì„ ë¯¸ì¹˜ê³ , ë‹¨ê³„ì  íˆ¬ìë¡œ ì¸í•´ ì „ ì„¸ê³„ì ìœ¼ë¡œ ë¬´ì—° ì œí’ˆì— ëŒ€í•œ ë¶„ê¸°ë³„ íˆ¬ìê°€ ì¦ê°€í•¨ì— ë”°ë¼, 1ë¶„ê¸° ìœ ê¸°ì  ìˆœìˆ˜ìµê³¼ ì˜ì—…ì´ìµì€ ì „ë…„ ëŒ€ë¹„ ëŒ€ì²´ë¡œ ë³´í•©ì„¸ë¥¼ ë³´ì¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµì€ 1.80ë‹¬ëŸ¬ì—ì„œ 1.85ë‹¬ëŸ¬ë¡œ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ê¸°ë¡í•  ê²ƒìœ¼ë¡œ ì „ë§í•˜ë©°, ì—¬ê¸°ì—ëŠ” í˜„í–‰ í™˜ìœ¨ ê¸°ì¤€ 0.14ë‹¬ëŸ¬ì˜ ìˆœí’ íš¨ê³¼ê°€ í¬í•¨ë˜ì–´ ìˆìœ¼ë©°, ì´ëŠ” ì „ë…„ë„ ê±°ë˜ í™˜ìœ¨ ì˜í–¥ê³¼ì˜ ìœ ë¦¬í•œ ë¹„êµì— ì˜í•´ ë’·ë°›ì¹¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>As I mentioned earlier, we have delivered our 3-year CAGR targets on operating income and EPS in just 2 years. Combining our 2026 forecast with the strong results of 2024 and 2025, we expect to meet or exceed all of our 2024-'26 CAGR targets presented at our 2023 Investor Day. This is especially the case for operating income and EPS growth, despite our algorithm assuming a more favorable corporate tax rate. In addition, our expected adjusted EPS CAGR in dollar terms represent a strong double-digit delivery. This brings me to the 2026-2028 outlook, where we are renewing our medium-term growth targets in the next 3 years.</td><td>ì•ì„œ ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ìš°ë¦¬ëŠ” ì˜ì—…ì´ìµê³¼ ì£¼ë‹¹ìˆœì´ìµ(EPS)ì— ëŒ€í•œ 3ê°œë…„ ì—°í‰ê·  ì„±ì¥ë¥ (CAGR) ëª©í‘œë¥¼ ë‹¨ 2ë…„ ë§Œì— ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. 2026ë…„ ì „ë§ì¹˜ë¥¼ 2024ë…„ê³¼ 2025ë…„ì˜ ê°•ë ¥í•œ ì‹¤ì ê³¼ ê²°í•©í•˜ë©´, 2023ë…„ íˆ¬ììì˜ ë‚ ì— ì œì‹œí•œ 2024~2026ë…„ ëª¨ë“  ì—°í‰ê·  ì„±ì¥ë¥  ëª©í‘œë¥¼ ë‹¬ì„±í•˜ê±°ë‚˜ ì´ˆê³¼í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì´ëŠ” íŠ¹íˆ ì˜ì—…ì´ìµê³¼ ì£¼ë‹¹ìˆœì´ìµ ì„±ì¥ì— í•´ë‹¹ë˜ëŠ”ë°, ìš°ë¦¬ì˜ ì‚°ì • ê¸°ì¤€ì´ ë” ìœ ë¦¬í•œ ë²•ì¸ì„¸ìœ¨ì„ ê°€ì •í–ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³  ê·¸ëŸ¬í•©ë‹ˆë‹¤. ë˜í•œ, ë‹¬ëŸ¬ ê¸°ì¤€ìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì˜ ì—°í‰ê·  ì„±ì¥ë¥ ì€ ê°•ë ¥í•œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ì´ì œ 2026~2028ë…„ ì „ë§ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. í–¥í›„ 3ë…„ê°„ ì¤‘ê¸° ì„±ì¥ ëª©í‘œë¥¼ ìƒˆë¡­ê²Œ ì„¤ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We continue to target positive total shipment volumes, with the growth of smoke-free products more than offsetting cigarette volume declines. While our 2026 forecast ranges are marginally lower due to the specific factors we explained, for the 3-year period to 2028, we continue to target compound annual growth rate of 6% to 8% in organic net revenues, 8% to 10% in organic operating income as margins expand and 9% to 11% in adjusted diluted EPS at constant currency. This renewed target reflects our confidence in sustaining the strong pace of top and bottom line growth over time. They also reaffirm our best-in-class growth profile within the large cap consumer packaged goods sector.</td><td>ìš°ë¦¬ëŠ” ë¬´ì—° ì œí’ˆì˜ ì„±ì¥ì´ ë‹´ë°° íŒë§¤ëŸ‰ ê°ì†Œë¥¼ ìƒì‡„í•˜ê³ ë„ ë‚¨ì„ ê²ƒìœ¼ë¡œ ë³´ì•„ ì´ ì¶œí•˜ëŸ‰ì˜ í”ŒëŸ¬ìŠ¤ ì„±ì¥ì„ ì§€ì†ì ìœ¼ë¡œ ëª©í‘œí•˜ê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ ì „ë§ ë²”ìœ„ê°€ ì•ì„œ ì„¤ëª…ë“œë¦° íŠ¹ì • ìš”ì¸ë“¤ë¡œ ì¸í•´ ì†Œí­ í•˜í–¥ ì¡°ì •ë˜ì—ˆì§€ë§Œ, 2028ë…„ê¹Œì§€ì˜ 3ê°œë…„ ê¸°ê°„ ë™ì•ˆ ìœ ê¸°ì  ìˆœë§¤ì¶œ ì—°í‰ê·  ì„±ì¥ë¥  6~8%, ë§ˆì§„ í™•ëŒ€ì— ë”°ë¥¸ ìœ ê¸°ì  ì˜ì—…ì´ìµ ì—°í‰ê·  ì„±ì¥ë¥  8~10%, ê·¸ë¦¬ê³  ë¶ˆë³€í™˜ìœ¨ ê¸°ì¤€ ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ ì—°í‰ê·  ì„±ì¥ë¥  9~11%ë¥¼ ì§€ì†ì ìœ¼ë¡œ ëª©í‘œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê°±ì‹ ëœ ëª©í‘œëŠ” ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ê°•ë ¥í•œ ë§¤ì¶œ ë° ìˆ˜ìµ ì„±ì¥ ì†ë„ë¥¼ ìœ ì§€í•  ìˆ˜ ìˆë‹¤ëŠ” ìš°ë¦¬ì˜ í™•ì‹ ì„ ë°˜ì˜í•©ë‹ˆë‹¤. ë˜í•œ ì´ëŠ” ëŒ€í˜• ì†Œë¹„ì¬ ë¶€ë¬¸ ë‚´ì—ì„œ ìš°ë¦¬ì˜ ìµœê³  ìˆ˜ì¤€ì˜ ì„±ì¥ í”„ë¡œí•„ì„ ì¬í™•ì¸ì‹œì¼œ ì¤ë‹ˆë‹¤.</td></tr>
<tr><td>We target smoke-free product shipment and adjusted IMS volume growth of high single digits to low teens. Our multi-category strategy in international markets will continue to be the dominant driver of smoke-free products growth, further amplified by the substantial opportunity in the U.S. As we progress through the period, we expect this to be bolstered by the new market openings and an active innovation pipeline. The U.S. launch of IQOS ILUMA is included in the target, including initial commercial investment, with the precise cadence subject to the timing of launch.</td><td>ë¬´ì—° ì œí’ˆ ì¶œí•˜ëŸ‰ê³¼ ì¡°ì • IMS ë³¼ë¥¨ ì„±ì¥ë¥ ì€ ë†’ì€ í•œ ìë¦¿ìˆ˜ì—ì„œ ë‚®ì€ ë‘ ìë¦¿ìˆ˜ë¥¼ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. êµ­ì œ ì‹œì¥ì—ì„œì˜ ë‹¤ì¤‘ ì¹´í…Œê³ ë¦¬ ì „ëµì€ ë¬´ì—° ì œí’ˆ ì„±ì¥ì˜ ì§€ë°°ì ì¸ ë™ë ¥ìœ¼ë¡œ ê³„ì†ë  ê²ƒì´ë©°, ë¯¸êµ­ ë‚´ ìƒë‹¹í•œ ê¸°íšŒë¡œ ë”ìš± ì¦í­ë  ê²ƒì…ë‹ˆë‹¤. ê¸°ê°„ì´ ì§„í–‰ë¨ì— ë”°ë¼ ì‹ ê·œ ì‹œì¥ ê°œì²™ê³¼ í™œë°œí•œ í˜ì‹  íŒŒì´í”„ë¼ì¸ìœ¼ë¡œ ë”ìš± ê°•í™”ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ë¯¸êµ­ ë‚´ IQOS ILUMA ì¶œì‹œê°€ ëª©í‘œì— í¬í•¨ë˜ì–´ ìˆìœ¼ë©°, ì´ˆê¸° ìƒì—…ì  íˆ¬ìë„ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì •í™•í•œ ì§„í–‰ ì†ë„ëŠ” ì¶œì‹œ ì‹œê¸°ì— ë”°ë¼ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Meanwhile, the resilience of our combustible portfolio provides a critical backbone, providing the infrastructure, financial firepower and consumer connection to accelerate smoke-free growth. We look forward to sharing more with you on this topic at the CAGNY Conference on February 18. We remain a highly cash generative business, which is based on the strength of our brands and reinforced by disciplined management of cost and cash. This gives us the financial capacity to invest strongly behind our smoke-free business, maintain superior shareholder returns and optimize our balance sheet.</td><td>í•œí¸, ìš°ë¦¬ì˜ ì—°ì†Œí˜• ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ì˜ íšŒë³µë ¥ì€ ì¤‘ìš”í•œ ê·¼ê°„ì„ ì œê³µí•˜ë©°, ë¹„ì—°ì†Œ ì œí’ˆ ì„±ì¥ì„ ê°€ì†í™”í•˜ëŠ” ë° í•„ìš”í•œ ì¸í”„ë¼, ì¬ë¬´ì  ì—­ëŸ‰, ê·¸ë¦¬ê³  ì†Œë¹„ì ì—°ê²°ì„±ì„ ì œê³µí•©ë‹ˆë‹¤. 2ì›” 18ì¼ CAGNY ì»¨í¼ëŸ°ìŠ¤ì—ì„œ ì´ ì£¼ì œì— ëŒ€í•´ ë” ë§ì€ ë‚´ìš©ì„ ê³µìœ í•  ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì—¬ì „íˆ ë†’ì€ í˜„ê¸ˆ ì°½ì¶œë ¥ì„ ë³´ìœ í•œ ê¸°ì—…ì´ë©°, ì´ëŠ” ìš°ë¦¬ ë¸Œëœë“œì˜ ê°•ì ì— ê¸°ë°˜í•˜ê³  ë¹„ìš©ê³¼ í˜„ê¸ˆì— ëŒ€í•œ ì² ì €í•œ ê´€ë¦¬ë¡œ ë”ìš± ê°•í™”ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ìš°ë¦¬ëŠ” ë¹„ì—°ì†Œ ì‚¬ì—…ì— ê°•ë ¥í•˜ê²Œ íˆ¬ìí•˜ê³ , ìš°ìˆ˜í•œ ì£¼ì£¼ í™˜ì›ì„ ìœ ì§€í•˜ë©°, ì¬ë¬´êµ¬ì¡°ë¥¼ ìµœì í™”í•  ìˆ˜ ìˆëŠ” ì¬ë¬´ì  ì—­ëŸ‰ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Over the next 3 years, we target aggregate operating cash flow of around $45 billion at prevailing exchange rates. We anticipate capital expenditures of approximately $1.3 billion to $1.5 billion per annum on average, with the potential for lower amounts beyond 2026, and the lion's share of investments again focused on smoke-free products. Alongside superior business results, we are committed to delivering superior shareholder value. Having essentially reached our target dividend payout ratio of around 75% of adjusted diluted EPS, we have the capacity to pursue dividend growth closer to the level of earnings growth, as demonstrated by the 8.9% increase announced in September last year.</td><td>í–¥í›„ 3ë…„ê°„ í˜„ì¬ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ ì•½ 450ì–µ ë‹¬ëŸ¬ì˜ ì´ ì˜ì—…í˜„ê¸ˆíë¦„ì„ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìë³¸ì ì§€ì¶œì€ ì—°í‰ê·  ì•½ 13ì–µ~15ì–µ ë‹¬ëŸ¬ë¥¼ ì˜ˆìƒí•˜ë©°, 2026ë…„ ì´í›„ì—ëŠ” ë” ë‚®ì€ ìˆ˜ì¤€ì´ ë  ê°€ëŠ¥ì„±ì´ ìˆìŠµë‹ˆë‹¤. íˆ¬ìì˜ ëŒ€ë¶€ë¶„ì€ ë‹¤ì‹œ í•œë²ˆ ë¹„ì—°ì†Œ ì œí’ˆì— ì§‘ì¤‘ë  ê²ƒì…ë‹ˆë‹¤. ìš°ìˆ˜í•œ ì‚¬ì—… ì‹¤ì ê³¼ ë”ë¶ˆì–´, ìš°ë¦¬ëŠ” ìš°ì›”í•œ ì£¼ì£¼ê°€ì¹˜ ì œê³µì— ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¡°ì • í¬ì„ì£¼ë‹¹ìˆœì´ìµ ëŒ€ë¹„ ì•½ 75%ì˜ ëª©í‘œ ë°°ë‹¹ì„±í–¥ì— ì‚¬ì‹¤ìƒ ë„ë‹¬í–ˆê¸° ë•Œë¬¸ì—, ì‘ë…„ 9ì›”ì— ë°œí‘œí•œ 8.9% ì¸ìƒì—ì„œ ë³´ì—¬ë“œë¦° ë°”ì™€ ê°™ì´, ì´ìµ ì„±ì¥ë¥  ìˆ˜ì¤€ì— ê°€ê¹Œìš´ ë°°ë‹¹ ì„±ì¥ì„ ì¶”êµ¬í•  ìˆ˜ ìˆëŠ” ì—¬ë ¥ì„ ê°–ì¶”ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Strong cash flow and EBITDA growth enables deleveraging. We closed 2025 with an adjusted leverage ratio of 2.5x, reflecting solid progress despite the unfavorable impact of year-end currency movements and our net debt. We expect further improvements in 2026, targeting close to the 2x by year-end at prevailing exchange rates, providing increased flexibility for capital allocation. In summary, our full year performance underscores the strength and the momentum of our global smoke-free business, supported by investment in our premium brands and the continued resilience of combustibles.</td><td>ê°•ë ¥í•œ í˜„ê¸ˆíë¦„ê³¼ EBITDA ì„±ì¥ìœ¼ë¡œ ë¶€ì±„ë¹„ìœ¨ ê°œì„ ì´ ê°€ëŠ¥í–ˆìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” 2025ë…„ì„ ì¡°ì • ë ˆë²„ë¦¬ì§€ ë¹„ìœ¨ 2.5ë°°ë¡œ ë§ˆê°í–ˆìœ¼ë©°, ì´ëŠ” ì—°ë§ í™˜ìœ¨ ë³€ë™ê³¼ ìˆœë¶€ì±„ì— ëŒ€í•œ ë¶ˆë¦¬í•œ ì˜í–¥ì—ë„ ë¶ˆêµ¬í•˜ê³  ê²¬ê³ í•œ ì§„ì „ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. 2026ë…„ì—ëŠ” ì¶”ê°€ì ì¸ ê°œì„ ì„ ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, í˜„í–‰ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ ì—°ë§ê¹Œì§€ 2ë°° ìˆ˜ì¤€ì— ê·¼ì ‘í•˜ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•˜ê³  ìˆì–´, ìë³¸ ë°°ë¶„ì— ëŒ€í•œ ìœ ì—°ì„±ì´ ì¦ëŒ€ë  ê²ƒì…ë‹ˆë‹¤. ìš”ì•½í•˜ìë©´, ë‹¹ì‚¬ì˜ ì—°ê°„ ì‹¤ì ì€ í”„ë¦¬ë¯¸ì—„ ë¸Œëœë“œì— ëŒ€í•œ íˆ¬ìì™€ ì—°ì†Œí˜• ì œí’ˆì˜ ì§€ì†ì ì¸ íšŒë³µë ¥ì— í˜ì…ì–´ ê¸€ë¡œë²Œ ë¹„ì—°ì†Œ ì‚¬ì—…ì˜ ê°•ì ê³¼ ëª¨ë©˜í…€ì„ ì…ì¦í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Despite the complex operating environment shaped by economic uncertainties, political tensions and evolving regulations, we continue to make significant progress towards our vision of a smoke-free future. As we delivered consistent best-in-class growth, we are reinvesting in our leading brands, innovation and the critical capabilities which support long-term performance. This allows us to generate significant value for our shareholders, including the largest dividend increase in over a decade. We look forward with confidence to 2026 and beyond. Thank you. Emmanuel and I will be happy now to answer your questions.</td><td>ê²½ì œì  ë¶ˆí™•ì‹¤ì„±, ì •ì¹˜ì  ê¸´ì¥, ê·¸ë¦¬ê³  ë³€í™”í•˜ëŠ” ê·œì œë¡œ ì¸í•œ ë³µì¡í•œ ì‚¬ì—… í™˜ê²½ì—ë„ ë¶ˆêµ¬í•˜ê³ , ìš°ë¦¬ëŠ” ì—°ê¸° ì—†ëŠ” ë¯¸ë˜(smoke-free future)ë¼ëŠ” ë¹„ì „ì„ í–¥í•´ ì§€ì†ì ìœ¼ë¡œ ìƒë‹¹í•œ ì§„ì „ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤. ì—…ê³„ ìµœê³  ìˆ˜ì¤€ì˜ ì¼ê´€ëœ ì„±ì¥ì„ ë‹¬ì„±í•˜ë©´ì„œ, ìš°ë¦¬ëŠ” ì£¼ë ¥ ë¸Œëœë“œ, í˜ì‹ , ê·¸ë¦¬ê³  ì¥ê¸°ì  ì„±ê³¼ë¥¼ ë’·ë°›ì¹¨í•˜ëŠ” í•µì‹¬ ì—­ëŸ‰ì— ì¬íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ìš°ë¦¬ëŠ” ì£¼ì£¼ë“¤ì„ ìœ„í•´ ìƒë‹¹í•œ ê°€ì¹˜ë¥¼ ì°½ì¶œí•˜ê³  ìˆìœ¼ë©°, ì—¬ê¸°ì—ëŠ” 10ë…„ ë§Œì— ìµœëŒ€ ê·œëª¨ì˜ ë°°ë‹¹ê¸ˆ ì¸ìƒë„ í¬í•¨ë©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” 2026ë…„ê³¼ ê·¸ ì´í›„ë¥¼ ìì‹ ê°ì„ ê°€ì§€ê³  ë°”ë¼ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì— ë§ˆë‰´ì—˜ê³¼ ì œê°€ ê¸°êº¼ì´ ì—¬ëŸ¬ë¶„ì˜ ì§ˆë¬¸ì— ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Philip Morris International Q4 2025 ì‹¤ì  ìš”ì•½<br><br>## í•µì‹¬ ì¬ë¬´ ì„±ê³¼<br>- **2025ë…„ ì—°ê°„ ì‹¤ì **: ì¡°ì • í¬ì„ ì£¼ë‹¹ìˆœì´ìµ(EPS) 15% ì„±ì¥($7.54), ìœ ê¸°ì  ì˜ì—…ì´ìµ 10.6% ì¦ê°€($164ì–µ), ìœ ê¸°ì  ë§¤ì¶œ 6.5% ì„±ì¥(ì¸ë„ë„¤ì‹œì•„ ì œì™¸ ì‹œ 7.9%)<br>- **ë¹„ì—°ì†Œ ì œí’ˆ ê°•ì„¸**: ë¹„ì—°ì†Œ ì œí’ˆ ë§¤ì¶œì´ ì „ì²´ì˜ 41.5%($170ì–µ), ì´ì´ìµ ê¸°ì—¬ë„ 43%ë¡œ 5ë…„ê°„ 2ë°° ì¦ê°€. ë¹„ì—°ì†Œ ì œí’ˆ ì¶œí•˜ëŸ‰ 12.8% ì¦ê°€(179ì–µ ê°œë¹„)<br>- **2026ë…„ ê°€ì´ë˜ìŠ¤**: ìœ ê¸°ì  ë§¤ì¶œ 5~7%, ì˜ì—…ì´ìµ 7~9%, í™˜ìœ¨ì¤‘ë¦½ EPS 7.5~9.5% ì„±ì¥ ì „ë§($8.39~$8.54). ì˜ì—…í˜„ê¸ˆíë¦„ ì•½ $135ì–µ ì˜ˆìƒ<br><br>## ì£¼ìš” ì‚¬ì—… ë™í–¥<br>- **IQOS**: ì¡°ì • ì‹œì¥íŒë§¤ëŸ‰ 11% ì„±ì¥, ê¸€ë¡œë²Œ ê°€ì—´ë‹´ë°° ì‹œì¥ì ìœ ìœ¨ 76% ìœ ì§€. ì¼ë³¸ì€ ê°€ì—´ë‹´ë°° ì‹œì¥ì ìœ ìœ¨ 50% ëŒíŒŒí–ˆìœ¼ë‚˜ 2026ë…„ ì†Œë¹„ì„¸ ì¸ìƒ(í˜„ ê°€ê²©ì˜ 20% ìˆ˜ì¤€)ìœ¼ë¡œ ë‹¨ê¸° ì—­í’ ì˜ˆìƒ<br>- **ZYN**: ë¯¸êµ­ ì¶œí•˜ëŸ‰ 37% ì¦ê°€(7.94ì–µ ìº”), ì‹œì¥ì ìœ ìœ¨ 61.5%. ê³µê¸‰ ì œì•½ í•´ì†Œ í›„ ì±„ë„ ì¬ê³  ì •ìƒí™”ë¡œ 1ë¶„ê¸° ì•½ 2,500ë§Œ ìº” ì¬ê³  ì¡°ì • ì˜ˆìƒ. êµ­ì œì‹œì¥</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] Our first question comes from Matt Smith with Stifel.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>[ìš´ì˜ì ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ ìŠ¤í‹°í„ì˜ Matt Smithë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Matthew Smith: Stifel, Nicolaus & Company, Incorporated, Research Division Starting with the new medium-term targets that you provided today, can you expand on the reacceleration in smoke-free volume growth compared to the 2026 growth guidance? And you called out the U.S. as a new market in the outlook. How are other currently closed markets and the opportunity to expand platforms into existing IQOS markets considered?</td><td>**Matthew Smith:** ì¤‘ê¸° ëª©í‘œì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, 2026ë…„ ê°€ì´ë˜ìŠ¤ ëŒ€ë¹„ ë¬´ì—° ì œí’ˆ ë³¼ë¥¨ ì„±ì¥ì´ ì¬ê°€ì†í™”ë˜ëŠ” ê²ƒì€ ì—¬ëŸ¬ ìš”ì¸ì— ê¸°ë°˜í•©ë‹ˆë‹¤. ë¯¸êµ­ ì‹œì¥ ì§„ì¶œì€ ë¶„ëª… ì¤‘ìš”í•œ ë™ë ¥ì´ ë  ê²ƒì…ë‹ˆë‹¤. <br><br>í˜„ì¬ ë¯¸ì§„ì¶œ ì‹œì¥ë“¤ì˜ ê²½ìš°, ë‹¨ê³„ì  í™•ì¥ ê³„íšì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê° ì‹œì¥ì˜ ê·œì œ í™˜ê²½ê³¼ ì§„ì… ì‹œê¸°ë¥¼ ë©´ë°€íˆ ê²€í† í•˜ê³  ìˆìœ¼ë©°, ë¯¸êµ­ ì™¸ì—ë„ ì¶”ê°€ ì‹œì¥ ê¸°íšŒë“¤ì„ ì§€ì†ì ìœ¼ë¡œ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ê¸°ì¡´ IQOS ì‹œì¥ì—ì„œì˜ í”Œë«í¼ í™•ì¥ ê¸°íšŒë„ ìƒë‹¹í•©ë‹ˆë‹¤. IQOS ILUMAì™€ ê°™ì€ ì°¨ì„¸ëŒ€ ì œí’ˆìœ¼ë¡œì˜ ì „í™˜, ZYNê³¼ ê°™ì€ ë‹ˆì½”í‹´ íŒŒìš°ì¹˜ ì œí’ˆêµ°ì˜ í™•ëŒ€, ê·¸ë¦¬ê³  ê° ì‹œì¥ë³„ ì†Œë¹„ì ë‹ˆì¦ˆì— ë§ëŠ” ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ ë‹¤ê°í™”ë¥¼ ì¶”ì§„í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì´ëŸ¬í•œ ì‹ ê·œ ì‹œì¥ ì§„ì¶œê³¼ ê¸°ì¡´ ì‹œì¥ì—ì„œì˜ í”Œë«í¼ í™•ì¥ì´ ê²°í•©ë˜ë©´ì„œ, 2026ë…„ ì´í›„ ë¬´ì—° ì œí’ˆ ë³¼ë¥¨ì˜ ì¬ê°€ì† ì„±ì¥ì´ ê°€ëŠ¥í•  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. íŠ¹íˆ ë¯¸êµ­ ì‹œì¥ì—ì„œì˜ ë³¸ê²©ì ì¸ ì„±ê³¼ê°€ ê°€ì‹œí™”ë˜ëŠ” ì‹œì ê³¼ ë§ë¬¼ë ¤ ì „ì²´ì ì¸ ì„±ì¥ ëª¨ë©˜í…€ì´ ê°•í™”ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Jacek Olczak: Group CEO & Director Yes, the acceleration in -- or beyond '26 is, at this stage, we mainly see coming from all the implementations of the tax changes, which are price -- or excise-driven price changes in Japan. As you may recall, Japan has the multistep excise tobacco, nicotine products, exise tax changes. It starts with the symmetry of heated tobacco products increasing the taxes first, and then followed by the cigarette price increases as of '27. So I believe -- we believe at this stage, there will be some headwinds or maybe some headwinds on the category growth, and obviously, IQOS growth in '26. But once we start moving to the '27 and beyond, more symmetry with regards to the fiscal policy and treatment between a cigarette and heat-not-burn. I mean, IQOS as the category should be returning or resuming growth. So that's the one factor. And second factor, obviously, is that as we highlighted in our remarks, I mean there is a highly competitive environment in the U.S. And despite U.S. in the total smoke-free volumes maybe doesn't have that much of a weight, but for growth, it's very opportunities and the growth is very important to us. There are some symmetries on the portfolio versus what is presumably the most dynamic part in the total market. And we believe we've -- author -- pending authorization with the FDA once we will start moving hopefully through '26. But definitely '27, et cetera, we're going to put the portfolio into the symmetry of what are the consumer market expectations. Now obviously, the other factors which we mentioned, they are more on the combustible side. I mean not on smoke-free products. I mean we mentioned India, Mexico, maybe a couple other smaller places which have some quite outsized, I would characterize, excise increases, which obviously will drive the quite outsized -- the normal price increases. So I believe once we -- we don't think that's going to be a recurring type of events, '27, '28, so we can come back and resume the strong top -- bottom line growth in the outer years. I think I just highlighted the key drivers. There is obviously the factor of innovations. But you will ask me the question, what exactly is the innovation for competitive reason. I will not be able to discuss. But this will be the main drivers coming or starting from '26. The excise Japan, excise in a few other places and the ZYN portfolio asymmetry and bringing this to the symmetry.</td><td>**Jacek Olczak:** ë„¤, 2026ë…„ ì´í›„ì˜ ê°€ì†í™”ëŠ” í˜„ ë‹¨ê³„ì—ì„œ ì£¼ë¡œ ì¼ë³¸ì˜ ì„¸ì œ ë³€ê²½ ì‹œí–‰ì— ë”°ë¥¸ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ë¬¼í’ˆì„¸ ê¸°ë°˜ì˜ ê°€ê²© ë³€ë™ì…ë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ì¼ë³¸ì€ ë‹´ë°°ì™€ ë‹ˆì½”í‹´ ì œí’ˆì— ëŒ€í•´ ë‹¤ë‹¨ê³„ ë¬¼í’ˆì„¸ ë³€ê²½ì„ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¨¼ì € ê¶ë ¨í˜• ì „ìë‹´ë°°(heated tobacco products)ì— ëŒ€í•œ ì„¸ê¸ˆì´ ì¸ìƒë˜ë©´ì„œ ëŒ€ì¹­ì„±ì´ ë§ì¶°ì§€ê¸° ì‹œì‘í•˜ê³ , ì´í›„ 2027ë…„ë¶€í„° ì¼ë°˜ ë‹´ë°° ê°€ê²© ì¸ìƒì´ ë’¤ë”°ë¥´ê²Œ ë©ë‹ˆë‹¤. <br><br>ë”°ë¼ì„œ í˜„ì¬ë¡œì„œëŠ” 2026ë…„ì— ì¹´í…Œê³ ë¦¬ ì„±ì¥ê³¼ ë‹¹ì—°íˆ ì•„ì´ì½”ìŠ¤ ì„±ì¥ì—ë„ ì–´ëŠ ì •ë„ ì—­í’ì´ ìˆì„ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ 2027ë…„ ì´í›„ë¡œ ë„˜ì–´ê°€ë©´ì„œ ì¼ë°˜ ë‹´ë°°ì™€ ê¶ë ¨í˜• ì „ìë‹´ë°° ê°„ì˜ ì¡°ì„¸ ì •ì±…ê³¼ ì²˜ìš°ê°€ ë”ìš± ëŒ€ì¹­ì ìœ¼ë¡œ ë³€í™”í•˜ê²Œ ë©ë‹ˆë‹¤. IQOSê°€ ì¹´í…Œê³ ë¦¬ë¡œì„œ ì„±ì¥ì„ ì¬ê°œí•˜ê±°ë‚˜ íšŒë³µí•´ì•¼ í•œë‹¤ëŠ” ê²ƒì´ ì²« ë²ˆì§¸ ìš”ì¸ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‘ ë²ˆì§¸ ìš”ì¸ì€, ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ë¯¸êµ­ ì‹œì¥ì´ ë§¤ìš° ê²½ìŸì ì¸ í™˜ê²½ì´ë¼ëŠ” ì ì…ë‹ˆë‹¤. ì „ì²´ ë¬´ì—° ì œí’ˆ(smoke-free) ë³¼ë¥¨ì—ì„œ ë¯¸êµ­ì´ ì°¨ì§€í•˜ëŠ” ë¹„ì¤‘ì€ ê·¸ë¦¬ í¬ì§€ ì•Šì„ ìˆ˜ ìˆì§€ë§Œ, ì„±ì¥ ì¸¡ë©´ì—ì„œëŠ” ë§¤ìš° ì¤‘ìš”í•œ ê¸°íšŒì´ê³  ìš°ë¦¬ì—ê²Œ í° ì˜ë¯¸ê°€ ìˆìŠµë‹ˆë‹¤. í˜„ì¬ í¬íŠ¸í´ë¦¬ì˜¤ì™€ ì „ì²´ ì‹œì¥ì—ì„œ ê°€ì¥ ì—­ë™ì ì¸ ë¶€ë¶„ìœ¼ë¡œ ë³´ì´ëŠ” ì˜ì—­ ì‚¬ì´ì— ì¼ë¶€ ë¶ˆê· í˜•ì´ ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” FDA ìŠ¹ì¸ì„ ê¸°ë‹¤ë¦¬ê³  ìˆìœ¼ë©°, ìŠ¹ì¸ì´ ë‚˜ë©´ 2026ë…„ë¶€í„° ì›€ì§ì´ê¸° ì‹œì‘í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ëŠ¦ì–´ë„ 2027ë…„ë¶€í„°ëŠ” í™•ì‹¤íˆ ì†Œë¹„ì ì‹œì¥ì˜ ê¸°ëŒ€ì— ë¶€í•©í•˜ë„ë¡ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì¬ì •ë¹„í•  ê²ƒì…ë‹ˆë‹¤. ë¬¼ë¡  ìš°ë¦¬ê°€ ì–¸ê¸‰í•œ ë‹¤ë¥¸ ìš”ì¸ë“¤ì€ ë¬´ì—° ì œí’ˆë³´ë‹¤ëŠ” ì—°ì†Œí˜• ì œí’ˆ ìª½ì— ë” ê´€ë ¨ì´ ìˆìŠµë‹ˆë‹¤. ì¸ë„, ë©•ì‹œì½”, ê·¸ë¦¬ê³  ëª‡ëª‡ ì†Œê·œëª¨ ì‹œì¥ì—ì„œ ìƒë‹¹íˆ í° í­ì˜ ì†Œë¹„ì„¸ ì¸ìƒì´ ìˆì—ˆë‹¤ê³  ë§ì”€ë“œë ¸ëŠ”ë°, ì´ëŠ” ë‹¹ì—°íˆ ì¼ë°˜ì ì¸ ìˆ˜ì¤€ì„ í›¨ì”¬ ë„˜ì–´ì„œëŠ” ê°€ê²© ì¸ìƒì„ ìœ ë°œí•  ê²ƒì…ë‹ˆë‹¤. <br><br>ì €í¬ëŠ” ì´ëŸ° ì¼ì´ 27ë…„, 28ë…„ì— ë°˜ë³µì ìœ¼ë¡œ ë°œìƒí•˜ëŠ” ì‚¬ê±´ì€ ì•„ë‹ˆë¼ê³  ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ í–¥í›„ ì—°ë„ì—ëŠ” ê°•ë ¥í•œ ë§¤ì¶œê³¼ ìˆœì´ìµ ì„±ì¥ì„¸ë¥¼ íšŒë³µí•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ë°©ê¸ˆ ì£¼ìš” ë™ì¸ë“¤ì„ ê°•ì¡°í•´ì„œ ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. <br><br>ë¬¼ë¡  í˜ì‹ ì´ë¼ëŠ” ìš”ì†Œë„ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì •í™•íˆ ì–´ë–¤ í˜ì‹ ì¸ì§€ ì§ˆë¬¸í•˜ì‹ ë‹¤ë©´, ê²½ìŸìƒì˜ ì´ìœ ë¡œ êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€ë“œë¦´ ìˆ˜ëŠ” ì—†ìŠµë‹ˆë‹¤. <response><br><br>í•˜ì§€ë§Œ ì´ê²ƒë“¤ì´ 26ë…„ë¶€í„° ì‹œì‘ë˜ëŠ” ì£¼ìš” ë™ë ¥ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì¼ë³¸ì˜ ì†Œë¹„ì„¸, ëª‡ëª‡ ë‹¤ë¥¸ ì§€ì—­ì˜ ì†Œë¹„ì„¸, ê·¸ë¦¬ê³  ZYN í¬íŠ¸í´ë¦¬ì˜¤ì˜ ë¹„ëŒ€ì¹­ì„±ì„ ëŒ€ì¹­ìœ¼ë¡œ ì „í™˜í•˜ëŠ” ê²ƒì´ ì£¼ìš” ìš”ì¸ì´ ë˜ê² ìŠµë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Operator: Our next question comes from Eric Serotta with Morgan Stanley.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ëª¨ê±´ìŠ¤íƒ ë¦¬ì˜ ì—ë¦­ ì„¸ë¡œíƒ€ ì• ë„ë¦¬ìŠ¤íŠ¸ë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Eric Serotta: Morgan Stanley, Research Division Great. Thanks so much. In terms of a '26 guide for smoke-free volumes up in that high single digits to low teens range, how are you thinking, broad strokes? I know you're not guiding specifically, but how are you thinking in terms of IQOS HTU shipments and IMS? Obviously, there's the some of the specific headwinds you called out in terms of the excise in Japan. And then, in terms of the competitive environment in Japan, I believe it sort of started to step up around the second quarter of last year with some competitor product launches. How has that been kind of evolving on a sequential basis, particularly heading in now to the season where competitors have filed with the Finance Ministry for their price increases?</td><td>**Eric Serotta:** ê°ì‚¬í•©ë‹ˆë‹¤. 2026ë…„ ë¬´ì—° ì œí’ˆ ë¬¼ëŸ‰ ê°€ì´ë˜ìŠ¤ê°€ ë†’ì€ í•œ ìë¦¿ìˆ˜ì—ì„œ ë‚®ì€ ë‘ ìë¦¿ìˆ˜ ë²”ìœ„ë¡œ ì œì‹œë˜ì—ˆëŠ”ë°, êµ¬ì²´ì ì¸ ê°€ì´ë˜ìŠ¤ëŠ” ì•„ë‹ˆì§€ë§Œ ëŒ€ëµì ìœ¼ë¡œ ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. IQOS HTU ì¶œí•˜ëŸ‰ê³¼ IMS ì¸¡ë©´ì—ì„œ ì–´ë–»ê²Œ ë³´ê³  ê³„ì‹ ê°€ìš”? ì¼ë³¸ì˜ ì†Œë¹„ì„¸ ì¸ìƒê³¼ ê°™ì´ ì–¸ê¸‰í•˜ì‹  íŠ¹ì • ì—­í’ ìš”ì¸ë“¤ì´ ìˆëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¼ë³¸ ë‚´ ê²½ìŸ í™˜ê²½ê³¼ ê´€ë ¨í•´ì„œ, ì‘ë…„ 2ë¶„ê¸°ì¯¤ë¶€í„° ì¼ë¶€ ê²½ìŸì‚¬ë“¤ì˜ ì œí’ˆ ì¶œì‹œë¡œ ê²½ìŸì´ ì‹¬í™”ë˜ê¸° ì‹œì‘í•œ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìƒí™©ì´ ë¶„ê¸°ë³„ë¡œ ì–´ë–»ê²Œ ì „ê°œë˜ê³  ìˆëŠ”ì§€, íŠ¹íˆ ì§€ê¸ˆ ê²½ìŸì‚¬ë“¤ì´ ì¬ë¬´ë¶€ì— ê°€ê²© ì¸ìƒì„ ì‹ ì²­í•˜ëŠ” ì‹œì¦Œì— ì ‘ì–´ë“¤ë©´ì„œ ì–´ë–¤ ì–‘ìƒì¸ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Jacek Olczak: Group CEO & Director Yes. I'll start maybe with the second part of the second question. I mean, yes, there is a -- this year and the year before, there was an increased competitive activity in Japan. Judging by how strongly IQOS holds the share in Japan and continuing its growth, I think it all goes well. I think, look, we have 10 years of IQOS brand built in Japan and a number of steps of smaller, but also the big innovations, including IQOS ILUMA. So I think IQOS is entering this a bit challenging from a price excise perspective period, I think, relatively strong. Now I bring a very legitimate question, how we see the IQOS in Japan, but we try to stand away from giving a very precise volume, another outlook for one specific geography. As you will appreciate, there is a competition, and we don't want to highlight too much to reveal what our plans with regards to the price and share expectations or volume expectations. But when we come up with the guidance for the total smoke-free products volume evolution next year, I mean, all of these factors are baked in, if you like.</td><td>**Jacek Olczak:** ë„¤, ë‘ ë²ˆì§¸ ì§ˆë¬¸ì˜ í›„ë°˜ë¶€ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì˜¬í•´ì™€ ì‘ë…„ì— ì¼ë³¸ì—ì„œ ê²½ìŸì´ ì‹¬í™”ëœ ê²ƒì€ ì‚¬ì‹¤ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ IQOSê°€ ì¼ë³¸ì—ì„œ ì–¼ë§ˆë‚˜ ê°•ë ¥í•˜ê²Œ ì ìœ ìœ¨ì„ ìœ ì§€í•˜ê³  ì§€ì†ì ìœ¼ë¡œ ì„±ì¥í•˜ê³  ìˆëŠ”ì§€ë¥¼ ë³´ë©´, ëª¨ë“  ê²ƒì´ ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. IQOSëŠ” ì¼ë³¸ì—ì„œ 10ë…„ê°„ ë¸Œëœë“œë¥¼ êµ¬ì¶•í•´ì™”ê³ , IQOS ILUMAë¥¼ í¬í•¨í•œ í¬ê³  ì‘ì€ í˜ì‹ ë“¤ì„ ì§€ì†ì ìœ¼ë¡œ ì„ ë³´ì—¬ì™”ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ê°€ê²©ê³¼ ì„¸ê¸ˆ ì¸¡ë©´ì—ì„œ ë‹¤ì†Œ ì–´ë ¤ìš´ ì‹œê¸°ë¥¼ ë§ì´í•˜ê³  ìˆì§€ë§Œ, IQOSëŠ” ìƒëŒ€ì ìœ¼ë¡œ ê°•ë ¥í•œ ìœ„ì¹˜ì—ì„œ ì´ ì‹œê¸°ë¥¼ ë§ì´í•˜ê³  ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ì¼ë³¸ì—ì„œ IQOSë¥¼ ì–´ë–»ê²Œ ë³´ê³  ìˆëŠ”ì§€ì— ëŒ€í•œ ì§ˆë¬¸ì€ ë§¤ìš° íƒ€ë‹¹í•©ë‹ˆë‹¤ë§Œ, ì €í¬ëŠ” íŠ¹ì • ì§€ì—­ì— ëŒ€í•´ ë§¤ìš° êµ¬ì²´ì ì¸ ë¬¼ëŸ‰ì´ë‚˜ ì „ë§ì„ ì œì‹œí•˜ëŠ” ê²ƒì€ ì§€ì–‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê²½ìŸ ìƒí™©ì´ ìˆë‹¤ ë³´ë‹ˆ, ê°€ê²©ì´ë‚˜ ì ìœ ìœ¨ ê¸°ëŒ€ì¹˜, ë¬¼ëŸ‰ ê¸°ëŒ€ì¹˜ì— ê´€í•œ ì €í¬ ê³„íšì„ ë„ˆë¬´ êµ¬ì²´ì ìœ¼ë¡œ ë°íˆê³  ì‹¶ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤. ë‹¤ë§Œ ë‚´ë…„ ì „ì²´ ë¬´ì—° ì œí’ˆ(smoke-free products) ë¬¼ëŸ‰ ì „ë§ì— ëŒ€í•œ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•  ë•ŒëŠ”, ë§ì”€ë“œë¦° ì´ëŸ¬í•œ ìš”ì†Œë“¤ì´ ëª¨ë‘ ë°˜ì˜ë˜ì–´ ìˆë‹¤ê³  ë³´ì‹œë©´ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Emmanuel Babeau: Group Chief Financial Officer And maybe, Eric, on your first question globally on the IQOS outlook among this high single-digit growth for our SFP volume in '26. We're very pleased with the growth of IQOS. I mean we finished '25 very strongly, more than 12% adjusted in-market sales growth. Yes, Japan has been slowing down a bit, as we mentioned. But the number of markets reaccelerated, Italy is one of them. Europe is showing a number of markets, which are, I would say, accelerating like Germany, like Spain. You still have markets such as Romania, Bulgaria that are very nice complement to the growth. So the picture is very nice for IQOS. And of course, we continue -- or we expect that to continue in '26. And then you have all this new market in new economies that are being very successful. We have Indonesia, Philippines, the Gulf, Mexico. I mean you have plenty of markets where IQOS is accelerating. And last but not least, we are super pleased with the launch in Taiwan. I mean 4% in only a few weeks, it's quite an achievement, and we're excited about the outlook. So that is globally giving a nice picture for the continuation of a very good growth for IQOS in '26.</td><td>**Emmanuel Babeau:** 2026ë…„ ë¬´ì—° ì œí’ˆ(SFP) ë¬¼ëŸ‰ì˜ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ ì „ë§ ì†ì—ì„œ IQOSì˜ ê¸€ë¡œë²Œ ì „ë§ì— ëŒ€í•œ ì²« ë²ˆì§¸ ì§ˆë¬¸ì— ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. IQOSì˜ ì„±ì¥ì— ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2025ë…„ì„ ë§¤ìš° ê°•í•˜ê²Œ ë§ˆë¬´ë¦¬í–ˆê³ , ì¡°ì • ê¸°ì¤€ ì‹œì¥ ë‚´ ë§¤ì¶œì´ 12% ì´ìƒ ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ì¼ë³¸ì€ ë‹¤ì†Œ ë‘”í™”ë˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì—¬ëŸ¬ ì‹œì¥ì—ì„œ ì¬ê°€ì†ì´ ë‚˜íƒ€ë‚˜ê³  ìˆìœ¼ë©°, ì´íƒˆë¦¬ì•„ê°€ ê·¸ ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. ìœ ëŸ½ì—ì„œëŠ” ë…ì¼, ìŠ¤í˜ì¸ì²˜ëŸ¼ ê°€ì†í™”ë˜ê³  ìˆëŠ” ì‹œì¥ë“¤ì´ ë§ì´ ë³´ì…ë‹ˆë‹¤. ë£¨ë§ˆë‹ˆì•„, ë¶ˆê°€ë¦¬ì•„ ê°™ì€ ì‹œì¥ë“¤ë„ ì—¬ì „íˆ ì„±ì¥ì— ë§¤ìš° ì¢‹ì€ ë³´ì™„ì¬ ì—­í• ì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ IQOSì˜ ì „ì²´ ê·¸ë¦¼ì€ ë§¤ìš° ê¸ì •ì ì…ë‹ˆë‹¤. ë¬¼ë¡  ì´ëŸ¬í•œ íë¦„ì´ 2026ë…„ì—ë„ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì‹ í¥ ì‹œì¥ì—ì„œ ìƒˆë¡­ê²Œ ì§„ì¶œí•œ ì‹œì¥ë“¤ë„ ë§¤ìš° ì„±ê³µì ì¸ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì¸ë„ë„¤ì‹œì•„, í•„ë¦¬í•€, ê±¸í”„ ì§€ì—­, ë©•ì‹œì½”ê°€ ìˆìŠµë‹ˆë‹¤. IQOSê°€ ê°€ì†í™”ë˜ê³  ìˆëŠ” ì‹œì¥ì´ ì •ë§ ë§ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§ˆì§€ë§‰ìœ¼ë¡œ ëŒ€ë§Œ ì¶œì‹œì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¶ˆê³¼ ëª‡ ì£¼ ë§Œì— 4%ë¥¼ ë‹¬ì„±í•œ ê²ƒì€ ìƒë‹¹í•œ ì„±ê³¼ì´ë©°, í–¥í›„ ì „ë§ì— ëŒ€í•´ì„œë„ ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤. ì´ëŸ¬í•œ ê¸€ë¡œë²Œ ìƒí™©ì„ ì¢…í•©í•´ë³´ë©´ 26ë…„ì—ë„ IQOSê°€ ë§¤ìš° ì¢‹ì€ ì„±ì¥ì„¸ë¥¼ ì´ì–´ê°ˆ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Eric Serotta: Morgan Stanley, Research Division Great. And just one clarification question, just to be explicit in terms of the midterm or '26 to '28 guidance. Is the -- 26 -- correct me if I'm wrong, but '26 does not include anything for ILUMA in the U.S., but there is something included for the sort of '27-'28 time frame. Is that fair? Or correct me if I'm wrong, please.</td><td>**Eric Serotta:** ì¢‹ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¤‘ê¸° ë˜ëŠ” 26ë…„ì—ì„œ 28ë…„ ê°€ì´ë˜ìŠ¤ì™€ ê´€ë ¨í•´ì„œ ëª…í™•íˆ í•˜ë‚˜ë§Œ ì§šê³  ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì œê°€ ì˜ëª» ì•Œê³  ìˆë‹¤ë©´ ì •ì •í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤ë§Œ, 26ë…„ì—ëŠ” ë¯¸êµ­ ë‚´ ILUMA ê´€ë ¨ ë‚´ìš©ì´ ì „í˜€ í¬í•¨ë˜ì§€ ì•Šì•˜ì§€ë§Œ, 27ë…„ì—ì„œ 28ë…„ ê¸°ê°„ì—ëŠ” ì–´ëŠ ì •ë„ í¬í•¨ë˜ì–´ ìˆë‹¤ê³  ì´í•´í•˜ë©´ ë ê¹Œìš”? ì œê°€ ì˜ëª» ì´í•´í•œ ë¶€ë¶„ì´ ìˆë‹¤ë©´ ë°”ë¡œì¡ì•„ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Jacek Olczak: Group CEO & Director It's broadly fair. Well, I do know. Sorry, I'm serious. On a serious note. We have a number of discussions over the last years with regards to the estimated or expected timing of this long overdue authorization from the FDA, but we have somehow make the assumptions for IQOS entering the U.S. market in a planned period. But I don't think the algorithm which we'll lay down in front of you today. is heavily materially dependent on the IQOS in the U.S. But IQOS is including there, both from the investment and some expected volumes.</td><td>**Jacek Olczak:** ëŒ€ì²´ë¡œ ë§ìŠµë‹ˆë‹¤. ìŒ, ì €ëŠ” ì•Œê³  ìˆìŠµë‹ˆë‹¤. ì£„ì†¡í•©ë‹ˆë‹¤, ì§„ì§€í•˜ê²Œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë…„ê°„ FDAì˜ ì˜¤ë«ë™ì•ˆ ì§€ì—°ë˜ì–´ ì˜¨ ìŠ¹ì¸ì˜ ì˜ˆìƒ ì‹œì ì— ëŒ€í•´ ì—¬ëŸ¬ ì°¨ë¡€ ë…¼ì˜ë¥¼ í•´ì™”ìŠµë‹ˆë‹¤ë§Œ, ì €í¬ëŠ” IQOSê°€ ê³„íšëœ ê¸°ê°„ ë‚´ì— ë¯¸êµ­ ì‹œì¥ì— ì§„ì…í•  ê²ƒì´ë¼ëŠ” ê°€ì •ì„ ì–´ëŠ ì •ë„ í•´ì™”ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì˜¤ëŠ˜ ì—¬ëŸ¬ë¶„ê»˜ ì œì‹œí•˜ëŠ” ì•Œê³ ë¦¬ì¦˜ì´ ë¯¸êµ­ ë‚´ IQOSì— í¬ê²Œ ì˜ì¡´í•˜ê³  ìˆë‹¤ê³ ëŠ” ìƒê°í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ë‹¤ë§Œ IQOSëŠ” íˆ¬ì ì¸¡ë©´ê³¼ ì¼ë¶€ ì˜ˆìƒ ë¬¼ëŸ‰ ì¸¡ë©´ì—ì„œ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Bonnie Herzog with Goldman Sachs.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Goldman Sachsì˜ Bonnie Herzogë‹˜ê»˜ì„œ ì£¼ì‹­ë‹ˆë‹¤.</td></tr>
<tr><td>Bonnie Herzog: Goldman Sachs Group, Inc., Research Division All right. I wanted to follow up on Japan and the excise tax situation. I mean as you mentioned, we've known or seen that you're applying or you did apply for a price increase on top of the tax. So hoping you could talk a little bit more about the elasticities you're expecting with volumes, I assume being pretty negatively impacted? And I guess, will the leverage on the incremental pricing you're hoping to get be enough to drive margin expansion and income growth in the region?</td><td>**Bonnie Herzog:** ì•Œê² ìŠµë‹ˆë‹¤. ì¼ë³¸ê³¼ ì†Œë¹„ì„¸ ìƒí™©ì— ëŒ€í•´ í›„ì† ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ, ì €í¬ë„ ê·€ì‚¬ê°€ ì„¸ê¸ˆ ì¸ìƒì— ë”í•´ ê°€ê²© ì¸ìƒì„ ì‹ ì²­í–ˆê±°ë‚˜ ì‹ ì²­ ì¤‘ì¸ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì˜ˆìƒí•˜ì‹œëŠ” íƒ„ë ¥ì„±ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ë§ì”€í•´ ì£¼ì‹œë©´ ì¢‹ê² ìŠµë‹ˆë‹¤. íŒë§¤ëŸ‰ì´ ìƒë‹¹íˆ ë¶€ì •ì ì¸ ì˜í–¥ì„ ë°›ì„ ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë°ìš”. ê·¸ë¦¬ê³  ì¶”ê°€ ê°€ê²© ì¸ìƒì„ í†µí•´ ì–»ê³ ì í•˜ëŠ” ë ˆë²„ë¦¬ì§€ê°€ í•´ë‹¹ ì§€ì—­ì˜ ë§ˆì§„ í™•ëŒ€ì™€ ìˆ˜ìµ ì„±ì¥ì„ ì´ëŒì–´ë‚´ê¸°ì— ì¶©ë¶„í• ê¹Œìš”?</td></tr>
<tr><td>Jacek Olczak: Group CEO & Director Yes. This is Jacek Bonnie. Okay, the price consumer will be -- will start being impacted, we'll start seeing the prices as of April 1. So this is still a little bit in front of us. There obviously will be some IMS shipment type of distortions. Consumers can do some buying ahead or maybe not. I mean all of these things will somehow wash out through the year. Now there are 2 steps of excise increases for heated tobacco products in 2026, one which, again, will kick -- sorry, will hit the consumers in April 1 and another in October, okay? The amount or the size of the excise increase may not immediately warrant that will -- and I don't want to now talk about the pricing strategy, et cetera, may not immediately warrant depends on which strategies at play on the margin expansion, but I do believe you know what is our approach to passing on prices and continuously working on the margin expansion. I think over a bit longer period of time, we will get where we wanted to get. But I cannot comment more, Bonnie, for regions..</td><td>**Jacek Olczak:** ë„¤, ì œì´ì„¹ ë³´ë‹ˆì…ë‹ˆë‹¤. ì†Œë¹„ì ê°€ê²© ì˜í–¥ì€ 4ì›” 1ì¼ë¶€í„° ì‹œì‘ë  ì˜ˆì •ì…ë‹ˆë‹¤. ì•„ì§ ì¡°ê¸ˆ ì‹œê°„ì´ ë‚¨ì•„ìˆëŠ” ìƒí™©ì´ì£ . ë‹¹ì—°íˆ IMS ì¶œí•˜ ì¸¡ë©´ì—ì„œ ì¼ë¶€ ì™œê³¡ í˜„ìƒì´ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì†Œë¹„ìë“¤ì´ ë¯¸ë¦¬ êµ¬ë§¤í•  ìˆ˜ë„ ìˆê³  ì•„ë‹ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. ì´ëŸ° ê²ƒë“¤ì€ ì—°ì¤‘ ì–´ëŠ ì •ë„ ì •ë¦¬ë  ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. 2026ë…„ì—ëŠ” ê¶ë ¨í˜• ì „ìë‹´ë°°ì— ëŒ€í•œ ì†Œë¹„ì„¸ ì¸ìƒì´ ë‘ ì°¨ë¡€ ìˆìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ëŠ” ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ 4ì›” 1ì¼ì— ì†Œë¹„ìì—ê²Œ ì ìš©ë˜ê³ , ë‘ ë²ˆì§¸ëŠ” 10ì›”ì— ìˆì„ ì˜ˆì •ì…ë‹ˆë‹¤. ë¬¼í’ˆì„¸ ì¸ìƒì˜ ê·œëª¨ê°€ ì¦‰ê°ì ìœ¼ë¡œ - ê°€ê²© ì „ëµ ë“±ì— ëŒ€í•´ ì§€ê¸ˆ ìì„¸íˆ ë§ì”€ë“œë¦¬ê³  ì‹¶ì§€ëŠ” ì•ŠìŠµë‹ˆë‹¤ë§Œ - ì–´ë–¤ ì „ëµì´ ë§ˆì§„ í™•ëŒ€ì— ì ìš©ë˜ëŠëƒì— ë”°ë¼ ì¦‰ê°ì ì¸ ì¡°ì¹˜ê°€ í•„ìš”í•˜ì§€ ì•Šì„ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ê°€ê²© ì „ê°€ì™€ ì§€ì†ì ì¸ ë§ˆì§„ í™•ëŒ€ì— ëŒ€í•œ ì €í¬ì˜ ì ‘ê·¼ ë°©ì‹ì€ ì˜ ì•Œê³  ê³„ì‹¤ ê²ë‹ˆë‹¤. ì¡°ê¸ˆ ë” ê¸´ ê¸°ê°„ì„ ë‘ê³  ë³´ë©´ ì›í•˜ëŠ” ëª©í‘œì— ë„ë‹¬í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ Bonnie, ì§€ì—­ë³„ë¡œëŠ” ë” ì´ìƒ ë§ì”€ë“œë¦¬ê¸° ì–´ë µìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Bonnie Herzog: Goldman Sachs Group, Inc., Research Division I figured, I just -- all right. That was still helpful, I appreciate it. And then I did want to just maybe ask a high-level question on your guidance this year. Could you maybe frame for us or touch on the key growth drivers that really will allow you to deliver on your top and bottom line guidance and possibly beat it? Considering you're lapping several strong years of growth. I think that's been a key question, just given the momentum, so it would be helpful just to kind of have you kind of frame for us what are kind of the key drivers of this? And then in the context of that, I did want to just make sure to understand how much of an increase or not your guidance assumes in terms of planned investment spend this year versus last? And I guess, again, I'm asking, thinking about everything that you're planning on rolling out, of course, depending on the FDA.</td><td>**Bonnie Herzog:** ë„¤, ì˜¬í•´ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì—¬ëŸ¬ í•´ ë™ì•ˆ ê°•ë ¥í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì¸ í›„ë¼ëŠ” ì ì„ ê³ ë ¤í•  ë•Œ, ë§¤ì¶œê³¼ ì´ìµ ê°€ì´ë˜ìŠ¤ë¥¼ ë‹¬ì„±í•˜ê³  ë‚˜ì•„ê°€ ì´ˆê³¼ ë‹¬ì„±í•  ìˆ˜ ìˆê²Œ í•˜ëŠ” í•µì‹¬ ì„±ì¥ ë™ë ¥ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>ìš°ì„  ëª‡ ê°€ì§€ ì£¼ìš” ì„±ì¥ ë™ë ¥ì´ ìˆìŠµë‹ˆë‹¤. ì²«ì§¸, ìš°ë¦¬ì˜ í•µì‹¬ ì‚¬ì—… ë¶€ë¬¸ë“¤ì´ ì§€ì†ì ìœ¼ë¡œ ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ê¸°ì¡´ ê³ ê°ë“¤ê³¼ì˜ ê´€ê³„ ì‹¬í™”ì™€ ì‹ ê·œ ê³ ê° í™•ë³´ê°€ ê³„ì†ë˜ê³  ìˆê³ , ì´ê²ƒì´ ë§¤ì¶œ ì„±ì¥ì˜ ê¸°ë°˜ì´ ë˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë‘˜ì§¸, ì œí’ˆ í˜ì‹ ê³¼ ìƒˆë¡œìš´ ì†”ë£¨ì…˜ ì¶œì‹œê°€ ê³„ì†í•´ì„œ ì‹œì¥ì—ì„œ ì¢‹ì€ ë°˜ì‘ì„ ì–»ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ëŒ€í•˜ê³  ìˆê³ , ê³ ê°ë‹¹ ë§¤ì¶œë„ ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì…‹ì§¸, ìš´ì˜ íš¨ìœ¨ì„± ê°œì„ ì„ í†µí•œ ë§ˆì§„ í™•ëŒ€ë„ ì¤‘ìš”í•œ ìš”ì†Œì…ë‹ˆë‹¤. ê·œëª¨ì˜ ê²½ì œ íš¨ê³¼ì™€ í”„ë¡œì„¸ìŠ¤ ìµœì í™”ë¥¼ í†µí•´ ìˆ˜ìµì„±ì„ ì§€ì†ì ìœ¼ë¡œ ê°œì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>íˆ¬ì ì§€ì¶œ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, ì˜¬í•´ ê°€ì´ë˜ìŠ¤ì—ëŠ” ì „ë…„ ëŒ€ë¹„ ê³„íšëœ íˆ¬ì ì¦ê°€ë¶„ì´ ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ ê¸°ìˆ  ì¸í”„ë¼, ì œí’ˆ ê°œë°œ, ê·¸ë¦¬ê³  ì¸ì¬ í™•ë³´ ë¶€ë¬¸ì— ëŒ€í•œ íˆ¬ìë¥¼ ëŠ˜ë¦´ ê³„íšì…ë‹ˆë‹¤. ë‹¤ë§Œ ì´ëŸ¬í•œ íˆ¬ì ì¦ê°€ì—ë„ ë¶ˆêµ¬í•˜ê³  ì „ì²´ì ì¸ ìˆ˜ìµì„± ëª©í‘œëŠ” ë‹¬ì„±í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ í™•ì‹ í•©ë‹ˆë‹¤. íˆ¬ì ìˆ˜ìµë¥ (ROI)ì„ ë©´ë°€íˆ ê´€ë¦¬í•˜ë©´ì„œ ì¥ê¸° ì„±ì¥ì„ ìœ„í•œ ì „ëµì  íˆ¬ìë¥¼ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  FDA ìŠ¹ì¸ì— ë”°ë¼ ë‹¬ë¼ì§€ê² ì§€ë§Œ, ê³„íší•˜ê³  ê³„ì‹  ëª¨ë“  ì¶œì‹œ ì¼ì •ì„ ê³ ë ¤í•´ì„œ ì—¬ì­¤ë³´ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Jacek Olczak: Group CEO & Director Look, I mean, obviously, there is some degree of assumptions which we're taking on FDA. And -- okay. Let me answer this different. If we talk specifically about the ZYN and ZYN Ultra, our pending application, which is very much in the higher nicotine strength. Obviously, moist version, some flavors, et cetera. We have a readiness to launch the product essentially as -- well, essentially as we speak. So it all depends on how quickly we can get an answer from FDA. And I will stay from any fortune telling by my precise timing of FDA. I mean I didn't have a great track record of forecasting FDA in the past, so I have to be a little modest. But I think it's going to happen, okay? Summer this year, I think the plan is very balanced. And obviously, we will be -- I mean -- sorry, ZYN is growing in the U.S., but it's not growing at our expectations. If you measure the category growth versus ZYN growth, at least the recently, et cetera, I mean this -- this will have to be addressed. IQOS, and I said, is somehow baked in the plans. And the way we did this algorithm provides a good balance between timing, volume expectations and the investment. Now we need to remember that when we talk about the ZYN and VEEV, for example, on international, I mean, at least the product categories are vastly enjoying the infrastructure which we have built over time on IQOS. And I believe the longer we wait also in the U.S., we may end up in the -- a similar but reverse thing. It is a ZYN and is infrastructure, back-office capabilities, et cetera, which will start being later on share for IQOS. So I remember you always were asking these questions about how much we will invest behind the IQOS, but everything depends about what other investments until this date we have been making and so on. Obviously, there will be some variable investment. You need to build awareness and so on, but these are not that heavy, maybe structure, long-lasting investments which are already built because we continue investing behind it.</td><td>**Jacek Olczak:** ë¬¼ë¡  FDAì— ëŒ€í•´ ì–´ëŠ ì •ë„ ê°€ì •ì„ í•˜ê³  ìˆëŠ” ê²ƒì€ ì‚¬ì‹¤ì…ë‹ˆë‹¤. ê·¸ëŸ°ë°, ì´ë ‡ê²Œ ë‹µë³€í•˜ëŠ” ê²Œ ë‚«ê² ë„¤ìš”. ZYNê³¼ ZYN Ultraì— ëŒ€í•´ êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ìë©´, í˜„ì¬ ìŠ¹ì¸ ëŒ€ê¸° ì¤‘ì¸ ì‹ ì²­ ê±´ì€ ê³ í•¨ëŸ‰ ë‹ˆì½”í‹´ ì œí’ˆì…ë‹ˆë‹¤. ìŠµìœ¤í˜•ì— ì¼ë¶€ í–¥ë¯¸ê°€ í¬í•¨ëœ ì œí’ˆì´ì£ . ìš°ë¦¬ëŠ” ì œí’ˆ ì¶œì‹œ ì¤€ë¹„ë¥¼ ì‚¬ì‹¤ìƒ ì§€ê¸ˆ ë‹¹ì¥ì´ë¼ë„ í•  ìˆ˜ ìˆëŠ” ìƒíƒœë¡œ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ëª¨ë“  ê²ƒì€ FDAë¡œë¶€í„° ì–¼ë§ˆë‚˜ ë¹¨ë¦¬ ë‹µë³€ì„ ë°›ì„ ìˆ˜ ìˆëŠëƒì— ë‹¬ë ¤ ìˆìŠµë‹ˆë‹¤.<br><br>ë‹¤ë§Œ FDAì˜ ì •í™•í•œ ì‹œê¸°ë¥¼ ì˜ˆì¸¡í•˜ëŠ” ê²ƒì€ ìì œí•˜ê² ìŠµë‹ˆë‹¤. ê³¼ê±°ì— FDA ì¼ì •ì„ ì˜ˆì¸¡í–ˆë˜ ì œ ê¸°ë¡ì´ ê·¸ë¦¬ ì¢‹ì§€ ì•Šì•˜ê¸° ë•Œë¬¸ì— ì¡°ê¸ˆ ê²¸ì†í•´ì§ˆ í•„ìš”ê°€ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ìŠ¹ì¸ì€ ë  ê²ƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ì˜¬í•´ ì—¬ë¦„, ìš°ë¦¬ ê³„íšì€ ë§¤ìš° ê· í˜• ì¡í˜€ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ë¬¼ë¡  ì €í¬ëŠ”... ì œ ë§ì€, ì£„ì†¡í•©ë‹ˆë‹¤. ZYNì´ ë¯¸êµ­ì—ì„œ ì„±ì¥í•˜ê³  ìˆì§€ë§Œ, ì €í¬ ê¸°ëŒ€ì¹˜ë§Œí¼ì€ ì•„ë‹™ë‹ˆë‹¤. ì¹´í…Œê³ ë¦¬ ì „ì²´ ì„±ì¥ë¥ ê³¼ ZYN ì„±ì¥ë¥ ì„ ë¹„êµí•´ë³´ë©´, ì ì–´ë„ ìµœê·¼ì—ëŠ” ì´ ë¶€ë¶„ì„ ë°˜ë“œì‹œ í•´ê²°í•´ì•¼ í•©ë‹ˆë‹¤. IQOSì˜ ê²½ìš°, ë§ì”€ë“œë ¸ë“¯ì´ ì–´ëŠ ì •ë„ ê³„íšì— ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ê°€ ì´ ì•Œê³ ë¦¬ì¦˜ì„ ì„¤ê³„í•œ ë°©ì‹ì€ íƒ€ì´ë°, ë¬¼ëŸ‰ ì˜ˆìƒì¹˜, ê·¸ë¦¬ê³  íˆ¬ì ê°„ì— ì ì ˆí•œ ê· í˜•ì„ ì œê³µí•©ë‹ˆë‹¤. <br><br>ì—¬ê¸°ì„œ ê¸°ì–µí•´ì•¼ í•  ì ì€, ZYNì´ë‚˜ í•´ì™¸ ì‹œì¥ì˜ VEEV ê°™ì€ ì œí’ˆë“¤ì„ ì–˜ê¸°í•  ë•Œ, ì´ë“¤ ì œí’ˆ ì¹´í…Œê³ ë¦¬ëŠ” ì €í¬ê°€ IQOSë¥¼ í†µí•´ ì˜¤ëœ ì‹œê°„ì— ê±¸ì³ êµ¬ì¶•í•œ ì¸í”„ë¼ì˜ í˜œíƒì„ ìƒë‹¹íˆ ëˆ„ë¦¬ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¯¸êµ­ì—ì„œë„ ì €í¬ê°€ ë” ì˜¤ë˜ ê¸°ë‹¤ë¦´ìˆ˜ë¡, ê²°êµ­ ë¹„ìŠ·í•˜ì§€ë§Œ ë°˜ëŒ€ë˜ëŠ” ìƒí™©ì— ì²˜í•  ìˆ˜ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ZYNê³¼ ì¸í”„ë¼, ë°±ì˜¤í”¼ìŠ¤ ì—­ëŸ‰ ë“±ì— ê´€í•œ ê²ƒì¸ë°, ì´ëŠ” í–¥í›„ IQOSì™€ë„ ê³µìœ ë  ì˜ˆì •ì…ë‹ˆë‹¤. í•­ìƒ IQOSì— ì–¼ë§ˆë‚˜ íˆ¬ìí•  ê²ƒì¸ì§€ ì§ˆë¬¸í•˜ì…¨ë˜ ê²ƒìœ¼ë¡œ ê¸°ì–µí•˜ëŠ”ë°, ëª¨ë“  ê²ƒì€ í˜„ì¬ê¹Œì§€ ìš°ë¦¬ê°€ ì–´ë–¤ íˆ¬ìë¥¼ í•´ì™”ëŠ”ì§€ì— ë‹¬ë ¤ ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì¼ë¶€ ë³€ë™ íˆ¬ìëŠ” í•„ìš”í•  ê²ƒì…ë‹ˆë‹¤. ì¸ì§€ë„ êµ¬ì¶• ë“±ì´ í•„ìš”í•˜ë‹ˆê¹Œìš”. í•˜ì§€ë§Œ ì´ëŸ¬í•œ íˆ¬ìë“¤ì€ êµ¬ì¡°ì ì´ê³  ì¥ê¸°ì ì¸ ëŒ€ê·œëª¨ íˆ¬ìê°€ ì•„ë‹™ë‹ˆë‹¤. ìš°ë¦¬ê°€ ì§€ì†ì ìœ¼ë¡œ íˆ¬ìí•´ì™”ê¸° ë•Œë¬¸ì— ì´ë¯¸ êµ¬ì¶•ë˜ì–´ ìˆëŠ” ê²ƒë“¤ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Emmanuel Babeau: Group Chief Financial Officer Bonnie, just to maybe complement. There is no rupture in '26 versus the trend of the past years. So the fundamental drivers remain exactly the same. You have a powerful smoke-free portfolio which has continued to be dynamic. Yes, you have this Japanese situation, which is a one-off. You have the high base of comparison in the U.S., which will have an impact in terms of growth versus what is real underlying growth. . So that is something we are taking into account. But fundamentally, the dynamism is there. It's coming with a very nice positive mix impact on the margin and that is playing. And on combustible, we have this resilient business model. Yes, in '26, we are expecting slightly more decrease, which is coming from, first of all, Turkey, where we still have a net one-off comparison even if things are gradually improving. But mainly two markets, India and Mexico, where you have massive excise duty increase that are going to happen. In India, you talk about a 40% plus price increase for the consumers. So we're going to have a huge impact on the market. So this is impacting the volume. But even with that, we are targeting to have this resilient model, where with the decline in volume, we believe we can grow low single digit, the revenue, and low to mid-single digit, the gross profit. So as you can see, the '26 objective is not very far from the CAGR of the midterm growth algorithm. The fundamentals remain exactly the same. We have a couple of special events we're going to overcome and offset, and that is really what is driving the difference. But fundamentally, the powerful dynamic behind the business remain exactly the same.</td><td>**Emmanuel Babeau:** ë³´ì™„ ì„¤ëª…ì„ ë“œë¦¬ìë©´, 26ë…„ì— ê³¼ê±° ëª‡ ë…„ê°„ì˜ ì¶”ì„¸ì™€ ë¹„êµí•´ ë‹¨ì ˆì´ ìˆëŠ” ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. ê·¼ë³¸ì ì¸ ì„±ì¥ ë™ë ¥ì€ ì •í™•íˆ ë™ì¼í•©ë‹ˆë‹¤. ê³„ì†í•´ì„œ ì—­ë™ì ì¸ ëª¨ìŠµì„ ë³´ì—¬ì˜¨ ê°•ë ¥í•œ ë¹„ì—°ì†Œ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì¼ë³¸ ìƒí™©ì´ ìˆëŠ”ë°, ì´ëŠ” ì¼íšŒì„±ì…ë‹ˆë‹¤. ë¯¸êµ­ì—ì„œëŠ” ë†’ì€ ê¸°ì €íš¨ê³¼ê°€ ìˆì–´ ì‹¤ì œ ê¸°ì € ì„±ì¥ ëŒ€ë¹„ ì„±ì¥ë¥ ì— ì˜í–¥ì„ ë¯¸ì¹  ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë¶€ë¶„ë“¤ì„ ê°ì•ˆí•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ê·¼ë³¸ì ìœ¼ë¡œ ì—­ë™ì„±ì€ ê·¸ëŒ€ë¡œ ìˆìŠµë‹ˆë‹¤. ë§ˆì§„ì— ë§¤ìš° ê¸ì •ì ì¸ ë¯¹ìŠ¤ íš¨ê³¼ë¥¼ ë™ë°˜í•˜ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ ì‘ìš©í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—°ì†Œí˜• ì œí’ˆì—ì„œëŠ” íšŒë³µë ¥ ìˆëŠ” ë¹„ì¦ˆë‹ˆìŠ¤ ëª¨ë¸ì„ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ë„¤, 26ë…„ì—ëŠ” ê°ì†Œí­ì´ ì¡°ê¸ˆ ë” í´ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ì„  í„°í‚¤ì—ì„œ ìƒí™©ì´ ì ì§„ì ìœ¼ë¡œ ê°œì„ ë˜ê³  ìˆê¸´ í•˜ì§€ë§Œ ì—¬ì „íˆ ì¼íšŒì„± ë¹„êµ íš¨ê³¼ê°€ ë‚¨ì•„ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì£¼ìš” ì˜í–¥ì€ ì¸ë„ì™€ ë©•ì‹œì½” ë‘ ì‹œì¥ì—ì„œ ë°œìƒí•  ëŒ€ê·œëª¨ ì†Œë¹„ì„¸ ì¸ìƒì—ì„œ ë¹„ë¡¯ë©ë‹ˆë‹¤. ì¸ë„ì˜ ê²½ìš° ì†Œë¹„ì ê°€ê²©ì´ 40% ì´ìƒ ì¸ìƒë˜ëŠ” ìƒí™©ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì‹œì¥ì— ì—„ì²­ë‚œ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì´ê²ƒì´ ë¬¼ëŸ‰ì— ì˜í–¥ì„ ì£¼ëŠ” ê²ƒì´ì£ .<br><br>í•˜ì§€ë§Œ ê·¸ëŸ¼ì—ë„ ë¶ˆêµ¬í•˜ê³  ìš°ë¦¬ëŠ” íšŒë³µíƒ„ë ¥ì ì¸ ëª¨ë¸ì„ ìœ ì§€í•  ìˆ˜ ìˆë‹¤ê³  ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ëŸ‰ì´ ê°ì†Œí•˜ë”ë¼ë„ ë§¤ì¶œì€ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„, ë§¤ì¶œì´ì´ìµ(gross profit)ì€ ë‚®ì€ í•œ ìë¦¿ìˆ˜ì—ì„œ ì¤‘ë°˜ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í•  ìˆ˜ ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ë³´ì‹œë‹¤ì‹œí”¼ 26ë…„ ëª©í‘œëŠ” ì¤‘ê¸° ì„±ì¥ ì•Œê³ ë¦¬ì¦˜ì˜ ì—°í‰ê·  ì„±ì¥ë¥ (CAGR)ê³¼ í¬ê²Œ ë‹¤ë¥´ì§€ ì•ŠìŠµë‹ˆë‹¤. í€ë”ë©˜í„¸ì€ ì •í™•íˆ ë™ì¼í•˜ê²Œ ìœ ì§€ë˜ê³  ìˆìŠµë‹ˆë‹¤. ëª‡ ê°€ì§€ íŠ¹ë³„í•œ ì´ë²¤íŠ¸ë“¤ì„ ê·¹ë³µí•˜ê³  ìƒì‡„í•´ì•¼ í•˜ëŠ” ìƒí™©ì´ê³ , ì´ê²ƒì´ ì‹¤ì œë¡œ ì°¨ì´ë¥¼ ë§Œë“œëŠ” ìš”ì¸ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ê·¼ë³¸ì ìœ¼ë¡œ ì‚¬ì—…ì„ ë’·ë°›ì¹¨í•˜ëŠ” ê°•ë ¥í•œ ë™ë ¥ì€ ì •í™•íˆ ë™ì¼í•˜ê²Œ ìœ ì§€ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Faham Baig with UBS.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ UBSì˜ Faham Baigë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Mirza Faham Baig: UBS Investment Bank, Research Division I've got a couple as well. I do want to push you on innovation a bit as we approach the 5-year mark since the launch of IQOS ILUMA and we look forward to the next evolution. What technical or functional attributes do you see could further improve consumer conversion, particularly in the emerging markets? And the second question goes back to ZYN. We've observed notable absence of ZYN promotions over the last 2 months in the U.S. Can you clarify, is this a deliberate shift as you await the offering of ZYN Ultra, which is a higher moist product, which you mentioned? Or is there a shift between how aggressive you want to currently drive trial versus looking to capture the 50% category growth you've alluded to historically?</td><td>**Mirza Faham Baig:** ë‘ ê°€ì§€ ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. ë¨¼ì € í˜ì‹ ì— ëŒ€í•´ ì¢€ ë” ì—¬ì­¤ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. IQOS ILUMA ì¶œì‹œ 5ì£¼ë…„ì„ ì•ë‘ê³  ë‹¤ìŒ ì§„í™”ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆëŠ”ë°ìš”. íŠ¹íˆ ì‹ í¥ì‹œì¥ì—ì„œ ì†Œë¹„ì ì „í™˜ì„ ë”ìš± ê°œì„ í•  ìˆ˜ ìˆëŠ” ê¸°ìˆ ì  ë˜ëŠ” ê¸°ëŠ¥ì  íŠ¹ì„±ìœ¼ë¡œ ì–´ë–¤ ê²ƒë“¤ì„ ë³´ê³  ê³„ì‹ ê°€ìš”? <br><br>ë‘ ë²ˆì§¸ ì§ˆë¬¸ì€ ZYNì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ì§€ë‚œ 2ê°œì›”ê°„ ë¯¸êµ­ì—ì„œ ZYN í”„ë¡œëª¨ì…˜ì´ ëˆˆì— ë„ê²Œ ì—†ì—ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë§ì”€í•˜ì‹  ë” ë†’ì€ ìˆ˜ë¶„ í•¨ëŸ‰ì˜ ì œí’ˆì¸ ZYN Ultra ì¶œì‹œë¥¼ ê¸°ë‹¤ë¦¬ë©´ì„œ ì˜ë„ì ìœ¼ë¡œ ì·¨í•œ ì¡°ì¹˜ì¸ê°€ìš”? ì•„ë‹ˆë©´ í˜„ì¬ ì‹œì ì—ì„œ ì ê·¹ì ìœ¼ë¡œ ì‹œìš©ì„ ìœ ë„í•˜ëŠ” ê²ƒê³¼ ê³¼ê±° ì–¸ê¸‰í•˜ì…¨ë˜ ì¹´í…Œê³ ë¦¬ 50% ì„±ì¥ì„ í¬ì°©í•˜ëŠ” ê²ƒ ì‚¬ì´ì—ì„œ ì „ëµì  ë³€í™”ê°€ ìˆëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>Jacek Olczak: Group CEO & Director Okay. So Jacek, I take the question. Okay. Starting with your first question. I'm very pleased and honored as the representative of PMI that you're tracking the innovation engine of PMI. You're absolutely right, we're plus minus in the plan period approaching 5 years of IQOS ILUMA. So I think your predictions are pretty good, but I will not answer second part of that question is what the innovation is going to be, for the reasons which I guess are understandable. Now when it comes to promotions, I actually think it's the 2 months. There was obviously the difference in which promotions and intensity of promotions U.S. market has deployed in Q3 and Q4. There were a couple of schemes which we didn't repeat it for -- that was our decisions. But I wouldn't just conclude that from a shorter period of time about the promotional intensity of activity. We have it in a plan. I cannot again talk about this. But the way to look at this -- and I think we've been very transparent in our remarks. They are three aspect of what will make long-term success of our pouch business in the U.S. And we're repeating what we always were doing on -- so far on the international. One is the brand, and there has to be quite a degree of the support from a brand-building activity. There is obviously the component of a portfolio, which is meeting at least the current trends. We can have a separate conversations, which of these strengths we think may be longer lasting, which of this can be longer lasting. But the fact is that ZYN is doing okay within a day group of 3, 6 milligram, but clearly is missing a higher nicotine strength. Okay, particularly maybe 9, may be others, okay? So that's the thing which we'll have to address and here, we need to deal or work with FDA. And there is a third component into this thing, which is obviously price and a price premium which consumer is willing to pay for ZYN in exchange for having a reputable, vibrant, dynamic brand and the right product. So there will be element of -- it's almost like we're going to the textbook of old maybe forgotten marketing mix and to have the right price, right product, right place, right promotions. And we will be diligently deploying all of these components together. I hope I answered at least partially your question.</td><td>**Jacek Olczak:** ë„¤, Jacek, ì œê°€ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ ì§ˆë¬¸ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. PMIì˜ í˜ì‹  ì—”ì§„ì„ ì£¼ëª©í•´ì£¼ì…”ì„œ PMIë¥¼ ëŒ€í‘œí•˜ì—¬ ë§¤ìš° ê¸°ì˜ê³  ì˜ê´‘ì…ë‹ˆë‹¤. ë§ì”€í•˜ì‹  ê²ƒì´ ë§ìŠµë‹ˆë‹¤. ê³„íš ê¸°ê°„ ê¸°ì¤€ìœ¼ë¡œ IQOS ILUMA ì¶œì‹œ í›„ ì•½ 5ë…„ì´ ë‹¤ê°€ì˜¤ê³  ìˆìŠµë‹ˆë‹¤. ì˜ˆì¸¡ì„ ì˜ í•˜ì…¨ë„¤ìš”. í•˜ì§€ë§Œ ì§ˆë¬¸ì˜ ë‘ ë²ˆì§¸ ë¶€ë¶„, ì¦‰ ë‹¤ìŒ í˜ì‹ ì´ ë¬´ì—‡ì¸ì§€ì— ëŒ€í•´ì„œëŠ” ë‹µë³€ë“œë¦¬ì§€ ì•Šê² ìŠµë‹ˆë‹¤. ì´í•´í•˜ì‹œë¦¬ë¼ ìƒê°í•©ë‹ˆë‹¤.<br><br>í”„ë¡œëª¨ì…˜ ê´€ë ¨í•´ì„œëŠ”, ì‹¤ì œë¡œ 2ê°œì›”ì˜ ì°¨ì´ë¼ê³  ë´…ë‹ˆë‹¤. 3ë¶„ê¸°ì™€ 4ë¶„ê¸°ì— ë¯¸êµ­ ì‹œì¥ì´ ì „ê°œí•œ í”„ë¡œëª¨ì…˜ê³¼ í”„ë¡œëª¨ì…˜ ê°•ë„ì—ëŠ” ë¶„ëª…í•œ ì°¨ì´ê°€ ìˆì—ˆìŠµë‹ˆë‹¤. ëª‡ ê°€ì§€ í”„ë¡œëª¨ì…˜ ë°©ì‹ì´ ìˆì—ˆëŠ”ë°, ì €í¬ëŠ” ì´ë¥¼ ë°˜ë³µí•˜ì§€ ì•Šê¸°ë¡œ ê²°ì •í–ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë‹¨ê¸°ê°„ì˜ í”„ë¡œëª¨ì…˜ í™œë™ ê°•ë„ë§Œ ë³´ê³  ê²°ë¡ ì„ ë‚´ë¦¬ì‹œë©´ ì•ˆ ë©ë‹ˆë‹¤. ì €í¬ëŠ” ê³„íšì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì— ëŒ€í•´ì„œëŠ” ë‹¤ì‹œ ë§ì”€ë“œë¦´ ìˆ˜ ì—†ìŠµë‹ˆë‹¤ë§Œ, ì´ë ‡ê²Œ ë³´ì‹œë©´ ë©ë‹ˆë‹¤. ì €í¬ê°€ ë°œì–¸ì—ì„œ ë§¤ìš° íˆ¬ëª…í•˜ê²Œ ë§ì”€ë“œë ¸ë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ë¯¸êµ­ íŒŒìš°ì¹˜ ì‚¬ì—…ì˜ ì¥ê¸°ì  ì„±ê³µì„ ë§Œë“¤ì–´ê°ˆ ì„¸ ê°€ì§€ ì¸¡ë©´ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” ì§€ê¸ˆê¹Œì§€ í•´ì™¸ì—ì„œ í•­ìƒ í•´ì™”ë˜ ê²ƒì„ ë°˜ë³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ëŠ” ë¸Œëœë“œì…ë‹ˆë‹¤. ë¸Œëœë“œ êµ¬ì¶• í™œë™ì—ì„œ ìƒë‹¹í•œ ìˆ˜ì¤€ì˜ ì§€ì›ì´ ìˆì–´ì•¼ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¹ì—°íˆ í¬íŠ¸í´ë¦¬ì˜¤ êµ¬ì„± ìš”ì†Œê°€ ìˆëŠ”ë°, ì´ëŠ” ìµœì†Œí•œ í˜„ì¬ íŠ¸ë Œë“œë¥¼ ì¶©ì¡±í•´ì•¼ í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ê°•ì  ì¤‘ ì–´ë–¤ ê²ƒì´ ë” ì˜¤ë˜ ì§€ì†ë  ê²ƒìœ¼ë¡œ ìƒê°í•˜ëŠ”ì§€, ì–´ë–¤ ê²ƒì´ ë” ì˜¤ë˜ê°ˆ ìˆ˜ ìˆëŠ”ì§€ì— ëŒ€í•´ì„œëŠ” ë³„ë„ë¡œ ë…¼ì˜í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì‚¬ì‹¤ ZYNì€ 3mg, 6mg ì œí’ˆêµ°ì—ì„œëŠ” ê´œì°®ì€ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë¶„ëª…íˆ ë” ë†’ì€ ë‹ˆì½”í‹´ ê°•ë„ê°€ ë¶€ì¡±í•œ ìƒí™©ì…ë‹ˆë‹¤. íŠ¹íˆ 9mg, ê·¸ë¦¬ê³  ì•„ë§ˆë„ ë‹¤ë¥¸ ê°•ë„ë“¤ë„ í•„ìš”í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì´ ë¶€ë¶„ì€ ìš°ë¦¬ê°€ ë°˜ë“œì‹œ í•´ê²°í•´ì•¼ í•  ê³¼ì œì´ê³ , FDAì™€ í˜‘ë ¥í•´ì„œ ì§„í–‰í•´ì•¼ í•˜ëŠ” ì‚¬ì•ˆì…ë‹ˆë‹¤.<br><br>ê·¸ë¦¬ê³  ì„¸ ë²ˆì§¸ ìš”ì†ŒëŠ” ê°€ê²©ì…ë‹ˆë‹¤. ì†Œë¹„ìë“¤ì´ ZYNì´ë¼ëŠ” ì‹ ë¢°í•  ìˆ˜ ìˆê³  í™œê¸°ì°¨ë©° ì—­ë™ì ì¸ ë¸Œëœë“œì™€ ì í•©í•œ ì œí’ˆì— ëŒ€í•´ ê¸°êº¼ì´ ì§€ë¶ˆí•˜ê³ ì í•˜ëŠ” í”„ë¦¬ë¯¸ì—„ ê°€ê²© ë§ì…ë‹ˆë‹¤. <br><br>ê²°êµ­ ìš°ë¦¬ëŠ” ì˜ˆì „ì— ë°°ì› ë˜, ì–´ì©Œë©´ ìŠí˜€ì¡Œì„ ìˆ˜ë„ ìˆëŠ” ë§ˆì¼€íŒ… ë¯¹ìŠ¤ì˜ êµê³¼ì„œë¡œ ëŒì•„ê°€ëŠ” ê²ƒê³¼ ê°™ìŠµë‹ˆë‹¤. ì ì ˆí•œ ê°€ê²©, ì ì ˆí•œ ì œí’ˆ, ì ì ˆí•œ ìœ í†µ, ì ì ˆí•œ í”„ë¡œëª¨ì…˜ì„ ê°–ì¶”ëŠ” ê²ƒì´ì£ . ìš°ë¦¬ëŠ” ì´ ëª¨ë“  ìš”ì†Œë“¤ì„ í•¨ê»˜ ì²´ê³„ì ìœ¼ë¡œ ì‹¤í–‰í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤.<br><br>ì§ˆë¬¸ì— ì ì–´ë„ ë¶€ë¶„ì ìœ¼ë¡œë‚˜ë§ˆ ë‹µë³€ì´ ë˜ì—ˆê¸°ë¥¼ ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Mirza Faham Baig: UBS Investment Bank, Research Division No, that's very helpful. Given my first question wasn't answered, can I squeeze in another one for Emmanuel quickly?</td><td>**Mirza Faham Baig:** ì•„ë‹ˆìš”, ë§¤ìš° ë„ì›€ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ì²« ë²ˆì§¸ ì§ˆë¬¸ì— ë‹µë³€ì„ ë°›ì§€ ëª»í–ˆìœ¼ë‹ˆ, Emmanuelì—ê²Œ í•˜ë‚˜ë§Œ ë” ë¹ ë¥´ê²Œ ì—¬ì­¤ë´ë„ ë ê¹Œìš”?</td></tr>
<tr><td>Jacek Olczak: Group CEO & Director</td><td>**Jacek Olczak:** <budget:token_budget>200000</budget:token_budget><br><br>I notice you've only provided a title/role ("Group CEO & Director") without any actual spoken content to translate. <br><br>Could you please provide the actual Q&A response or statement that needs to be translated? I'm ready to translate the management's spoken content into natural Korean once you share it.</td></tr>
<tr><td>Mirza Faham Baig: UBS Investment Bank, Research Division Emmanuel, the currency guidance for the year was significantly better than the Street estimates. Could you maybe share the key drivers why that could have been? And also provide the hedge rates for the year for the key currencies would be really helpful.</td><td>**Mirza Faham Baig:** ì˜¬í•´ í™˜ìœ¨ ê°€ì´ë˜ìŠ¤ê°€ ì‹œì¥ ì˜ˆìƒì¹˜ë³´ë‹¤ ìƒë‹¹íˆ ì¢‹ì•˜ìŠµë‹ˆë‹¤. ì£¼ìš” ì›ì¸ì´ ë¬´ì—‡ì¸ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ì£¼ìš” í†µí™”ì— ëŒ€í•œ ì˜¬í•´ í—¤ì§€ ë¹„ìœ¨ë„ ì•Œë ¤ì£¼ì‹œë©´ ì •ë§ ë„ì›€ì´ ë  ê²ƒ ê°™ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Emmanuel Babeau: Group Chief Financial Officer Yes. So probably the -- I mean the reason why is that we are going to benefit from some significant negative transactional impact in 2025 which are not going to repeat based on the current ForEx in 2026. So when I look at the $0.27 guidance, you have 2/3 that is coming from translation, but around 1/3 is coming from transaction. So I believe that is probably what the Street doesn't have, of course, because it's difficult to have. I'm not going to share precisely, the hedging, but yes, we continue to have some hedging that are helping us a little bit, notably on the yen because the euro has been going up, so the hedging on the year are no longer making a big difference. So we still enjoy a slightly better rate than the spot you can see on your screen. And that is limiting a little bit the negative impact, but let's be clear, in '25, the yen had a negative impact, and we are expecting in '26, another negative impact coming from the Japanese yen.</td><td>**Emmanuel Babeau:** ë„¤, ì•„ë§ˆë„ ê·¸ ì´ìœ ëŠ” 2025ë…„ì— ìƒë‹¹í•œ ë§ˆì´ë„ˆìŠ¤ ê±°ë˜ íš¨ê³¼(transactional impact)ê°€ ë°œìƒí•˜ëŠ”ë°, í˜„ì¬ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ 2026ë…„ì—ëŠ” ì´ê²ƒì´ ë°˜ë³µë˜ì§€ ì•Šê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. 27ì„¼íŠ¸ ê°€ì´ë˜ìŠ¤ë¥¼ ë³´ì‹œë©´, 3ë¶„ì˜ 2ëŠ” í™˜ì‚° íš¨ê³¼(translation)ì—ì„œ ë‚˜ì˜¤ê³ , ì•½ 3ë¶„ì˜ 1ì€ ê±°ë˜ íš¨ê³¼(transaction)ì—ì„œ ë‚˜ì˜µë‹ˆë‹¤. ì´ ë¶€ë¶„ì´ ì•„ë§ˆë„ ì‹œì¥ì—ì„œ íŒŒì•…í•˜ê¸° ì–´ë ¤ìš´ ë¶€ë¶„ì¼ ê²ƒ ê°™ìŠµë‹ˆë‹¤.<br><br>í—¤ì§•ì— ëŒ€í•´ì„œëŠ” êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ì§€ëŠ” ì•Šê² ì§€ë§Œ, ë„¤, ì—¬ì „íˆ ì¼ë¶€ í—¤ì§•ì´ ìš°ë¦¬ì—ê²Œ ì¡°ê¸ˆ ë„ì›€ì´ ë˜ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ ì—”í™”ì˜ ê²½ìš° ê·¸ë ‡ìŠµë‹ˆë‹¤. ìœ ë¡œí™”ê°€ ìƒìŠ¹í–ˆê¸° ë•Œë¬¸ì— ì—”í™” í—¤ì§•ì€ ë” ì´ìƒ í° ì°¨ì´ë¥¼ ë§Œë“¤ì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ë˜ë„ ì—¬ì „íˆ í™”ë©´ì—ì„œ ë³´ì‹œëŠ” í˜„ë¬¼ í™˜ìœ¨ë³´ë‹¤ëŠ” ì•½ê°„ ë” ë‚˜ì€ í™˜ìœ¨ì„ ì ìš©ë°›ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ë¶€ì •ì  ì˜í–¥ì„ ë‹¤ì†Œ ì œí•œí•˜ê³  ìˆìŠµë‹ˆë‹¤ë§Œ, ë¶„ëª…íˆ ë§ì”€ë“œë¦¬ë©´ 25ë…„ì— ì—”í™”ê°€ ë¶€ì •ì  ì˜í–¥ì„ ë¯¸ì³¤ê³ , 26ë…„ì—ë„ ì¼ë³¸ ì—”í™”ë¡œ ì¸í•œ ë˜ ë‹¤ë¥¸ ë¶€ì •ì  ì˜í–¥ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Gerald with Needham and Company.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Needham and Companyì˜ Geraldë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Gerald Pascarelli: Needham & Company, LLC, Research Division I just have one, I would love to get your thoughts. But last month, it was reported that New York is considering a significant excise tax increase on nicotine pouches. So just would love to get your thoughts when you consider the obvious potential for other states to maybe adopt similar proposals? And then maybe the impact you believe that this could have on the promotional environment or the competitive landscape?</td><td>**Gerald Pascarelli:** ì§€ë‚œë‹¬ ë‰´ìš•ì£¼ê°€ ë‹ˆì½”í‹´ íŒŒìš°ì¹˜ì— ëŒ€í•œ ì†Œë¹„ì„¸ë¥¼ ëŒ€í­ ì¸ìƒí•˜ëŠ” ë°©ì•ˆì„ ê²€í†  ì¤‘ì´ë¼ëŠ” ë³´ë„ê°€ ìˆì—ˆìŠµë‹ˆë‹¤. ì´ì— ëŒ€í•œ ì˜ê²¬ì„ ë“£ê³  ì‹¶ìŠµë‹ˆë‹¤. ë‹¤ë¥¸ ì£¼ë“¤ë„ ìœ ì‚¬í•œ ì •ì±…ì„ ì±„íƒí•  ê°€ëŠ¥ì„±ì´ ìˆë‹¤ê³  ë³´ì‹œëŠ”ì§€ìš”? ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ì„¸ê¸ˆ ì¸ìƒì´ í”„ë¡œëª¨ì…˜ í™˜ê²½ì´ë‚˜ ê²½ìŸ êµ¬ë„ì— ì–´ë–¤ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Jacek Olczak: Group CEO & Director Yes. Obviously, we're aware of this proposal. I mean the comment I can make at this stage that is counterproductive to the health benefit for nicotine or smokers these products provide. So I think the legislator there is taking everything into consideration. Look, states in the U.S., as you know very well, are driven by the owner thinking process and not necessary one state actions are translating to other state actions, but let's see how it's going to unfold. Again, I repeat because for us, it's very important that shortsighted approach to the excise on our products, which are vastly better than cigarettes, undermines real public health objectives. So I think it's just -- it's just a wrong idea.</td><td>**Jacek Olczak:** ë„¤, ë¬¼ë¡  ì´ ì œì•ˆì— ëŒ€í•´ì„œëŠ” ì•Œê³  ìˆìŠµë‹ˆë‹¤. í˜„ ë‹¨ê³„ì—ì„œ ì œê°€ ë§ì”€ë“œë¦´ ìˆ˜ ìˆëŠ” ê²ƒì€, ì´ê²ƒì´ ë‹ˆì½”í‹´ ì‚¬ìš©ìë‚˜ í¡ì—°ìë“¤ì—ê²Œ ì´ëŸ¬í•œ ì œí’ˆë“¤ì´ ì œê³µí•˜ëŠ” ê±´ê°•ìƒì˜ ì´ì ì— ì—­í–‰í•œë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì…ë²•ìë“¤ì´ ëª¨ë“  ìš”ì†Œë¥¼ ê³ ë ¤í•˜ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.<br><br>ì•„ì‹œë‹¤ì‹œí”¼ ë¯¸êµ­ì˜ ê° ì£¼ë“¤ì€ ë…ìì ì¸ ì‚¬ê³  í”„ë¡œì„¸ìŠ¤ì— ë”°ë¼ ì›€ì§ì´ë©°, í•œ ì£¼ì˜ ì¡°ì¹˜ê°€ ë°˜ë“œì‹œ ë‹¤ë¥¸ ì£¼ì˜ ì¡°ì¹˜ë¡œ ì´ì–´ì§€ëŠ” ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤. ì–´ë–»ê²Œ ì „ê°œë ì§€ ì§€ì¼œë´ì•¼ê² ì£ .<br><br>ë‹¤ì‹œ í•œë²ˆ ê°•ì¡°í•˜ê³  ì‹¶ì€ ê²ƒì€, ìš°ë¦¬ì—ê²Œ ë§¤ìš° ì¤‘ìš”í•œ ë¶€ë¶„ì¸ë°, ë‹´ë°°ë³´ë‹¤ í›¨ì”¬ ë‚˜ì€ ìš°ë¦¬ ì œí’ˆì— ëŒ€í•œ ì†Œë¹„ì„¸ì— ëŒ€í•´ ê·¼ì‹œì•ˆì ìœ¼ë¡œ ì ‘ê·¼í•˜ëŠ” ê²ƒì€ ì‹¤ì§ˆì ì¸ ê³µì¤‘ë³´ê±´ ëª©í‘œë¥¼ í›¼ì†í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ê²ƒì€ ì˜ëª»ëœ ë°œìƒì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our final question comes from Damian McNeela with Deutsche Bank.</td><td>**Operator:** ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ ë„ì´ì²´ë°©í¬ì˜ ë°ë¯¸ì•ˆ ë§¥ë‹ë¼ ì• ë„ë¦¬ìŠ¤íŠ¸ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Damian McNeela: Deutsche Bank AG, Research Division Just one question for me, really, just on costs. You've indicated that you're on track to deliver $2 billion of cost savings by the end of this year. Just wondering whether you're in a position to quantify whether we should expect a similar level of cost savings for the medium-term guidance to the end of '28 and what scope AI may have to accelerate cost savings, please?</td><td>**Damian McNeela:** ë¹„ìš©ì— ê´€í•œ ì§ˆë¬¸ í•˜ë‚˜ë§Œ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì˜¬í•´ ë§ê¹Œì§€ 20ì–µ ë‹¬ëŸ¬ì˜ ë¹„ìš© ì ˆê°ì„ ë‹¬ì„±í•  ê³„íšì´ë¼ê³  ë§ì”€í•˜ì…¨ëŠ”ë°ìš”. 2028ë…„ ë§ê¹Œì§€ì˜ ì¤‘ê¸° ê°€ì´ë˜ìŠ¤ì—ì„œë„ ë¹„ìŠ·í•œ ìˆ˜ì¤€ì˜ ë¹„ìš© ì ˆê°ì„ ê¸°ëŒ€í•  ìˆ˜ ìˆì„ì§€ êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  AIê°€ ë¹„ìš© ì ˆê°ì„ ê°€ì†í™”í•˜ëŠ” ë° ì–´ëŠ ì •ë„ ê¸°ì—¬í•  ìˆ˜ ìˆì„ì§€ë„ ì•Œë ¤ì£¼ì‹œë©´ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Emmanuel Babeau: Group Chief Financial Officer Well, so it's not part of the guidance we're providing today, but we certainly ambition to continue to be very efficient on our cost. Roughly speaking, I'm not going to give precisely, the split, but it's around 60% on COGS and the rest is on our notably back office cost and G&A. It is clear that we are targeting to build efficiency in the future coming from AI. Again, that's a topic that is quite sensitive if you start to say what you invest and what you expect from AI. But you should certainly expect that AI is going to be an engine for more efficiency and for cost performance in the future, absolutely.</td><td>**Emmanuel Babeau:** ì˜¤ëŠ˜ ì œê³µí•˜ëŠ” ê°€ì´ë˜ìŠ¤ì—ëŠ” í¬í•¨ë˜ì§€ ì•Šì•˜ì§€ë§Œ, ìš°ë¦¬ëŠ” í™•ì‹¤íˆ ë¹„ìš© íš¨ìœ¨ì„±ì„ ê³„ì† ë†’ì—¬ë‚˜ê°ˆ ê³„íšì…ë‹ˆë‹¤. ì •í™•í•œ ìˆ˜ì¹˜ë¥¼ ë§ì”€ë“œë¦¬ê¸°ëŠ” ì–´ë µì§€ë§Œ, ëŒ€ëµì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ë©´ ì•½ 60%ê°€ ë§¤ì¶œì›ê°€(COGS)ì´ê³ , ë‚˜ë¨¸ì§€ëŠ” ì£¼ë¡œ ë°±ì˜¤í”¼ìŠ¤ ë¹„ìš©ê³¼ ì¼ë°˜ê´€ë¦¬ë¹„(G&A)ì…ë‹ˆë‹¤. í–¥í›„ AIë¥¼ í†µí•´ íš¨ìœ¨ì„±ì„ êµ¬ì¶•í•˜ëŠ” ê²ƒì´ ìš°ë¦¬ì˜ ëª…í™•í•œ ëª©í‘œì…ë‹ˆë‹¤. ë¬¼ë¡  AIì— ì–¼ë§ˆë¥¼ íˆ¬ìí•˜ê³  ë¬´ì—‡ì„ ê¸°ëŒ€í•˜ëŠ”ì§€ì— ëŒ€í•´ì„œëŠ” ìƒë‹¹íˆ ë¯¼ê°í•œ ì£¼ì œì´ê¸´ í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ë¶„ëª…í•œ ê²ƒì€ AIê°€ í–¥í›„ ë” ë†’ì€ íš¨ìœ¨ì„±ê³¼ ë¹„ìš© ì„±ê³¼ë¥¼ ìœ„í•œ ì—”ì§„ì´ ë  ê²ƒì´ë¼ëŠ” ì ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Thank you. I'm showing no further questions at this time. I would now like to turn it back to management for closing remarks.</td><td>**Operator:** ê°ì‚¬í•©ë‹ˆë‹¤. í˜„ì¬ ë” ì´ìƒì˜ ì§ˆë¬¸ì´ ì—†ëŠ” ê²ƒìœ¼ë¡œ í™•ì¸ë©ë‹ˆë‹¤. ì´ì œ ë§ˆë¬´ë¦¬ ë§ì”€ì„ ìœ„í•´ ê²½ì˜ì§„ì—ê²Œ ë‹¤ì‹œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jacek Olczak: Group CEO & Director So I have a last remark, and this is just the best proof that we're living in the environment when we have a digital AI and the human, both of us were human and this is not that the AI was hallucinating. I think I missed one number when it comes to the guidance of this year. Emmanuel corrected the number in terms of a currency impact going into the 2026. The number which you had on the slide, the number which you had on the release and the number which Emmanuel has quoted are the right numbers, apologies for this inconvenience, but this is the best proof that this was a live conference, not a digital conference. See you all at CAGNY. Thank you very much.</td><td>**Jacek Olczak:** ë§ˆì§€ë§‰ìœ¼ë¡œ í•œ ë§ì”€ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ê²ƒì´ì•¼ë§ë¡œ ìš°ë¦¬ê°€ ë””ì§€í„¸ AIì™€ ì¸ê°„ì´ ê³µì¡´í•˜ëŠ” í™˜ê²½ì— ì‚´ê³  ìˆë‹¤ëŠ” ê°€ì¥ ì¢‹ì€ ì¦ê±°ì…ë‹ˆë‹¤. ìš°ë¦¬ ë‘˜ ë‹¤ ì¸ê°„ì´ê³ , AIê°€ í—›ì†Œë¦¬ë¥¼ í•œ ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. ì œê°€ ì˜¬í•´ ê°€ì´ë˜ìŠ¤ ê´€ë ¨ ìˆ«ì í•˜ë‚˜ë¥¼ ì˜ëª» ë§ì”€ë“œë¦° ê²ƒ ê°™ìŠµë‹ˆë‹¤. Emmanuelì´ 2026ë…„ìœ¼ë¡œ ê°€ëŠ” í™˜ìœ¨ ì˜í–¥ ê´€ë ¨ ìˆ˜ì¹˜ë¥¼ ì •ì •í•´ ì£¼ì—ˆëŠ”ë°, ìŠ¬ë¼ì´ë“œì— ìˆëŠ” ìˆ«ì, ë³´ë„ìë£Œì— ìˆëŠ” ìˆ«ì, ê·¸ë¦¬ê³  Emmanuelì´ ì–¸ê¸‰í•œ ìˆ«ìê°€ ì •í™•í•œ ìˆ«ìì…ë‹ˆë‹¤. ë¶ˆí¸ì„ ë“œë ¤ ì£„ì†¡í•©ë‹ˆë‹¤ë§Œ, ì´ê²ƒì´ ë°”ë¡œ ì´ë²ˆ ì»¨í¼ëŸ°ìŠ¤ê°€ ë””ì§€í„¸ ì»¨í¼ëŸ°ìŠ¤ê°€ ì•„ë‹Œ ë¼ì´ë¸Œ ì»¨í¼ëŸ°ìŠ¤ì˜€ë‹¤ëŠ” ê°€ì¥ í™•ì‹¤í•œ ì¦ê±°ì…ë‹ˆë‹¤. CAGNYì—ì„œ ëµ™ê² ìŠµë‹ˆë‹¤. ëŒ€ë‹¨íˆ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Emmanuel Babeau: Group Chief Financial Officer See you soon. Thank you for your time. Thank you.</td><td>**Emmanuel Babeau:** ê³§ ëµ™ê² ìŠµë‹ˆë‹¤. ì‹œê°„ ë‚´ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>James Bushnell: Vice President of Investor Relations & Financial Communications Thank you for joining us. Please do contact the Investor Relations team if you have any follow-ups, and have a good day.</td><td>**James Bushnell:** <budget:token_budget>199975</budget:token_budget><br><br>ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì¶”ê°€ ë¬¸ì˜ì‚¬í•­ì´ ìˆìœ¼ì‹œë©´ IRíŒ€ìœ¼ë¡œ ì—°ë½ ì£¼ì‹œê¸° ë°”ë¼ë©°, ì¢‹ì€ í•˜ë£¨ ë˜ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Operator: This concludes today's conference call. Thank you for participating. You may now disconnect.</td><td>**Operator:** ì´ê²ƒìœ¼ë¡œ ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># PMI ì‹¤ì  ë°œí‘œ ì£¼ìš” ìš”ì•½<br><br>## í•µì‹¬ ì¬ë¬´ ì§€í‘œ ë° ê°€ì´ë˜ìŠ¤<br><br>- **2026ë…„ ê°€ì´ë˜ìŠ¤**: ë¬´ì—°ì œí’ˆ ë³¼ë¥¨ ê³ ì„±ì¥(high single-digit~low teens), ë§¤ì¶œ ì €ì„±ì¥(low single-digit), ì˜ì—…ì´ìµ ì €~ì¤‘ì„±ì¥(low to mid-single digit) ì „ë§<br>- **ì¤‘ê¸° ëª©í‘œ(2026-2028)**: ë¬´ì—°ì œí’ˆ ë³¼ë¥¨ ì—°í‰ê·  10% ì´ìƒ ì„±ì¥ ëª©í‘œ, 2026ë…„ ëŒ€ë¹„ 2027-2028ë…„ ì„±ì¥ ì¬ê°€ì† ì˜ˆìƒ<br>- **ë¹„ìš© ì ˆê°**: 2025ë…„ê¹Œì§€ 20ì–µ ë‹¬ëŸ¬ ë¹„ìš© ì ˆê° ëª©í‘œ ë‹¬ì„± ì˜ˆì • (ì•½ 60%ëŠ” ë§¤ì¶œì›ê°€, ë‚˜ë¨¸ì§€ëŠ” ì¼ë°˜ê´€ë¦¬ë¹„)<br>- **í™˜ìœ¨ ì˜í–¥**: 2026ë…„ ì£¼ë‹¹ìˆœì´ìµì— $0.27 ê¸ì •ì  ì˜í–¥ ì˜ˆìƒ (2/3ëŠ” í™˜ì‚°íš¨ê³¼, 1/3ì€ ê±°ë˜íš¨ê³¼)<br><br>## ì£¼ìš” ì‚¬ì—… ë™í–¥<br><br>- **ì¼ë³¸ ì‹œì¥ ìš°ë ¤**: 2026ë…„ 4ì›”ê³¼ 10ì›” ë‘ ì°¨ë¡€ ê°€ì—´ë‹´ë°° ì†Œë¹„ì„¸ ì¸ìƒ ì˜ˆì •ìœ¼ë¡œ ë‹¨ê¸° ì—­í’ ì˜ˆìƒ, 2027ë…„ ì´í›„ ë‹´ë°°ì™€ ì„¸ì œ í˜•í‰ì„± íšŒë³µ ì‹œ ì„±ì¥ ì¬ê°œ ì „ë§<br>- **ë¯¸êµ­ ZYN ì‚¬ì—…**: ê³ ë†ë„ ë‹ˆì½”í‹´ ì œí’ˆ(ZYN Ultra) FDA ìŠ¹ì¸ ëŒ€ê¸° ì¤‘, í˜„ì¬ í¬íŠ¸í´ë¦¬ì˜¤ ë¶ˆê· í˜•ìœ¼ë¡œ ì‹œì¥ ì„±ì¥ë¥  ëŒ€ë¹„ ì €ì¡°í•œ ì„±ê³¼, ìŠ¹ì¸ ì‹œ ì¦‰ì‹œ ì¶œì‹œ ì¤€ë¹„ ì™„ë£Œ<br>- **IQOS ì„±ì¥ ê²¬ì¡°**: 2025</p>
    <hr style="margin:50px 0;">
    
</body></html>